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GENERAL INTRODUCTION 11
1Hematopoietic stem cells (HSCs) as source for all blood cells
The blood in our body consists of many different cell types. HSCs, which reside in the bone 
marrow (BM), are able to produce all the different cells present in our blood system, includ-
ing platelets, red blood cells, and white blood cells. This involves a highly controlled process 
of both self-renewal, to maintain the pool of HSCs and differentiation. The processes of self-
renewal and differentiation are coordinated by many signaling pathways, such as Notch [1], 
Wnt [2], BMP [3] and several others [4]. Aberrancies in genes constituting these pathways, 
either congenital or acquired, can influence these processes, eventually leading to arrests in 
development or to the development of hematological malignancies.
Under normal circumstances, HSCs give rise to all white blood cells, including both innate 
and adaptive immune cells. The innate immune system is already present at birth and 
is a nonspecific defense against pathogens and therefore is able to respond quickly. It is 
comprised of different cells types, including mast cells, macrophages, neutrophils, eosino-
phils, dendritic cells and natural killer (NK) cells. The cells of the adaptive immune system, 
comprised of B cells and T cells, are also present at birth similar to the cells from the 
innate immune system. However, cells from the adaptive immune system respond in an 
antigen-specific manner. These cells express receptors specific for antigens and upon an-
tigen encounter, they will proliferate but also form memory cells. These memory cells are 
able to respond quicker upon a second encounter with the same antigen; a characteristic 
that is made use of by vaccination, thereby providing protection against the pathogen. The 
adaptive immune system is only found in vertebrates [5-7].
HSCs are rare cells that are difficult to characterize precisely by marker expression alone. The 
most robust criterion to determine true stem cell potential is the ability to provide long-term 
repopulation of an entire host with all hematopoietic lineages [8]. In mice, this is often as-
sessed by performing transplantations into secondary recipients to determine self-renewal 
capacity [9, 10]. For human HSCs, this is of course not feasible in a clinical setting. Murine HSCs 
are characterized by the expression of Sca-1, C-kit, low expression levels of the Thy-1, low to 
absent expression of CD34 and the lack of lineage markers (e.g., B220, Mac-1, Gr-1, CD3, CD4, 
CD8 and Ter119). The most widely used HSC population in the mouse is the so called LSK 
population: lineage marker negative, Sca-1+, and C-kit+. Within this population, at least three 
subsets can be distinguished, namely, long-term [11-14] and short-term [12] HSCs, often by 
using CD34 in combination with the FLT3 marker and so-called Multipotent progenitors (MPP) 
that have largely lost true self-renewal capacity. Other markers are continuously evaluated 
and added in an attempt to more precisely define true HSCs. Of note are the so-called SLAM 
markers CD50 and CD48 which further subdivide the LSK population into cells enriched for 
long-term or short term repopulating stem cells and multipotent progenitors [15, 16].
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Human HSCs and their clinical use
The regenerative capacity of HSC is of great use in the clinic for the treatment of many 
diseases affecting the blood system; leukemia, lymphoma, SCID, and hemoglobinopathies, 
encompassing thalassemia and sickle cell disease [17]. Either autologous or allogeneic stem 
cells are used for transplantation, often depending on the availability of donor material. As 
a first step in the transplantation procedure, the cells of the immune system in the patient 
are often depleted by chemotherapy, which is called conditioning, and then the patient will 
receive donor-derived HSC that can engraft and develop a new healthy immune system. 
HSCs can be isolated from different sources; BM, mobilized peripheral blood and umbilical 
cord blood, all of which are used in the clinic for transplantation [18]. In a clinical setting, the 
CD34+ fraction is used for transplantation as these cells can be isolated in a good laboratory 
practice (GLP) setting. However, already in 1997, it was described that the phenotype of HSCs 
could be further refined to CD34+CD38- containing a frequency of 1 in 617 cells with true 
HSC potential, defined by the capacity to repopulate a NOD/SCID mouse [19]. Thereafter, it 
was shown that this cell fraction can be divided into 3 groups based on the expression of 
both CD90 and CD45RA. The Lin-CD34+CD38- CD90+CD45RA- cell population isolated from 
umbilical cord blood was demonstrated to have multi-lineage BM engraftment potential 
when 10 cells were transplanted [20]. This cell population could be further subdivided by 
CD49f discrimination of which the CD49f+ population contained a frequency of LT-HSC of 1 
in 10.5 cells [21]. This illustrates that currently, we are not yet able to identify the one cell 
phenotype that is most primitive and contains the highest long term repopulating capacity. 
Currently, the human HSC is described to be most enriched within the Lin-CD34+CD38-
CD45RA-CD90+CD49f+ population followed by the MPP that has lost expression of both 
CD90 and CD49f [22] (Figure 1). From the MPP two cell types branch off; the CD34+CD38-
CD45RA+CD90- MLP (multi-lymphoid progenitor) that can give rise to NK, B, and T cells, and 
the Lin- CD34+CD38+CD45RA-CD135+ CMP (common myeloid progenitor) that can give rise 
to the megakaryocytic-erythroid progenitor (MEP) and granulocyte-monocyte progenitor 
(GMP) [23]. The MLP is similar to common lymphoid progenitor (CLP), a progenitor proposed 
to be a precursor for lymphocytes but not for myeloid cells derived from many studies on 
hematopoiesis in the mouse [24-26]. In humans, this has been studied less extensively. The 
MLP comprises mostly lymphoid restricted cells, but also has some myeloid developmental 
potential, hence it cannot be considered as the human counterpart of the mouse common 
lymphoid progenitor. Instead, this population seems closer to lymphoid-primed multipo-
tent progenitors, the so-called LMPPs [27]. Importantly, recent insights have identified a 
novel lineage of lymphocytes, the innate like lymphocytes (ILC) that do not express antigen-
specific receptors but share many other properties with T cells [28-30]. Three subgroups 
are commonly distinguished based on the cytokines they produce and the transcription 
factors required for their development, a characteristic they also share with specific T cells 
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1subsets. The classical NK cells are now referred to as part of the ILC1 cells and Lymphoid 
tissue inducer cells belong to the ILC3 family. Cells from the myeloid lineage, erythrocytes 
and granulocytes are progeny from the MEP and GMP progenitor types. Also on the gene 
expression level, there is a separation between lymphoid fate and a myeloid fate at the MLP 
stage [31]. Many of the transcription factors that are important in HSCs are known to be 
causative of leukemia when deregulated, for example, RUNX1, MLL, SCL/TAL1 and LMO2 [32, 
33]. Under homeostatic conditions, the number of stem cells has to stay constant, which can 
be achieved by asymmetric cell division, through which one daughter cell keeps the stem cell 
identity and the other differentiates. The mechanism regulating asymmetric vs. symmetric 
remain poorly understood in mammals, particularly in HSCs. Depending on their localization, 
HSCS can divide symmetrically to expand the HSC pool (for instance during embryonic life 
in the fetal liver) or asymmetrically [34-36]. Adult HSCs are mostly quiescent. Indeed, most 
of the true stem cell activity is present in dormant LT-HSCs [37]. Additionally, the activation 
of dormant stem cells, for instance by inflammatory signals such as interferons, seems to 
be reversible as cycling HSCs return to the dormancy upon re-attainment of homeostasis 
[38]. Dormancy is thought to be a protective mechanism against exhaustion of HSCs, despite 
self-renewal properties, as there might be a limited self-renewal potential [39].
Figure 1
Figure 1. Schematic representation of the main lineage commitment steps in hematopoiesis. 
HSCs with the self-renewal capacity are placed at the top of  the hierarchy, develop to several multipotent progenitors 
which give rise to mature blood cells through a step wise process of  lineage commitment. HSC, hematopoietic stem 
cell; MPP, multipotent progenitor; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; GMP, 
granulocyte-monocyte progenitor, MEP, megakaryocyte-monocyte progenitor, pDC, plasmacytoid dendritic cell; cDC, 
conventional dendritic cell; NK, natural killer
14 CHAPTER 1
Embryonic origin of HSCs
Blood tissues originate from mesoderm lineages during the embryogenesis. The first re-
stricted cell types called hemangioblast which is thought to be derived from the common 
precursor of endothelial and hematopoietic lineages, [5, 32, 40]. However, it is difficult to 
determine the origin of the hematopoietic lineage due to the high mobility of the blood, 
and diverse localization of hematopoietic cells during embryogenesis, until the definitive 
hematopoietic organs are fully formed and functional.
Yolk sac (YS) is the first site of hematopoiesis in the mouse, which is formed between 
embryonic days 7 (E7) and E8 when the circulation is not established yet. This temporary 
hematopoietic organ mainly produces primitive erythrocytes cells and myeloid progenitors 
[41, 42]. Subsequently, adult HSCs are developed around E10.5 in the para-aortic splanch-
nopleura-(pSp-) also called aorta-gonads-mesonephros (AGM) region [43, 44]. These cells 
are colocalized with the endothelial cells in the ventral region of the dorsal aorta, [45], 
which raised the possibility of the development a “hemogenic endothelium” lineage as 
mentioned previously [46-49]. However, another hypothesis suggests that hematopoietic 
precursors are developed in sub aortic patches and then these cells migrate to the dorsal 
aorta via mesenchyme [50]. Immediately after being developed in the AGM region, HSCs 
can be found in other tissues such as the YS, placenta and fetal liver [51]. It is plausible that 
HSCs are developed in these organs de novo, or due to the local expansion. It has been 
proven that the hematopoietic cells migrate from the AGM, YS, and placenta into the fetal 
liver, which becomes the main hematopoietic organ until birth when BM hematopoiesis 
is established [52, 53]. Several studies have shown that human embryonic hematopoiesis 
follows very similar pattern to the murine fetal hematopoiesis [54] (Figure 2).
In the fetus, the liver is a major organ for HSC expansion and differentiation [55]. Although 
common precursors of myeloid and erythroid cells can be detected in the liver as early 
as E9.5, the first definitive HSCs seed the fetal liver at E11.5. The first phenomenon after 
colonization is a massive expansion of HSCs (38-fold between E12 and E16) which has 
been proven via competitive repopulating experiments. As HSCs start to emigrate from the 
liver into other organs such as the spleen and BM around E16, their repopulating potential 
decreases  [56] (Figure 2). Despite adult HSCs, fetal HSCs are actively cycling, and they 
have greater self-renewal potential compared to the BM HSCs [9, 57].
The balance between HSC repopulation and differentiation toward mature blood cells is 
crucial to maintain enough HSC pool in one hand and to provide quick and sufficient blood 
cells during injury on the other hand. This balance is controlled by multiple evolutionary 
conserved signaling pathways including the Wnt, Notch, Smad, and Hedgehog pathways. 
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1A large body of evidence has shown the presence of a complex molecular cross-talk 
between HSCs and the niche cells in their close vicinity, leading to the definition of one 
adhesion and signaling unit termed “stem-cell-niche synapse”, in analogy to the neuronal 
and immunological synapses [58]. In order to maintain the stem cell niche integrity, two 
different interactions are required. One to provide the adhesion among cells, and another 
to provide adhesion to the extracellular matrix, in order to trigger the activation of specific 
signaling pathways which potentially influence HSCs fate decisions, survival, and prolifera-
tion. The induction of signaling pathways can be mediated via three distinct mechanisms. 
Notch signaling is induced by cell-cell interactions via the binding of membrane associated 
ligands and receptors. Other signaling pathways such as Wnt, Smad/TGF/BMP/Activin, and 
Hedgehog are activated through binding of soluble factors to specific receptors located 
both on the HSCs and on the niche cell. Thirdly, hematopoietic cytokines like stem cell 
factor and thrombopoietin play an important role via binding to the Kit receptor, and the 
Mpl receptor respectively [58].
Figure 2
Figure 2. Main anatomical sites of hematopoiesis during embryonic development. 
Bars depict the ages at which mouse and human hematopoietic sites are active. AGM, aorta-gonad-mesonephros region; 
FL, fetal liver; YS, yolk sac.
16 CHAPTER 1
T cell development in the thymus
T-cell development occurs in the thymus, while all other blood cell lineages develop in 
the BM. The thymus is a bilobed organ located behind the sternum, above the heart. It is 
significantly large at birth, but the volume of true thymic tissue decreases by aging, during 
a process called thymic involution [59, 60]. Organogenesis of the murine thymus starts at 
E10.5. Bilateral endodermal proliferations of the third pharyngeal pouch invade the underly-
ing mesenchyme to form the thymic primordium or anlage [61]. In humans, this starts at the 
end of the fourth week of gestation. At E12.5 (4-7 weeks in man), the primordia separate 
from the pharynx and migrate to their definitive location, where they fuse to form a single 
organ [62, 63]. The importance of the thymus as an essential microenvironment for T cell 
development is proven by children suffering from the DiGeorge syndrome, in which some-
times thymus is completely missing. These children have a severely low number of T cells 
or even a complete absence of T cells [64]. BM hematopoietic progenitors enter circulation 
and migrate to the thymus where they commit to the T-cell lineage and further maturate 
to the functional T lymphocytes. Since thymic progenitors lose their self-renewal potential, 
a continuous import of progenitors from the BM is required to maintain T-lymphopoiesis 
[65]. However, upon deprivation of thymus from BM derived progenitors the thymus can 
maintain autonomous T-cell development for several months [66], a turnover process which 
is regulated by bone marrow progenitor colonization. It has been shown that the thymocyte 
turnover is regulated by natural cell competition between young BM derived progenitors 
and old thymus resident progenitors. When the thymus is relieved from outside competition, 
intrathymic precursors persist, self-renew, resulting in the development of T-ALL Leukemia 
[33].
T-cell development proceeds through a series of discrete phenotypic stages that can be 
characterized by the expression of several important membrane molecules, most nota-
bly CD4 and CD8 (Figure 3). In both humans and mice, thymocyte development occurs 
through successive CD4-CD8- (double negative, DN), CD4+CD8+ (double positive, DP) 
and CD4+CD8-CD3+ or CD8+CD4-CD3+ (single positive, SP) stages. The DN subset can be 
further subdivided into four stages (DN1 till DN4) in mice and humans [67-69]. The precise 
identity of the progenitors that seed the thymus is still controversial due to the fact that 
heterogeneous subpopulations of BM progenitors contain T-cell lineage potential, and 
also the extremely low number of cells seeding the thymus. These progenitors enter the 
thymus via veins in the cortical tissue close to the corticomedullary junction, from which 
they migrate into the thymic tissue [70] (Figure 3). Although few progenitors migrate to 
the thymus, they significantly proliferate in response to the environmental signals they 
encounter, while starting a T-cell transcriptional program. These initial signals are provided 
via cytokines like SCF and Flt3L, Wnt and Notch signaling pathway. 
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1Several types of progenitors have been suggested to seed the thymus and most of them 
are known to circulate and express chemokine receptors and adhesion molecules, shown 
to be involved in the thymus migration and seeding. These consist of Ccr7, Ccr9, and 
the P-selectin ligand Psgl1, among others. Despite several subpopulation candidates of 
thymus-settling, one major progenitor source contains lymphoid-primed multipotent 
progenitors (LMPP) [71, 72]. These progenitors are defined as Lin-Sca1+c-Kit+Flt3+ and, 
besides T-cell potential, they can develop into macrophages, dendritic cells, NK cells, and 
B-cells, but not erythrocytes or megakaryocytes lineages [73-75], at least in the mouse. 
In humans, the earliest cells in the thymus have retained some erythroid potential [69], 
which also is reflected in the abundant erythroid gene program that is expressed in human 
ETP-ALL [76]. 
After entering the thymus T-cell precursors develop through distinct stages. Progression 
through these steps involves gradual phases of lineage specification, characterized by 
the acquisition of a T-cell specific transcriptional program. Concomitantly to the lineage 
specification events, T-cell precursors gradually and irreversibly lose alternative non-T 
lineages potential till they are fully committed to the T-cell lineage. While the B-cell po-
tential is rapidly lost by the majority of the progenitors entering the thymus, the potential 
to become dendritic cells (DCs), natural killer (NK) cells and macrophages are preserved 
until later stages. Initial studies identified cells with a CD3-CD4-CD8-CD25-CD44+ surface 
phenotype (named DN1) as the most immature T-cell progenitors in the thymus. Further 
studies demonstrated that this is still a highly heterogeneous population also containing 
mature NK, NKT-cells, and γδ T-cells. In addition, effective T-lineage progenitor activity 
was shown to reside in a small subset of DN1 cells expressing c-Kit, which is termed early 
thymic progenitors (ETP) [24, 77-79]. ETPs are very efficient in the generation of DN2 cells 
(defined as CD3-CD4-CD8-CD25+CD44+) but they still maintain NK, DC, myeloid and at 
a lower extent also B-cell potential. Similarly to the LMPPs, a small portion of ETPs also 
expresses Flt3 and CCR9. These are believed to be the most immature T-cell progenitors 
in the thymus in the mouse. 
The presence of alternative lineage potential in T-cell progenitors suggests the existence of 
mechanisms to dictate a T-cell fate at the expense of other lineages. The most well-known 
instructive signal to promote T-cell development is the Notch signals. Activation of the 
Notch signaling pathway by ligands of the Delta family was shown to be essential to induce 
T-cell commitment [80-84]. While Notch signaling appears to be involved in the restriction 
of alternative lineage potentials e.g. by inhibiting B-cell and myeloid cell development, 
it may alternatively promote survival and expansion of the T-cell progenitor populations 
[85-87]. Another signaling pathway shown to be essential for these early events in T-cell 
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development is the Wnt signaling pathway, which is currently seen as a rate-limiting posi-
tive regulator of the transition to the DN2 stage [88, 89].  
T cell progenitors migrate through different anatomical zones in the thymus which may 
provide different signals to help the establishment of a T-cell development program (Fig-
ure 3) [90, 91]. As ETPs migrating through the cortical region towards the subcapsular zone 
they become more restricted to the T-cell lineage and start expressing important genes 
for T-cell receptor (TCR) rearrangements, assembly and signaling, such as recombinase 
activating gene 1 (Rag1) and Rag2, CD3 chains and Lck, [67]. The progressive upregula-
tion of T-cell identity genes is accompanied by the acquisition of a DN2 (CD3-CD4-CD8-
CD25+CD44+) and DN3 (CD3-CD4-CD8 CD25+CD44-) surface phenotypes, a process called 
T cell commitment. T cell commitment process has been studied more extensively which 
resulted in the identification of more intermediate stages namely DN2a, DN2b, DN3a, 
and DN3b. DN2a T cells also express a high level of c-kit and are believed to be the last 
uncommitted stage of T cell development. The expression of c-kit diminishes significantly 
at the DN2b stage while they lose their capacity to differentiate into any non-T cell lineage 
anymore [92]. CD27 expression subdivides DN3a and DN3b pre- and post-selection DN3 
cells respectively. Detailed gene expression analysis revealed that regulatory changes 
associated with the β-selection occur between these two stages of DN3 [93]. The DN3a 
stage is characterized by an arrest in cell-cycle allowing in this way the rearrangement of 
the Tcrb genes, which encodes for the variable region of the antigen receptors in T-cells. 
These rearrangements occur through a process termed V(D)J recombination which allows 
the generation of a high diversity of antigen receptors [94]. Successful rearrangement of 
the Tcrb gene is functionally tested for its expression on the cell membrane. Productively 
rearranged Tcrβ chains are coupled to an invariant pre-Tα chain to form the Pre-TCR com-
plex. Signaling through the Pre-TCR induces proliferation, survival and differentiation, 
in a process called β-selection. Cells that pass the β-selection are educated to develop 
into the αβ-T cell lineage [95, 96] and acquire DN4 (Thy+CD3-CD4-CD8-CD25-CD44-), ISP 
(CD3-CD4-CD8+ in mice or CD3-CD4+CD8- in humans) and later DP (CD4+CD8+) surface 
phenotypes. After these highly proliferative stages, another arrest in proliferation hap-
pens when the cells reach the DP stage and start rearranging the Tcra gene. Efficient Tcra 
rearrangement leads to the expression of a TCRαβ complex on the cell surface. These 
TCRαβ complexes are then functionally tested for the recognition of self MHC (major his-
tocompatibility complex) molecules (positive selection) and absence of reactivity against 
self-antigens (negative selection) [97]. Therefore this stage is identified by high apoptosis 
rate in order to eliminate non-functional and auto-reactive T-cells [97, 98]. Concurrently 
with the positive and negative selection processes, cells with a functional T-cell receptor 





Figure 3. T cell developmental stages in the thymus.
Cross-section of  an adult thymic lobule representing the migration route of  T-cell precursors during development. Im-
migrant precursors move to the thymus through blood vessels and enter near the cortico–medullary junction, the early 
T-cell precursors (ETP) subsequently migrate, and differentiate to double negative (DN), double positive (DP) and 
finally to single positive (SP) stages, through the discrete microenvironments of  the thymus. β-selection occurs at DN3a 
to DN3b transition at the outer portion of  the thymus (subcapsular zone). A directional reversal of  migration back 
across the cortex towards the medulla occurs for the later stages of  thymocyte development. ISP, immature single positive; 
TCR, T-cell receptor.
Wnt signaling pathway
The terminology of Wnt originates from a combination of the names for the Drosophila me-
lanogaster segment-polarity gene Wingless, and Integrase-1 [99], a mouse proto-oncogene 
that was discovered as an integration site for mouse mammary tumor virus. Integrase-1 is 
the vertebrate homolog of D. melanogaster Wingless, suggesting a key role of the gene in 
carcinogenesis [100]. There are 19 Wnt genes in the human and mouse genomes, all encod-
ing lipid-modified secreted glycoproteins. 
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The involvement of Wnt signaling pathway in various developmental processes has been 
shown by many studies. Among all cell-fate specification, progenitor-cell proliferation, 
dorsal axis development, and control of asymmetric cell division are the most important 
processes. In the hematopoietic system, Wnt pathways also play an important role as a 
proliferative growth factor, but also to determine cell-fate decisions, as morphogens do 
in other tissues. The number of studies on the Wnt signaling by immunologists and he-
matologists has augmented dramatically during the past few years. Initially, the pathways 
were only fascinating for developmental immunologists where it was thought that Wnt 
signaling is only important during T cell development by providing proliferative signals to 
immature thymocyte. Nowadays, Wnt signaling is also a hot topic in the field of immune-
hematology where the role of Wnt signaling is heavily under investigation e.g in the self-
renewal of hematopoietic stem cells, the maturation of DCs, peripheral T-cell activation 
and migration, and the development of leukemias.
There are at least three different Wnt pathways: the canonical Wnt pathway, which in-
volves β-catenin (also known as cadherin-associated protein-β) and members of the T-cell 
factor (Tcf)/ lymphocyte-enhancer binding factor (Lef) family; the planar cell polarity (PCP) 
pathway; and the Wnt-Ca2+ pathway.
Canonical Wnt signaling
Canonical Wnt pathway, known as β-catenin dependent Wnt signaling, is the most studied 
and best defined Wnt pathway. The majority of studies in immune-hematology have focused 
on this pathway in which β-catenin is the central player [101, 102] (Figure 4). This 92 kD 
protein has two functions: cell adhesion via cadherin, and activator of the canonical Wnt 
pathway.
In the absence sufficient triggers in the environment, the pathway is off. As a result, free 
cytoplasmic β-catenin is kept at very low levels via proteasomal degradation. β-catenin 
degradation is achieved through active phosphorylation at conserved regions by the ser/
thr kinases glycogen synthase kinase 3β (Gsk-3β) and Casein Kinase 1 (Ck1). These proteins 
consist the so called destruction complex, that also includes the scaffolding proteins axis 
inhibition protein 1 and 2 (Axin1 and Axin2), and the tumor suppressor protein adeno-
matous polyposis coli (Apc). First, β catenin is phosphorylated on Ser45 by Ck1, and then 
on Ser33, Ser37 and Thr41 by Gsk-3β to form recognition sites for the ubiquitin ligase 
β-transducin repeat-containing protein (β-Trcp), resulting in its ubiquitylation and subse-
quent proteasomal breakdown [103] (Figure 4A).
In the presence of surrounding Wnt proteins, and upon binding of these soluble proteins 
to the Frizzled receptor and the coreceptor low-density lipoprotein receptor-related 
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1protein 5 (Lrp5) or Lrp6 at the cell membrane, the signaling cascade is induced. When 
the complex of Frizzled–Lrp5/Lrp6 is formed, the ser/thr kinases is inhibited which is 
mediated by Dishevelled (Dlv). This phenomenon results in the disruption of the destruc-
tion complex, thereby β-catenin is stabilized in the cytoplasm. Accumulation of β-catenin 
probably in its amino-terminally dephosphorylated form [104] is followed by translocation 
to the nucleus where it binds to Tcf/Lef transcription factors. In normal conditions, Tcf 
assembles a transcriptional repressor complex [105]. Formation of the active β-catenin/
Tcf transcription-factor complex induces upregulation of Wnt target genes particularly 
Axin-2, c-Myc, and cyclinD1 (Figure 4B). Recent biochemical studies have revealed dual 
roles for Gsk-3β and Ck1. It has shown that they function not only as a negative regulator 
by promoting β-catenin phosphorylation and degradation, but also function as a positive 
regulator. By phosphorylation of specific residues of Lrp6, they allow docking of Axin to be 
rescued from the destruction complex. Therefore, despite their inhibitory form in cytosolic 
forms, membrane associated Gsk-3β and Ck1 stimulate Wnt signaling upon activation of 
the pathway [106-108]. 
The canonical Wnt pathway is known to be strictly regulated at different levels (reviewed 
in [109]). Binding of Wnts to the receptor complex can be actively prohibited by naturally 
occurring soluble decoy receptors such as secreted Frizzled-related protein (sFrp) and 
Wnt inhibitory factor 1 (Wif1) [110]. This Wnt antagonist binds directly to soluble Wnt 
proteins in order to inhibit their binding to the Wnt receptor complex. Next group of 
soluble Wnt antagonist consists of the Dickkopf homologs (Dkk), which bind to the Lrp5/
Lrp6 co-receptors and inhibit their function. In addition, Dkks can interact with another 
type of transmembrane receptors, the Kremens (Krm). Krm/Dkk1/Lrp6 form a ternary 
complex that disrupts Wnt/Lrp6 signaling by promoting endocytosis and removal of the 
Wnt receptor from the membrane [111]. The first evidence that Wnt signaling is important 
in stem cells originated from a Tcf-4 knockout experiment in which mutant mice do not 
develop crypt stem cell compartments. Gene expression analysis revealed that Lgr5/
Gpr49 (target of Tcf4 gene) is highly expressed in crypt stem cells, same as multiple other 
tissues [112]. Parallel studies showed that R-spondin receptor family, which acts as a Wnt 
agonist, provide growth stimuli for these crypts. The story got completed with the finding 
that Lgr5 constitutes the receptor for R-spondins in a complex with Frizzled/Lrp [113]. 
The Lgr5/R-spondin complex acts by neutralizing Rnf43 and Znrf3, two transmembrane E3 
ligases that remove Wnt receptors from the stem cell surface. Rnf43/Znrf3 are themselves 
encoded by Wnt target genes and constitute a negative Wnt feedback loop [114]. In the 
nucleus, the cell autonomous inhibitor of β-catenin and Tcf (ICAT) prevent the interaction 
of β-catenin with Tcf and Lef molecules, thereby inhibiting assembly of the active bipartite 
transcription-factor complex [115]. At least eight isoforms of Tcf with different potential 
for binding to β-catenin are created by alternative splicing and promoter usage, thereby 
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Figure 4
Figure 4. Canonical or Wnt-β-catenin-Tcf/Lef signaling. 
A) When the Wnt signalling is off, β-catenin levels in the cytoplasm and nucleus are kept low due to the continuous phos-
phorylation by the serine/threonine kinases Ck1 (casein kinase 1) and Gsk3β (glycogen synthase kinase 3β), leading 
to binding of  β-transducin-repeat-containing protein (βTrcp) and to ubiquitylation and degradation by the proteasome. 
The destruction complex is composed of  Ck1 and Gsk3β, as well as the anchor proteins Axin1 (axis inhibition protein 
1 ) and Apc (adenomatous polyposis coli). In the nucleus, Tcf  (T-cell factors) are bound by co-repressors such as Grg/
Tle (Groucho/transducin-like enhancer) proteins that silenced expression of  Wnt target genes. Other components of  the 
repressor complex include CTbP (C-terminal binding protein) and Hdac (histone deacetylases). β-catenin in the nucleus 
is prohibited from binding to Tcf  by ICAT (cell autonomous inhibitor of  β-catenin and Tcf). The Frizzled receptor 
complex (composed of  Frizzled and Lrp5 (Ldl receptor related protein 5) or Lrp6) can also be actively inhibited by 
receptor-bound soluble inhibitors such as Dkk1 (Dickkopf  homolog 1). B) Upon binding of  a lipid-modified Wnt pro-
tein to the receptor complex, a signaling cascade is triggered. LRP is phosphorylated by Ck1 and Gsk3β, and Axin1 
is recruited to the plasma membrane. The kinases in the β-catenin destruction complex are inactivated and β-catenin 
translocate to the nucleus to form an active transcription factor complex with Tcf, results in transcription of  a large set 
of  target genes. In the nucleus, β-catenin binds to Tcf  and Lef  factors and recruits co-factors such as legless (Lgs; also 
known as Bcl9) and Pygopus (Pygo), Cbp/p300, Brahma and Med12/mediator to initiate transcription. Dvl, mam-
malian homologue of  Drosophila Dishevelled.
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1manipulating the responsiveness of cells to canonical Wnt signals [116]. While the longer 
Tcf isoforms contain the amino-terminal catenin-binding domain, the shorter forms lack 
this region, therefore, cannot bind to catenin and function as naturally occurring repres-
sors of the pathway. 
The target genes which could be activated by the canonical Wnt signaling pathway are not 
completely discovered. These genes could vary among different tissues. In general, Axin2, 
c-Myc, CyclinD1, n-Myc, Lef1, and Cd44 have revealed to be regulated by Wnt signaling in 
various tissues [117-120]. These genes are involved in cell cycle regulation, apoptosis and 
proliferation, and in the induction of the Wnt signals in positive feedback loop.
Non-canonical Wnt signaling
As mentioned previously there are other types of Wnt signaling pathways which are 
independent of β-catenin so called non-canonical Wnt pathway, among all the Planar Cell 
Polarity (PCP) and the Wnt-Ca2+ pathways are best defined in model organisms such as D. 
melanogaster, Xenopus laevis and C. elegans, and have been shown to affect hematopoiesis 
and lymphopoiesis [121, 122].
Binding of non-canonical Wnt ligands such as Wnt5a and Wnt11 to Frizzled and Dvl (and 
probably G-proteins), without the involvement of Lrp5 and Lrp6 coreceptors, induce PCP 
signaling [123] (Figure 5). It has been shown that downstream pathways of Dvl are involved 
in various mechanisms. For example Dvl indices cytoskeletal re-organization by activation 
of Daam (Dishevelled associated activator of morphogenesis), subsequent induction of the 
RhoA (Ras homolog gene-family member A)-Rock (Rho-associated coiled-coil-containing 
protein kinase) pathways [124]. Dvl also activates Rac1, and both of these small GTPases 
(RhoA and Rac1) activate the Jun N-terminal kinase (Jnk, stress-response) pathway, which 
affects the cytoskeleton and cell shaping. Other important roles of the PCP pathway are 
the positional adjustment in model organisms, cell adhesion, and migration by regulating 
the cytoskeleton modification, and blockage of canonical Wnt signaling in lymphocytes 
by phosphorylation of cytoplasmic β-catenin protein [121, 122]. Several downstream ele-
ments of the PCP pathways affect the actin cytoskeleton and cell polarity, although this is 
not supposed to be true during hematopoiesis.
Binding of non-canonical Wnt5a ligand to e.g. Frizzled-2 receptor could trigger yet another 
pathway, known as Wnt-Ca2+ pathway which could inhibit canonical Wnt pathway [125, 
126]. The Wnt-Frizzled binding via a G protein, activates phospholipase C (Plc), leading 
to the cleavage of phosphatidylinositol-4,5- bisphosphate (PtdIns(4,5)P2) to inositol tri-
sphosphate (InsP3) and diacylglycerol (DAG) (Figure 5), which activates protein kinase C 
(PKC). InsP3 binding to its receptor on intracellular calcium storage cause accumulation 
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of the cytoplasmic level of Ca2+ ions, which is low in normal conditions. The elevation of 
Ca2+ concentration induces the phosphatase calcineurin and several calcium dependent 
kinases, including PKC (Protein Kinase C). Pkc itself upregulate the calcineurin expres-
sion, which ultimately leads to the Nfat activation (nuclear factor of activated T cells). 
In Xenopus spp., the Wnt-Ca2+ pathway has been shown to control ventral patterning, 
partially via  Xenopus Nfat. Nfat is known to be involved in T-cell receptor (TCR)-mediated 
activation and interleukin-2 (IL-2) production in T cells which could be regulated via Wnt-
Ca2+ downstream components. [127, 128]. Another interesting association of Wnt and 
Nfat signaling has been described in T cells where Gsk3β play a role in exporting Nfat out 
of the nucleus [129].
The presence of nineteen mammalian Wnt ligands which can bind to 10 different FZDs 
receptors to activate various downstream pathways such as WNT/β-catenin, WNT/planar 
cell polarity, and WNT/Ca2+ pathway, make the study of this pathway complicated. In the 
last decade, various in vitro and in vivo gain of function and loss of function models have 
been developed to unravel these functions. Nevertheless, our knowledge at the cell mem-
brane level where Wnt ligands activate FZD receptors, to trigger specific mechanisms and 
associated components, and as result to determine the ultimate function of Wnt pathway 
is yet incomplete. First of all, the level of WNT/ FZD interaction is generally unknown in 
particular in mammals, and it is unclear which WNT/FZD combinations can activate certain 
signaling pathways. Secondly, selective binding of a specific FZD receptor to downstream 
signaling pathways is not fully understood. However, the binding of several WNTs/FZDs 
complex and the physiological outcome of this interaction has been the subject of several 
studies which are reviewed in [130], and some of the most important ones will be men-
tioned here. FZD2 triggers both canonical and non-canonical Wnt-Ca2+ pathways. WNT-5A 
has been shown to bind to FZD3, triggering non-canonical WNT pathway. WNT 5A also 
triggers β -catenin signaling in HEK293 cells via FZD4, which can be inhibited when it is 
cotransfected with the non-canonical receptor ROR2. WNT-7A and WNT-3A bind to FZD5/
CRD, as shown by an ELISA-based protein binding assay. Some studies have identified FZD6 
as a negative regulator of the β-catenin dependent pathway. The binding of WNT-3 and 
FZD7 results in the increased stabilization of β -catenin in human hepatocellular carcinoma 
cells and might play a role in cancer development. Purified and secreted forms of FZD5, 
FZD7, and FZD8 CRD region has shown to antagonize WNT-3A-induced β -catenin accu-
mulation in L-cells, whereas, in mouse embryonic stem cells, the same CRDs can inhibit 
spontaneous mesoderm development and induce neural differentiation. Lastly, it has been 





Figure 5. Non-canonical Wnt signaling. 
A) Planar cell polarity (PCP) signaling does not involve β-catenin, Lrp (LDL receptor related protein) or Tcf  (T-cell 
factors), but leads to the activation of  the small GTPases RhoA (Ras homologue gene-family member A) and Rac1, 
which upregulate the stress kinase Jnk (Jun N-terminal kinase) and Rock (Rho-associated coiled-coil-containing protein 
kinase 1) and result in remodelling of  the cytoskeleton and modifications in cell adhesion and motility. Through largely 
unknown mechanisms, canonical β-catenin signaling can be inhibited by the PCP pathway. B) Wnt-Ca2+ signaling 
is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that 
subsequently activate the kinases PKC (protein kinase C) and CamkII (calcium calmodulin mediated kinase II) and 
the phosphatase calcineurin. The activation of  Plc (phospholipase C) by Dvl (mammalian homolog of  Drosophila Di-
shevelled) leads to the cleavage of  PtdIns(4,5)P2 (phosphatidylinositol bisphosphate) into InsP3 (inositol trisphosphate) 
and DAG (diacylglycerol). DAG, together with calcium, activates PKC, whereas InsP3 binding to receptors on the 
membranes of  intracellular calcium storage causes a transient increase in cytoplasmic free calcium, often also inducing an 
increase from extracellular supplies. AP1, activator protein 1; Cdc42, cell-division cycle 42; Daam, the Dishevelled-
associated activator of  morphogenesis; Nfat, nuclear factor of  activated T cells; Pde6, phosphodiesterase 6.
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Tyrosine kinase receptor and their relation with Wnt signaling
Some of the Receptor Tyrosine Kinase (RTK) family members including, Ryk (related to recep-
tor tyrosine kinase), Ror (RTK-like orphan receptor), and MuSK (muscle-specific kinase) have 
an extraordinary connection to Wnt signaling pathway, thereby accounts for Wnt signal-
ing receptors [131]. Ryk protein consists of a Wnt-inhibitory factor-1 (WIF-1) domain in its 
extracellular region and is reported to function as a receptor (or co-receptor) for Wnts [132] 
(Figure 6). The role of Ryk was initially discovered during screening for genes involved in 
Drosophila CNS axon pathfinding [133]. For a long time, it was believed that Ryk does not 
contain active tyrosine kinase catalytic activity because of the mutations in the vital ATP-
ase sites. A breakthrough in understanding Ryk function stem from the study in Drosophila 
where binding of the WNT5 protein to Ryk receptor has been shown [134]. It turned out 
that the Ryk-WNT5 interaction triggers the development of the embryonic CNS [135]. Dr. 
Baltimore and his coworkers have shown that Ryk can also directly binds to Wnt-1 and Wnt-
3a via its WIF domain. This binding induces a canonical downstream pathway which results 
in TCF activation. In this in vitro model, the extracellular domain of Ryk forms a ternary 
complex with Frizzled and Wnt-1. The intracellular domain of Ryk interacts with Dishevelled, 
in order to induce TCF activation in response to Wnt-3a activation. They have shown that 
Ryk-Wnt3a interaction is crucial for the development of neurite outgrowth in dorsal root 
ganglia explants [136].
The majority of functional studies focus on the role of Ryk in CNS development during 
embryogenesis. There are only a handful of studies in which the roles of Ryk in hemato-
poiesis and thymopoiesis have been studied. More than 20 years ago, the laboratory of Dr. 
Belmont studied the expression pattern and function of Ryk in the hematopoietic system. 
Gene expression, as well as protein expression analysis, revealed that Ryk expression is 
regulated during hematopoietic development by lineage commitment and stage of matu-
ration [137]. After two decades, a study in the laboratory of Prof. Nemeth revealed that 
Wnt5a ligand induces HSC quiescence through a non-canonical Wnt signaling pathway, 
which leads to an increased reconstitution after transplantation. Their further investiga-
tion demonstrated that Wnt5a regulates HSC quiescence and hematopoietic repopulation 
via binding of Wnt5a to the Ryk receptor, a process in which suppression of reactive oxygen 




Figure 6. Cooperative binding of Ryk to Wnt, Dvl, or adaptor and scaffold proteins. 
Many different transmembrane proteins that participate in Wnt signal transduction have now been identified. Domains 
important for Wnt binding (CRD in Fz, Ror, MuSK; WIF in Ryk) or for Dvl binding (PDZ-binding motif  
“PDZB”) are shown. Fz, LRP5, or LRP6 are essential for canonical Wnt signaling; there is evidence that Ryk 
contributes to this in some contexts. Ryk and Fz have also been implicated in various non-canonical signaling processes. 
Similarly, several other receptor proteins may participate on the basis of  proposed Wnt-binding domains, established 
protein-protein interactions, or both. Double-headed arrows indicate biochemically confirmed direct or indirect associa-
tions. Conjectural associations are denoted with a question mark. Other crucial interactions between these proteins not 
discussed in the text (e.g., between the Dvl DEP domain and Fz in non-canonical signaling) are not shown.
Roles of Wnt signaling in hematopoiesis
Several reports have shown the importance of canonical and non-canonical Wnt signaling in 
HSC biology. Today, a large body of evidence has proven that Wnt signaling plays crucial roles 
in the self-renewal of HSCs and proliferation of progenitor cells. However, several questions 
are not fully addressed yet. For example, under which physiological condition, e.g. homeo-
stasis or proliferation, Wnt signaling is crucial, or what is the optimal dosage of Wnt signaling 
activity for HSC repopulation, and which transcriptional activator is crucial in this process.
First evidence for the involvement of Wnt signaling during hematopoiesis stem from 
the gene expression data where differential expression level of several Wnt signaling 
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components in LT-HSC, primitive progenitors, and BM niche compartments, both in mice 
[139] and humans [140], and in adults as well as in fetal hematopoietic organs have been 
observed. These expression patterns include both paracrine and autocrine effects of Wnt 
ligands [141]. Wnt5a, Wnt2b, and Wnt10b have shown to trigger in vitro proliferation of 
human HSCs and primitive progenitors, in order to maintain an immature phenotype and 
sustain HSC pool. On the other hand, in vitro reporter assays have shown that murine HSCs 
residing in the BM niche are responsive to the canonical Wnt signals due to high expres-
sion Wnt receptors, and induce -β-catenin-Tcf/Lef downstream pathway [142]. Induction 
of canonical Wnt signaling by using purified Wnt3a results in an increased reporter activity 
in Bcl2 (B-cell lymphoma 2)-transgenic LSK cells and thereby enhanced self-renewal of the 
cells [143]. Consistently, blockage of this pathway through ectopic expression of Axin1 or 
by using a truncated form of Frizzled leads to a reduction of HSC proliferation in vitro and 
subsequently diminished repopulation potential of the transplanted cells in vivo [142]. An-
other evidence on the role of canonical Wnt signaling in maintenance of HSC pool comes 
from a gain of function study in which overexpression of constitutively active β-catenin 
in lymphoid or myeloid progenitors produced uncommitted cells with multilineage dif-
ferentiation potential [144].
An important investigation carried on in our laboratory in which a mouse model with a 
germline mutation specifically in the Wnt3a gene was used. This study has shown that 
Wnt3a canonical signaling is essential for self-renewal of fetal liver HSCs. Of interest, Wn-
t3a deficiency effect on HSCs could not be substituted by any other Wnt protein expressed 
in fetal liver and resulted in the full inhibition of the canonical Wnt signaling pathway, 
indicating that Wnt3a plays a non-redundant role in the regulation of fetal liver HSC func-
tion. The fact that other expressed Wnt proteins in fetal liver, are not able to compensate 
for Wnt3a deficiency suggests that either only Wnt3a is present specifically in the niche or 
exact ligand-receptor complex containing Wnt3a is required for fetal liver HSC expansion 
[145]. Another study from our laboratory unraveled the dosage dependency of HSCs on 
canonical Wnt signaling pathway. In this study Luis et al. used different transgenic mouse 
lines carrying different combinations of targeted mutations of the negative Wnt signal-
ing regulator Apc, thereby a gradient of different levels of Wnt signaling activation was 
generated. Controlled limiting-dilution competitive transplantation assays demonstrated 
that only a mild levels of Wnt signaling upregulation, approximately 2 fold higher than the 
normal physiological levels, leads to an enhanced HSC activity and increased repopulation. 
However,  intermediate to high levels of Wnt signaling activity cause lack of HSC repopula-
tion in recipient mice [146].  
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1Crucial signaling pathways in thymopoiesis
Notch signaling
Hematopoiesis and thymopoiesis, like other developmental processes, require a strict 
spatial and temporal control and harmonized gene expression programs. The majority of 
lineage commitment events in metazoans are controlled by merely a few signaling pathways 
including Wnt, Notch, TGF-β, Hedgehog, and receptor tyrosine kinases (RTK). Each pathway 
is frequently used in several processes, activating diverse subsets of target genes in various 
developmental contexts.
The Notch signal transduction pathway is not unique to developing T cells, but in the 
development of blood cells, its most prominent role is to induce a T cell gene program in 
mulita potent progenitor cells that arrive in the thymus [1]. In many other tissues and or-
gans, Notch signaling similarly regulates cell fate determination. Notch signaling involves 
cell-cell interactions, rather than binding of a soluble ligand to a receptor. There are four 
Notch receptors, named Notch-1 to 4. Signaling is initiated when the large extracellular 
domain of the Notch receptor binds a membrane bound ligand on a neighboring cell. The 
five Notch ligands in mammals are Delta-like-1, 3 and 4 and Jagged-1 and 2. Delta-like-2 is 
a non-expressed pseudogene. 
Interaction of Notch with a ligand induces proteolytic cleavage of the intracellular part 
of Notch (intracellular (IC-) Notch). IC-Notch then translocates to the nucleus and binds 
to the nuclear transcription factor CSL (CBF1 stands for core-promoter binding factor in 
humans, suppressor of hairless in Drosophila, Lag-1 in Caenorhabditis elegans; also called 
RBP-k in mouse). Binding of IC Notch to CSL induces the dislocation of co-repressors 
(coR) such as Mint and Nrarp, and recruitment of coactivators (coA), such as Mastermind 
(Maml), consequently leading to activation of Notch target genes [147]. In the thymus, 
there is an abundant expression of DLL-4, the Notch ligand that is mostly responsible for 
inducing a T cell lineage program on developing thymocytes [148]. Indeed Notch-1 KO 
mice show an arrest in T cell development at the DN1 stage with a relative increase of B 
cells in the thymus [84]. Conversely, ectopic expression of IC-notch in the BM leads to T 
cell development in the BM niche with DP cells containing Tcrb rearrangements [83].
Wnt signaling
Historically, the importance of Wnt signaling in the hematopoietic system was first docu-
mented from the effect of Wnt signaling during T-cell development in the thymus (Figure 
7). This was due to the observation that thymic epithelial cells (TEC) express a high level 
of Wnt proteins including Wnt3a and Wnt5a. Soluble Frizzled receptors which were used 
as decoys for Wnt proteins showed inhibition of thymocyte differentiation in fetal thymic 
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organ cultures (FTOC), an in vitro assay for T-cell development, mainly by blocking thymocyte 
proliferation [149]. Consistent with this study, the thyme of Wnt-1 and Wnt-4 double KO 
mice have a low thymocyte cellularity [150]. These observations were followed and more 
highlighted by other sequential studies showing the lack of T- and B-cell development in 
mice deficient for the Wnt-responsive transcription factors Tcf-1 and Lef-1, respectively [151, 
152]. At early ages, Tcf-1 KO mice have an incomplete block at the DN1, DN2 and ISP stages 
of thymocyte development, whereas mature mice have a full block at the DN1 stage (Figure 
7). Although Lef-1 deficient mice have a normal thymopoiesis, Tcf-1 and Lef-1 double KO 
mice have a complete block at the ISP stage, indicating redundancy in function of these 
transcription factors during thymopoiesis. A key observation was that Tcf-1 and Lef-1 are 
capable of binding to β-catenin and subsequently turn them into activator transcription 
factors [116, 149, 150, 153-155], which is consistent with the finding that  Wnt signaling 
provides proliferative signals to immature T and B cells [149, 150, 155].
Canonical Wnt pathway
As the number of progenitors seeding the thymus is limited, an enormous expansion of cells 
takes place during the early phase of T cell development. Cytokines, mainly IL7, but also 
Wnt proteins, are responsible for the initial proliferation of thymocytes before β-selection. 
Indeed, it was previously shown that Wnt proteins are secreted by thymic stromal cells, and 
canonical Wnt signaling is most active in the most immature DN stages [156]. In this regard, 
it is fitting that the first T cell specific target gene of the Notch pathway to be induced is Tcf-1 
(encoded by the gene confusingly named Tcf7), the nuclear protein responsible for transmit-
ting the nuclear response to Wnt signals. In this way, the Notch pathway starts a positive 
feedback loop in which T cell specific signal is amplified by Wnt signaling via Tcf-1. Our group 
has shown that especially early T cells are “hard wired” to respond to Wnt signals. As this 
differential responsiveness to Wnt signaling during different thymocyte stages is not caused 
by altered expression of Frizzled or Wnt proteins, but by increased expression of positively 
acting canonical Wnt factors (such as β-catenin) and decreased expression of inhibitory 
molecules (such as Axin1) in early DN thymocytes. [156]. Consistently, ICAT overexpression, 
a negative regulator of Wnt signaling, which blocks the interaction of β-catenin and Tcf/Lef 
transcription factors, partially inhibit early stages of T cell development but does not alter 
the later stages. The secreted Wnt inhibitor Dkk1, which blocks binding of Wnt proteins to 
the required Lrp co-receptor, inhibits thymocyte development similarly at the DN stages. 
This inhibition is dose dependent such that high levels of Dkk1 cause complete block at the 
very early DN1 stage of T cell development (Figure 7).
Wnt transduction in thymocytes by overexpressing activated forms of β-catenin caused 
enhanced thymocytes development [157], as a result of bypassing the requirement for 
pre-TCR signals in mice lacking a pre-TCR [158, 159], and upregulation of proliferation-as-
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1sociated genes in immature thymocytes [107]. Notably, conditional T-cell-specific deletion 
of β-catenin, using the proximal Lck promoter to control Cre expression, impaired T-cell 
development at the β-selection checkpoint, leading to a predominant decrease of mature 
T cells in circulation [160]. Another elegant study on the effect of Wnt signaling through 
β-catenin and Tcf is provided by using transgenic or retroviral reconstitution of Tcf1 KO 
mice with various isoforms of Tcf1 that can or cannot bind to β-catenin [161]. Only the 
forms of Tcf1 with the capability of binding to β-catenin could rescue T-cell development in 
Tcf1-deficient mice, which is consistent with an important role for canonical Wnt signaling 
through β-catenin in the early stages of T-cell development in the thymus. On the other 
hand, conditional deletion of the Apc tumor-suppressor gene, inhibits T-cell development, 
partially by affecting β-catenin signaling [162]. Conditional deletion of β-catenin only in 
thymocytes disrupts T cell development, suggesting that thymocyte development requires 
higher levels of Wnt signaling. Consistently, measurement of Wnt signaling activity with 
in vivo reporter assays [146] showed a significant difference between bone marrow stem/
progenitor cells and thymocytes (approximately 4 fold higher in thymocytes) in terms of 
Wnt signaling activity.
As an approach for understanding the controversies in the literature on Wnt signaling in 
HSCs, our group reported combinations of targeted mutations in Apc that were used in order 
to obtain a gradient of Wnt signaling activation. As mentioned previously, while HSC func-
tion was enhanced specifically with mild levels of Wnt signaling activity, only intermediate 
Wnt activation confers an advantage to the early stages of T-cell development. High and 
very high levels of Wnt signaling activation similarly to stabilization of β-Catenin, resulted 
in the accumulation of DN3 thymocytes and in impaired Tcrb gene rearrangements [146]. 
Despite the severe reduction in Tcrb gene rearrangements, Tcrβ- DP and SP cells could 
be detected in the thymus of these mice, although in reduced numbers, indicating that 
high Wnt signaling allows a bypass of the β-selection checkpoint. The reduced numbers 
of DP and SP thymocytes are probably due to the lack of proliferation and survival stimuli 
from a functional pre-TCR [158, 162]. In contrast, an intermediate activation of the Wnt 
pathway enhanced early stages of T-cell development while preserving Tcrb rearrange-
ments and maintaining developmental checkpoints. However, the numbers of DP cells was 
still reduced which may indicate that later stages of T-cell development have different Wnt 
signaling requirements [163]. In the agreement, in vitro cocultures with OP9 stromal cells 
expressing the Notch ligand Delta-1, in which positive and negative selection processes are 
less stringent [164] an increase in both DP and SP cells with intermediate but not higher 
levels of Wnt activation was observed. In summary, HSCs and thymocytes require different 
levels of Wnt activation with the thymocytes displaying higher Wnt activity. 
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Lack of Wnt3a also causes deficiency during T-cell development in murine due to a block 
at ISP to DP transition which results in decreased total cellularity [145]. The observation is 
because of deficiency in Wnt3a production by the thymic stroma since Wnt3a KO progeni-
tors stem cells differentiate normally in wild-type thymic lobes. This is in agreement with 
the fact that Wnt3a gene expression being restricted to the murine thymic epithelium 
[156]. The similarity between Wnt3a and Tcf1 deficiency phenotype in terms of thymopoi-
esis suggest that Wnt3a is directly regulating thymocytes development. These phenotypic 
similarities were later observed in Wnt1 and Wnt4 KO mice suggesting high functional 
redundancy among these Wnt proteins in the thymus.
It has been shown that canonical Wnt signaling is not only playing roles at early stages 
of T cell development but also is playing significant roles during positive and negative 
selection and the DP to SP transition. As some examples, it has shown that DP to CD4+ SP 
transition is regulated partially by β-catenin-Tcf signaling [165] and that Tcf1 KO mice have 
diminished expression level of CD4 on DP and CD4+ SP cells (Figure 7). A series of elegant 
experiments indicate that overexpression of stabilized β-catenin controls the positive 
selection of thymocytes [166, 167]. Full and simultaneous positive and negative selection 
of both CD4+ and CD8+ SP thymocytes only happened when stabilized β-catenin was over-
expressed, in contrast to the normal thymocyte development where the differentiation of 
CD8+ SP thymocytes lags behind of CD4+ SP thymocytes (Figure 7). 
The thymic microenvironment provides signals that are crucial for thymopoiesis. Although 
the lymph-node microenvironment produces similar signals, lymph node-derived progeni-
tors are not able to develop into mature T-cells when they are cultured with stromal cells 
that express the Notch ligand Delta-1. Lymph node stromal cells can generate most of the 
important signals for T-cell development, including IL-7, SCF, and the Delta1. However, 
they do not express Wnt transcripts [168]. Interestingly, Lymph-node T-cell progenitors 
can develop to mature T cells when they are cultured with stromal cells expressing Wnt4. 
This study, therefore, indicates that Wnt and Notch signals are functioning together in 




Figure 7. Effect of Wnt signaling during thymopoiesis in the thymus.
The first cells to arrive in the thymus are rare progenitor cells commonly referred to ETPs (early thymic progenitors), 
which reside in the DN (CD4–CD8– double negative (DN)) compartment. DN cells proliferate rapidly, partly medi-
ated by Wnt signaling. Inhibition of  the Wnt pathway, by ectopic expression of  soluble Frizzled receptor (which acts 
as a decoy receptor), Dickkopf  homologue 1 (Dkk1; which inhibits binding to Ldl receptor related protein (Lrp) co-
receptors) or the cell autonomous inhibitor of  β catenin and Tcf  (ICAT; which disrupts the β-catenin–Tcf  interaction) 
leads to inhibition of  T-cell development at various points in the DN developmental pathway. Similarly, incomplete 
blocks in T-cell development are observed at DN1, DN2 and ISP (immature single positive) stages of  development in 
Tcf1 (T-cell factor 1)-deficient mice. Wnt signaling also regulates the survival of  double positive (DP; CD4+CD8+) 
thymocytes by upregulating expression of  the anti-apoptotic protein Bcl-Xl and stabilized β-catenin effect positive selec-
tion and interleukin-7 receptor signaling, resulting in increased numbers of  CD8+ SP (single positive) thymocytes. 
Moreover, the levels of  CD4 on both DP and CD4+ SP cells are regulated in part by Tcf1 (not shown in the figure). 
HSC, hematopoietic stem cells; MLP, multi lineage progenitor.
Non-canonical Wnt pathway
Few reports have also shown the effect of non-canonical Wnt signaling during T cell develop-
ment. The role Wnt-Ca2+ pathway as an example has been investigated in Wnt5a KO mice, 
or by providing high levels of exogenous Wnt5a [122]. Wnt5a deficient mice die at birth 
due to severe anatomical abnormalities; as a result, T-cell development was studied in an 
ex vivo FTOC using thymic lobes obtained from embryonic day 14 (E14). This study proved 
that Wnt5a is important in the regulation of the αβ-lineage survival at DP stage. In Wnt5a 
KO FTOC the expression of proapoptotic gene Bax was downregulated, while expression of 
the antiapoptotic gene Bcl2 was upregulated, resulting in the inhibition of DP thymocytes 
apoptosis. On the other hand, exogenous Wnt5a augmented the apoptosis of fetal T cell 
progenitors [122]. It is also shown that Wnt5a triggers Ca2+ signaling by increasing free cyto-
plasmic Ca2+ to regulate the DP and mature SP thymocytes survival. Moreover, upregulation 
of non-canonical Wnt Ca2+ pathway inhibited the canonical Wnt signaling by downregula-
tion of β-catenin expression.
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Another study which addressed the role of the non-canonical pathway in thymopoiesis 
relates to the Wnt4 KO mice that die due to the renal failure shortly after birth [150]. It 
has shown that lymph-node-resident hematolymphoid progenitors are able to generate 
mature T cells when they are cultured in the presence but not in the absence of Wnt4 
protein. Using Wnt4 KO neonates, Louis et al found that Wnt4 is crucial for the main-
tenance of the bone-marrow HSCs and to sustain a normal thymic cellularity. In adult 
murine, Wnt4 overexpression induced the expansion of non-renewing lymphoid-primed 
multipotent progenitors (LMPPs; Flt3+ LSKs) downstream of hematopoietic stem cells 
(HSCs; Flt3– LSKs). Expansion of LMPPs was associated with a proportionate accumulation 
of ETPs and thymic seeding cells resulting in an increase in thymic cellularity. Notably, 
they showed that Wnt4 induced non-canonical JNK-dependent Wnt pathway [169, 170]. 
In follow up studies they showed that Wnt4 regulates homeostatic thymic cellularity in a 
thymic epithelial cell (TEC)–dependent manner. The absence of Wnt4 inhibited fetal and 
postnatal thymic expansion which led to diminished TEC numbers, a modification of the 
medullary-to-cortical TEC ratio, and a disproportionate loss of the most immature thymo-
cyte precursors which are highly express c-kit marker. Wnt4 and its downstream signaling 
pathways could be utilized as a promising candidate to improve thymic cellularity in the 
process of thymic atrophy [171].
Transcriptional drivers of T cell commitment
T-cell commitment depends on a collection of various transcription factors, each with its 
own expression profile including Myb, Runx1 with its partner CBFb, GATA-3, TCF-1 (encoded 
by Tcf7) and Bcl11b and E2A ( which encodes two alternative splice variants E12 and E47). 
Weber et al have shown that TCF-1 is highly expressed in the earliest thymic progenitors, 
and its expression is upregulated by Notch signals. However, when TCF-1 has ectopically 
expressed in bone marrow (BM) progenitors, it induces the development of T-lineage cells in 
the absence of Notch1 signals. Further characterization of these TCF-1-induced cells showed 
expression of several T-lineage genes, including T-cell-specific transcription factors Gata3 and 
Bcl11b, and components of the T-cell receptor [172]. In a related study by Germar et al, it has 
been proven that Tcf-1 is required at the earliest phase of T-cell development for progres-
sion beyond the early thymic progenitor stage. The earliest deficiency detected in Tcf-1 KO 
thymocytes was the reduced expression of c-kit at the DN1 stage of development. Tcf-1–KO 
cells at this stage showed increased apoptosis and have significantly reduced expression 
of genes involved in DNA metabolic processes, chromatin modification, and response to 
damage compared with their WT counterparts [173]. 
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1Induction of the T-cell developmental program initially depends on Notch signaling. Notch 
signaling is required to set up the first T cell specific genes, initially Tcf7, later Gata3 and also 
Bcl11b, the transcription factor that seals off the T cell commitment fate [174]. However, 
this signal is not a constant component of the regulatory state mix. Notch responsiveness 
is indispensable at the DP stage, but once triggered at the early stages of T cell develop-
ment, most of the regulatory genes that contribute positively to the T-cell program sustain 
maximal levels of expression even when Notch signaling is not active anymore [175]. 
Developing T cells initially express a considerable level of PU.1, but inhibit it completely 
during lineage commitment. This process takes surprisingly long, almost 14 days ( at least 
10-12 cell divisions) in the mouse and probably longer in humans based on OP9 cultures 
with human CD34+ cells [176]. Thus, these cells have only a short opportunity in which 
myeloid potential poses a threat to T lineage fidelity. In fact, the thymic microenvironment 
is nonpermissive for expression of this myeloid potential [177], although both in mouse 
and human systems B and myeloid potential can be detected.
The T-cell program is orchestrated by inducing expression of three transcription factors: 
Gata3, Tcf7, and Bcl11b, These transcription factors rely all in part on Notch signaling via 
RBP-j. GATA-3 is essential for T-cell development from the earliest stage throughout mul-
tiple later developmental checkpoints, and it is restricted in its hematopoietic expression 
to T cells and T-cell-like innate lymphoid cells [178]. GATA-3 can antagonize alternative 
lineage fates, through its ability to repress PU.1 and its ability to repress the B-cell program 
by downregulating Pax5 [179]. In early stages of T cells development GATA-3 expression 
is not controlled via a positive autoregulation process as it has shown that exogenous 
GATA-3 is not able to increase endogenous Gata3 expression, and early T cell progenitors 
lacking Gata-3 gene continue to express RNA from the Gata3 promoter at a comparable 
levels to the WT counterpart [179]. Thus, It seems that GATA-3 expression level depends 
on other factors. At the later stages of T-cell development, GATA-3 expression levels are 
regulated by the signaling pathways responding to TCR engagement and Stat6. Instead, 
Gata3 control after initial Notch-dependent induction is probably maintained by Myb and 
TCF-1 as likely positive regulators [180]. 
T cells commitment completes when thymocytes progress to DN2A stage and then increase 
expression of the Bcl11b gene [181, 182]. Indeed Bcl11b is turned on by Notch signaling 
and probably other factors and inhibits residual NK cell lineage potential in DN2 cells [177, 
182]. Bcl11b gene expression has one of the most significant increases in the level of 
expression from the ETP stage to the newly committed DN2b stage [181, 182]. Single-cell 
analysis using fluorescent reporter for the Bcl11b locus together with reporters for Bcl11a 
or Spi1 (PU.1) confirmed that ETP cells first activating Bcl11b expression but still sustain 
the expression of Bcl11a and PU.1, though they become downregulated afterward. DN2b 
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cells, which are functionally committed T cells, still clearly retain PU.1 protein as shown by 
single-cell fluorescent staining [183]. Recently the laboratory of Prof. Rothenberg unrav-
eled the mechanisms of Bcl11b activation during T lineage commitment by generating a 
knock-in fluorescent reporter at the Bcl11b locus and followed Bcl11b activation dynamics 
at the single-cell level using in vitro developmental assays together with flow cytometry 
and time-lapse live imaging. They showed that factors that are controlling Bcl11b expres-
sion amplitude differ from those that license the locus for expression competence, a regu-
latory strategy that enables the latter to have subsequent roles in mature T cell functional 
specialization. These factors work via three distinct, asynchronous mechanisms: an early 
locus ‘poising’ function dependent on TCF-1 and GATA-3, a stochastic-permissively func-
tion dependent on Notch signaling, and a separate amplitude control function dependent 
on Runx1, which is already expressed at HSC level [184].
Another transcription factor that is involved in inducing rearrangements in both T and B 
cells is E2A [185, 186]. Loss of E2A activity results in a partial block at the earliest stage of 
T-lineage development [187]. This early T-cell phenotype precedes the development T cell 
leukemias [188], as also occurs in thymocytes lacking Tcf1 [189]. Thus, both E2a and Tcf1 
are not only crucial as positively acting transcription factors, but also as tumor suppressor 
genes for the development of thymic lymphomas/leukemias.
Wnt signaling in hematological malignancies
In most solid tumors, constitutively active Wnt signaling is a significant contributing or even 
initiating event for the development of such cancers [102]. The prototypical example is colon 
carcinoma, in which carcinogenesis is caused by inactivating mutations in the tumor sup-
pressors Apc or Axin1 or activating mutations in β-catenin [190]. Recently, it has been shown 
that deregulated Wnt signaling is also crucial during the development of hematological ma-
lignancies. Although the underlying mechanism is not completely clear, mutations leading to 
the overexpression of Wnt genes or β-catenin and γ-catenin seem to be important.
Acute Myeloid Leukemia (AML)
AML is a clonal malignancy that arises in HSCs or myeloid progenitors cells. AML is frequently 
associated with chromosomal translocations leading to abnormal fusion proteins (such as 
AML1–ETO, PML–RARα, PLZF–RARα and CBF1–MYH11) or with activating mutations in the 
receptor tyrosine kinase Flt3, which is the receptor for the cytokine Flt3L.
Target genes of these fusion proteins have been shown to be associated with Wnt signaling, 
in particular, γ-catenin [191]. Furthermore, high levels of β-catenin expression in AML cells 
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1exhibit poor prognosis [192]. Eventually, to underscore the significance of Wnt signaling 
in myeloid cells, myeloid progenitor cells of patients with severe congenital neutropenia 
had a severe downregulation of Lef1 expression and its target genes. Thus, Lef1 plays an 
important role in normal human myelopoiesis [193].
Many studies demonstrate that epigenetic inactivation of Wnt pathway inhibitors by CpG 
island methylation provides an additional mechanism for the observed Wnt-pathway 
activity in AML leukemic cells. The methylation status of Wnt antagonists, such as sFRP-1, 
3, 4, and DKK1, was shown to be responsible for the activation of the Wnt pathway in AML 
cells and correlated with poor prognosis [194-199].
Another natural antagonist of the canonical Wnt-pathway is the Wnt protein Wnt5a. This 
particular Wnt protein activates the non-canonical Wnt-pathway and mice hemizygous 
for Wnt5a develop myeloid leukemias[121]. Also in human samples, Wnt5a appeared to 
function as a tumor suppressor. In normal B cells, myeloid cells and CD34+ bone marrow 
cells Wnt5a transcripts were readily detectable. Analysis of several acute lymphoblastic 
leukemias (ALLs) showed that in samples of both B-ALL and AML the levels of Wnt5a were 
greatly reduced or completely absent. In conclusion, active Wnt signaling appears to play 
an important role in the propagation/acceleration of AML and has been shown to be an 
important secondary oncogenic event in mouse models of AML to transform pre-LSCs 
into LSCs. Based on these insights, new therapeutic opportunities have been explored 
by investigators who show that small-molecule Wnt-pathway inhibitors, which inhibit the 
interaction between β-catenin and LEF1, selectively induce cell death in AML cell lines and 
primary AML blasts [200]. Recent studies in preclinical settings indicate the promise of 
Wnt inhibition to treat AML [201-203], suggesting that targeted therapy of leukemia stem 
cells in AML may become possible.
Chronic Myeloid Leukaemia (CML)
Most of the CML cases carry the classical Philadelphia chromosome, which is caused by a 
t(9,22) translocation leading to the generation of the abnormal BCR-ABL fusion protein. It 
has been shown that Wnt signaling is upregulated at the terminal phase of CML in which the 
disease resembles acute leukemia [204], but it is normal at other stages. 
Although β-catenin deficiency in mice significantly prevent the occurrence of BCR-ABL- 
induced CML, the development of BCR-ABL-induced BCP-ALL was not altered. As CML and 
ALL might originate from different cells, these studies conclude that the use of Wnt signal-
ing might depend on the tumor origin. In conclusion, as the fusion protein Bcr-Abl can 
actively modulate β-catenin levels in the cells, the most severely affected Wnt-pathway in 
CML is the canonical Wnt pathway. However, as recent studies show, in CML cells resistant 
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to tyrosine kinase inhibitors the non-canonical Wnt-pathway might interfere when the 
Bcr-Abl-mediated mechanism is inhibited. Therefore, novel therapeutics should not only 
be aimed at affecting the canonical Wnt-pathway but should also take into account the 
redundant effects of the non-canonical pathway, all in combination with tyrosine kinase 
inhibitors targeting BCR-ABL. 
Acute Lymphoblastic Leukemia (ALL)
As Wnt signaling together with Notch signals are crucial for normal T-cell development 
in the thymus, constitutively active Wnt signaling should lead to ALL [205]. Experimental 
evidence for this hypothesis has been demonstrated by taking advantage of conditional 
deletion of exon 3 in β-catenin, which results in a constitutively active form of β-catenin. As 
a result, β-catenin can no longer be phosphorylated and broken down in the proteasome 
[163]. This causes aggressive T-cell lymphomas that metastasize to the bone marrow and 
are transplantable into irradiated recipient mice. These tumors arise independently from 
Notch signals, suggesting that although the Notch and Wnt pathways cooperate during 
the early stages of T-cell development in the thymus, they can act independently during 
leukemogenesis. Another study revealed yet another mechanism by which oncogenic forms 
of β-catenin can cause thymic lymphomas; constitutively active forms of β-catenin were 
shown to cause p53-independent oncogene-induced-senescence, growth arrest and finally 
lymphoma development [206].
Of special interest, there are two recent studies that show a clear tumor suppressor role 
for Tcf1 in T-ALL development [189, 207]. Both studies show that mice deficient for Tcf1 
are highly susceptible to develop leukemias. The observed leukemias had a heterogeneous 
pattern of leukemia formation, which is expected as Tcf-deficiency leads to several incom-
plete and consecutive T cell blocks in development. Remarkable was the high expression 
of Lef1 in these leukemias (and Id2 in the DN3 lymphomas in the study by Yu et al). Both 
studies show that Tcf1 normally acts a suppressor of Lef1 protein levels in the thymus. 
Upon deletion of Tcf1, Lef1 protein levels become deregulated in all developmentally 
blocked thymic subsets, resulting in abnormally high levels of the long isoform of Lef1 
predisposing the thymocytes towards leukemic transformation. The question remains 
whether this Lef-mediated oncogenic effect, due to the absence of Tcf1 is a Wnt-mediated 
driven process or not. The study by Tiemessen et al could demonstrate elevated Wnt 
signaling activity in the Tcf1-deficient tumors by crossing the Tcf1-deficient mice to a 
Wnt-reporter mouse. As the study by Yu et al. could not demonstrate this, there might 
be a possibility that high Lef1 levels mediate leukemia formation in an additional Wnt-
independent way. The crossing of the Tcf1-deficient mouse to an inducible Lef1-knockout 
mouse confirmed the redundancy of both factors as there was an almost complete total 
lack of T cell development. However, in the double knock-out (Tcf/Lef) mice still, some 
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1leukemia formation (2 out of 13 mice) was reported. This may suggest the existence of an 
additional Wnt-pathway-independent mechanism causing these lymphomas. However, a 
key role for Lef1 was also found in a mouse model that deregulates the Notch pathway by 
ectopic expression of the intracellular domain of Notch1 [208]. This study showed that T 
cell lymphoma lines require high levels of Lef1 for their survival. Hence, deregulation of 
Lef1 expression, either via lack of the tumor suppressor Tcf1 or via increasing of the Notch 
pathway accelerates lymphomagenesis. Also in human cases of precursor T-ALL aberrantly 
active Wnt signaling has been reported [76, 209].
Aim of the thesis 
The capability of HSCs to self-renew and differentiate towards T cells is precisely controlled 
by multiple signals including Wnt signaling, supplying from the niche within the BM and 
thymus. Therefore, exploring the exact micro environmental signals that support HSCs and T 
cell progenitors development has been a major goal. This thesis describes studies aimed to 
understand the role of Wnt signaling pathways involved in the regulation of HSC self-renewal 
and T cell development in the BM and thymus respectively. Better understanding the role of 
Wnt signaling in hematopoiesis and thymopoiesis could be clinically relevant to improve de-
layed T cell reconstitution after SCT either by applying during ex vivo culture systems of HSCs 
before transplantation or by administrating in vivo to boost and/or sustain T cell potential. 
Therefore, the main aim of the studies in this thesis was to unravel the functional role of 
both canonical and non-canonical Wnt signals for hematopoiesis and T cell development.
As most of the studies on the role of Wnt signaling in hematopoiesis and T cell develop-
ment have focused more on the canonical Wnt signaling, in this thesis we gave an equal 
attention to both canonical and non-canonical Wnt in hematopoiesis and lymphopoiesis. 
Chapter 2 is a follow-up study on the report of Luis et al. in which our group showed that 
high level of Wnt signaling impaired HSC repopulation. Using gene expression analysis as 
well as functional studies, we explained the responsible mechanism underlying this obser-
vation. In chapter 3 we studied the role of a noncanonical Wnt receptor Ryk in hematopoi-
esis and lymphopoiesis. We used a loss of function model of Ryk KO mouse and performed 
in vitro and in vivo reconstitution assays. Chapter 4 of the thesis examines effects of both 
canonical and non-canonical Wnt signaling side by side during lymphopoiesis. In order to 
do that we used two gain of function models namely  Wnt3 and Wnt5a overexpression 
in in vitro and in vivo differentiation assays. Chapters 5 and 6 describe the role of Tcf-1 
in T cell development and malignancy using a Tcf-1 deficient mouse model. Chapter 5 
studied the role of this transcription factor in a loss-of function model to discover the role 
of Tcf-1 in T cell commitment. Chapter 6 explains the role of Tcf-1 in thymic lymphoma 
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development. Lastly, Chapter 7 discusses the significance and implications of the studies 
described, and provide directions for future research.  
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Summary
Canonical Wnt signaling regulates the self-renewal of most if not all stem cell systems. In the 
blood system, the role of Wnt signaling has been the subject of much debate but there is 
consensus that high Wnt signals lead to loss of reconstituting capacity. To better understand 
this phenomenon, we have taken advantage of a series of hypomorphic mutant Apc alleles 
resulting in a broad range of Wnt dosages in hematopoietic stem cells (HSCs) and performed 
whole-genome gene expression analyses. Gene expression profiling and functional studies 
show that HSCs with APC mutations lead to high Wnt levels, enhanced differentiation, and 
diminished proliferation but have no effect on apoptosis, collectively leading to loss of stem-
ness. Thus, we provide mechanistic insight into the role of APC mutations and Wnt signaling 
in HSC biology. As Wnt signals are explored in various in vivo and ex vivo expansion protocols 
for HSCs, our findings also have clinical ramifications.
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Introduction
In many tissues, including the blood, intestine and skin, old cells are eliminated and replen-
ished by newly developed cells from a small pool of stem cells. This rare population of stem 
cells is located in a specific microenvironment, the niche, and gives rise to several different 
lineages of abundant daughter cells (Mendez-Ferrer et al., 2010). The signals controlling the 
various stem cell fates (self-renewal, differentiation, quiescence, apoptosis, and others) are 
beginning to be elucidated. A number of evolutionary conserved pathways are important for 
the development and maintenance of adult stem cells, including Notch, bone morphogenic 
protein, hedgehog, fibroblast growth factor, transforming growth factor- β, and Wnt signals 
(Blank et al., 2008). Among these pathways, the Wnt pathway is seen as a dominant factor 
in self-renewal of many types of adult stem cells (Reya and Clevers, 2005). Compared with 
the convincing studies on the role of Wnt signaling in adult stem cells in skin and gut, a role 
for Wnt in adult hematopoietic stem cells (HSCs) has proved much more difficult to demon-
strate (reviewed in Luis et al., 2012). In studies reporting an important role for Wnt signaling 
in blood cells, Wnt seemed to be required for normal HSC self-renewal and therefore for 
efficient reconstitution after transplantation (Luis et al., 2011).
Several types of Wnt signaling can be discerned often referred to as the canonical or 
Wnt/β-catenin pathway and the non-canonical pathways (reviewed extensively in Staal et 
al., 2008). In the absence of Wnt ligands, cytoplasmic levels of β-catenin are kept very low 
through the action of a protein complex (the so-called destruction complex) that actively 
targets β-catenin for degradation. This complex is composed of two negative regulatory 
kinases, including glycogen synthase kinase 3β (GSK-3β) and at least two anchor proteins 
that also function as tumor suppressor proteins, namely Axin1 or Axin2 and APC (adeno-
matous polyposis coli). APC and Axin function as negative regulators of the pathway by 
sequestering β-catenin in the cytoplasm. Hence, inactivating mutations in Apc lead to 
higher β-catenin protein accumulation among other important events controlled by APC. 
Activation of the pathway by Wnt leads to inactivation of the destruction complex allowing 
buildup of β-catenin and its migration to the nucleus. In the nucleus, β-catenin binds to 
members of the TCF/LEF transcription factor family, thereby converting them from tran-
scriptional repressors into transcriptional activators.
Initial attempts to overexpress a constitutively active form of β-catenin in HSCs led to 
an increase in proliferation and repopulation capacity upon transplantation into lethally 
irradiated mice (Reya et al., 2003). However, later studies using conditional overexpression 
of a stabilized form of β-catenin led to a block in multilineage differentiation, and the 
exhaustion of long-term HSCs (Kirstetter et al., 2006; Scheller et al., 2006). This resulted in 
anemic mice and eventually led to lethality, i.e., the opposite effect when compared with 
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the improved transplantation setting reported earlier. These studies have created confu-
sion concerning the importance of Wnt in maintaining numbers and integrity of HSCs. 
Similarly, not all loss-of-function studies have produced clear phenotypes. The Mx-Cre sys-
tem has been used to drive deletion of β-catenin (Zhao et al., 2007) or both β-catenin and 
its homolog γ-catenin (Koch et al., 2008; Jeannet et al., 2008). However, no defects were 
reported in HSC function or cells within lymphoid tissues. Surprisingly, in vivo reporter 
assays revealed that the canonical Wnt signaling pathway was still active in HSCs despite 
the absence of both β- and γ-catenin (Jeannet et al., 2008). This could imply the existence 
of an alternative factor or generation of a hypomorphic allele permitting low levels of Wnt 
signaling that would negate hematopoietic defects. Heroic efforts to knock out the Porcn 
gene during hematopoiesis, which encodes an acyltransferase (porcupine) necessary for 
acylation of Wnts, enabling their secretion and binding to the frizzled receptors, have not 
resulted in hematopoietic defects; however, there also were no changes in Wnt signaling 
(Kabiri et al., 2015). The reasons for this are presently unknown, but incomplete dele-
tion or the lack of need for Wnt secretion have been suggested (Oostendorp, 2015). This 
demonstrates the high complexity and difficulty in generating bona fide null mutants for 
canonical Wnts in the hematopoietic system. Together with studies in which Wnt activity 
in HSCs was reported to be close to zero (Fleming et al., 2008; Luis et al., 2009; Zhao et 
al., 2007), these findings suggest that complete absence of Wnt signaling is detrimental to 
HSC function, but that up to a quarter of normal activity is sufficient for normal function. 
Our recent findings suggest that these very different results in both gain- of-function and 
loss-of-function studies can be largely explained by differences in levels of Wnt signaling 
achieved in different experimental circumstances. That is, when Wnt signaling is slightly 
enhanced over normal levels, HSCs show improved reconstitution capacity. However, 
when HSCs express high levels of Wnt signaling, they completely fail to reconstitute irradi-
ated recipient mice (Luis et al., 2011). Thus, different levels of activation of the pathway 
can account for the discrepancies in previous studies (Malhotra and Kincade, 2009).
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Results
Gene Expression Profiling and Correlation with Wnt Dosage
Previously, we have used a combination of two different hypomorphic alleles and a conditional 
deletion allele of the Apc gene resulting in a gradient of five distinct levels of Wnt signaling in 
vivo. In the Apc1572T and Apc1638N alleles, amino acid residues 1572 and 1638 have been 
targeted resulting in different levels and lengths of truncated Apc proteins, consequently 
leading to different levels of Wnt pathway activation. Deletion of Apc exon 15 within the 
Apc15lox allele was performed ex vivo by using a Cre-recombinase encoding retrovirus (Figure 
1A). LSK cells from wild-type (WT) mice (Apc+/+) transduced with the same viral construct 
were employed as controls for all experiments. Transduced cells were sorted and employed 
for gene expression profiling by Affymetrix genome-wide microarrays. In the current report, 
we focused on the differences between WT LSK cells, which efficiently reconstitute recipient 
mice, and the LSK cells with increased Wnt signaling activity (Apc1572T, Apc1638N, and the 
Apc15lox mutant alleles). Biological triplicates were used for each condition. As WT HSCs have 
low but detectable and slightly variable levels of Wnt signaling, and they form the basis for 
comparison of all other conditions, we used six replicates for WT HSCs.
Principal component analysis showed clear separation of the triplicate arrays per genotype 
corresponding to the different Wnt signaling levels (Figure 1B). Hierarchical clustering of 
the top 50 differentially expressed genes also revealed a clear separation of the different 
Wnt signaling clusters (Figure 1C).
Biological Processes Correlated with High Wnt Levels in HSC
Focusing on the most differentially expressed genes, a heat-map was constructed that 
clearly reveals the differences between WT and Apc15lox HSCs (Figure 2A). We used the gene 
expression data of all available probe sets across the 15 APC samples and applied Barnes-Hut 
t-distributed stochastic neighbor embedding (t-SNE) to map each individual gene or probe 
set into a 2D space. The 2D landscape illustrates genes/probe sets with similar behavior 
(Figure 2B). Genes that have highly correlated expression profiles will be located in close 
proximity in the map, whereas uncorrelated expression profiles should be far apart in the t-
SNE map. Genes that follow the increase in Wnt signaling cluster in a set of genes composed 
of known Wnt target genes, such as Axin2, Tcf7, and Lef1 (Figures 2C–2F). Genes that are 
anti-correlated with increased Wnt signaling can also be discerned and include Ccr9 and 
Cd3g (Figures 2G–2I).
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The differential gene expression as detected by microarray analysis was validated using 
digital Q-PCR (Figure S1A). Checking the biological processes involved in the differences 
between low and high Wnt signaling, we observed gene sets found in Wnt and Notch 
signaling but also differentiation into monocytes, myeloid cells, and B lymphocytes (Figure 
S1B). No differences were observed in apoptosis or cell-cycle-related genes. We confirmed 
these findings by specifically selecting published gene sets for these processes and check-
ing whether clustering with the published gene sets correlated with the Apc mutants. 
The differentially expressed genes we found were highly enriched in the B lymphoid and 
myeloid differentiation sig-natures but not for pro-apoptotic or anti-apoptotic genes 
(Figures S1B, S2, and S3).
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Previously, we have used a combination of two different
hypomorphic alleles and a conditional deletion allele of
the Apc gene resulting in a gradient of five distinct levels of
Wnt signaling in vivo. In the Apc1572T and Apc1638N al-
leles, amino acid residues 1572 and 1638 have been targeted
resulting in different levels and lengths of truncated Apc
proteins, consequently leading to different levels of Wnt
pathway activation. Deletion of Apc exon 15 within the
Apc15lox allele was performed ex vivo by using a Cre-
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from wild-type (WT) mice (Apc+/+) transduced with the
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Figure 1. Definition of a High Wnt Stem
Cell Signature
(A) Experimental setup. LSK cells from various
APC mutant mice were sorted from bone
marrow, transduced with Cre-GFP retrovirus
and GFP-transduced cells were again sorted
and used for further experiments.
(B) Principal component analysis plots of
all 15 biological samples used in this study.
The percentage of variance captured by each
of the first three principal components is
indicated.
(C) Hierarchical clustering of the various APC
mutants and WT HSCs indicating the top 50
differentially expressed genes and changes
in gene expression.
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Figure 1. Definition of a High Wnt Stem Cell Signature. 
(A) Experimental setup. LSK cells from various APC mutant mice were sorted from bone marrow, transduced with 
Cre-GFP retrovirus and GFP-transduced cells were again sorted and used for further experiments. (B) Principal com-
ponent analysis plots of  all 15 biological samples used in this study. The percentage of  variance captured by each of  the 
first three principal components is indicated. (C) Hierarchical clustering of  the various APC mutants and WT HSCs 
indicating the top 50 differentially expressed genes and changes in gene expression.
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Apc Mutants Causing High Levels of Wnt Signaling Inhibit Proliferation but Do Not 
Change Apoptosis
Ming et al. (2012) reported that HSCs with high Wnt signals have increased apoptosis due to 
a high level of Wnt signaling and impaired self-renewal in HSCs. In their study, an activated 
form of β-catenin was used resulting in increased Wnt signaling in HSCs to the same level as 
the Apc1638N mutant used here. We therefore also used a constitutively active β-catenin 
conditional allele targeted the same way as the conditional 15lox APC -/- LSK cells to check 
the Axin2 levels as readout for the Wnt signaling dosage. The β-catenin (∆Ex3) allele (Ha-
rada et al., 1999) gave 21-fold higher Axin2 levels in LSK cells compared with WT LSK cells 
transduced with GFP-Cre, whereas the 1638N resulted in 23-fold and the Apc15lox ~50-fold 
higher Axin2 mRNA levels. Thus, the Axin2 levels and hence activation of the Wnt pathway 
experiments. Transduced cells were sorted and employed for
gene expression profiling by Affymetrix genome-wide mi-
croarrays. In thecurre t report,we focusedonthedifferences
between WT LSK cells, which efficiently reconstitute recip-
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activity (Apc1572T, Apc1638N, and the Apc15lox mutant al-
leles). Biological triplicates were used for each condition. As
WTHSCshave lowbut detectable and slightly variable levels
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Principal component analysis showed clear separation
of the triplicate arrays per genotype corresponding to the
differentWnt signaling levels (Figure 1B). Hierarchical clus-
tering of the top 50 differentially expressed genes also
revealed a clear separation of the different Wnt signaling
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Biological Processes Correlated with High Wnt Levels
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Focusing on them st differentially expressed genes, a heat-
mapwas constructed that clearly reveals the differences be-
tweenWTand Apc15lox HSCs (Figure 2A).We used the gene
expression data of all available probe sets across the 15 APC
samples and applied Barnes-Hut t-distributed stochastic
neighbor embedding (t-SNE) to map each individual gene
or probe set into a 2D space. The 2D landscape illustrates
genes/probe sets with similar beha ior (Figure 2B). Genes
that have highly correlated expression profiles will be
located in close proximity in the map, whereas uncorre-
lated expression profiles should be far apart in the t-SNE
map. Genes that follow the increase in Wnt signaling clus-
ter in a set of genes composed of known Wnt target genes,
such as Axin2, Tcf7, and Lef1 (Figures 2C–2F). Genes that
Figure 2. t-SNE Landscape of APC Mutants
(A and B) t-SNE maps of all probe sets. Red colored lines are differentially expressed genes, green are in cluster 15, yellow show both
binding (TCF1/TCF7 or b-catenin), and differential expression. Text labels are shown only for the latter.
(C and G) Cluster 2 and 1 identified in t-SNE.
(D–F, H, and I) Selected genes with their expression in the various Apc mutants.
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Figure 2. t-SNE Landscape of APC Mutants. 
(A and B) t-SNE maps of  all probe sets. Red colored lines are differentially expressed genes, green are in cluster 15, 
yellow show both binding (TCF1/TCF7 or β-catenin), and differential expression. Text labels are shown only for the 
latter. (C an  G) Cluster 2 and 1 identified in t-SNE. (D–F, H, and I) Selected genes with their expression in the 
various Apc mutants.
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were similar. However, our gene expression analysis did not show any significant differen-
tially expressed genes associated with apoptosis. In order to study the putative involvement 
of apoptosis with a more functional approach, we performed two different apoptosis assays. 
First, we assessed apoptosis by annexin V/7-amino-actinomycin (7-AAD) staining of the ex 
vivo transduced LSK cells from Apc WT and Apc15lox/15lox (Figure 3A). At the beginning of cul-
ture, there was almost no apoptosis in both groups ( ~4% at day 0). After 3 days of culture, 
the percentage of annexin V+ apoptotic cells increased to ~16%. However, no difference was 
observed between the Apc WT and knockout (KO) groups. Next, we performed caspase-3 
staining in order to assess the apoptosis rate of ex vivo transduced LSK cells (Figure 3B). 
Similar to previous assays, there was hardly any caspase-3 positivity at the beginning of 
the culture, while it was elevated after 3 days of culture. However, again no difference was 
observed between the two groups. Subsequently, we analyzed the proliferation status of 
the transduced LSK cells by labeling the cells with proliferation dye EF670 (Figure 3C). While 
cells did not proliferate at the beginning of culture (filled gray histogram), Apc WT LSK cells 
proliferated around 4-fold more than Apc KO LSK cells. Therefore, although a high level of 
Wnt signaling does not affect apoptosis, it decreases proliferation of LSK cells after 3 days 
of culture.
High Wnt HSCs Show Enhanced Myeloid and B Lymphoid Differentiation Capacity
Our gene expression analysis revealed that LSK cells with high levels of Wnt induce upregula-
tion of B and myeloid-associated genes (Figure S2). In order to confirm this observation 
functionally, we performed in vitro B and myeloid differentiation assays using the OP9 
stromal cell line (Figure 4). LSK cells were sorted, transduced with the Cre-GFP retrovirus, 
and cultured for 14 days on OP9 cells. Apc lox15 LSK cells developed to granulocytes (CD11b+ 
Gr1+) with around 2-fold higher frequency, and developed to B cell line-age (B220+ CD19+) 
with around 2.5-fold higher frequency compared with WT LSK cells. Thus, we confirmed 
by functional assays that Apc mutations leading to a high level of Wnt signaling enhance 
differentiation toward B and myeloid lineages.
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show, both at the genetic level and in functional assays,
increased differentiation, diminished proliferation, and
no effects on apoptosis. The much stronger differentiation
toward mature blood linages coupled with loss of HSC pro-
liferation (see also Figure S4) is expected to lead to lower
reconstitution by HSCs. Collectively, these data explain
the lack of maintaining bona fide stemness in Apc exon
15 deleted HSCs. Thus, instead of increased apoptosis of
HSCs, here we offer another explanation for the loss of
reconstitution capacity induced by high Wnt levels.
An alternative interpretation of our data is that the
observed consequences of Apc mutant alleles are not Wnt
but rather APC dependent. Apc encodes for a multifunc-
tional protein involved in a broad spectrum of cellular
functions (Gaspar and Fodde, 2004). To date, most Apc
mutant mouse models are characterized by tumor pheno-
types that depend completely on Wnt dosage. Apc1638T,
the only targeted Apc mutation that does not affect Wnt
signaling at all, results in homozygous viable and tumor-
free animals, notwithstanding the deletion of the C-termi-
nal third of the protein containing many functional
domains (Smits et al., 1999, 2000). Deletion of only a few
amino acids encompassing crucial Axin-binding motifs
results in Wnt signaling activation, tumor formation, and
lack of reconstitution by HSCs, as we have shown before
(Luis et al., 2011). Finally, mutations affecting other mem-
bers of the Wnt pathway, such as Gsk3b and b-catenin,
result in levels of signaling activation and hematopoietic
defects that are fully in agreement with our results (Goes-
sling et al., 2009; Huang et al., 2009, 2012; Lane et al.,
2010). Therefore, the most likely explanation is that spe-
cific levels of Wnt signaling are the major determinant of
the observed differential effects on hematopoiesis. In addi-
tion, recent studies using recombinantWnt3a also showed
a dose-dependent effect on HSC biology (Famili et al.,
2015) where high Wnt3a leads to loss of human HSC pro-
liferation in vitro (Duinhouwer et al., 2015), underscoring
the differential effects we also have observed with the
different Apc alleles and correlating exactly with the Wnt
dosages caused by these mutations.
Figure 3. High Levels of Wnt Signaling
Do Not Affect Apoptosis
(A and B) Sorted BM LSK from Apc WT and
15lox/15lox were transduced with Cre virus
and cultured for 2 days to fulfill Cre recom-
bination activity. After culturing for 2 days
(day 0) and 5 days (day 3), cells were har-
vested and stained with annexin V/7-AAD
(left graph) or active caspase-3 (right
graph). Error bars represent the SD of three
replicates of one independent experiment.
(C) Sorted BM LSK from Apc WT and 15lox/
15lox were transduced with Cre virus,
cultured for 2 days and labeled with 5 mM
proliferation dye EF670orwithDMSO. The left
plot depicts representative histogram plots
and the right graphs show the percentage of
non-proliferative cells (A), proliferative cells
(B), and ratio of A/B. Error bars represent the
SD of three samples from individual mice in
one independent experiment. Two indepen-
dent experiments were done with similar
outcome. *p < 0.05 and **p < 0.01 (Mann-
Whitney U test).
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Figure 3. High Levels of Wnt Signaling Do Not Affect Apoptosis. 
(A and B) Sorted BM LSK from Apc WT and 15lox/15lox were transduced with Cre virus and cultured for 2 days 
to fulfill Cre recombination activity. After culturing for 2 days (day 0) and 5 days (day 3), cells were harvested and 
stained with annexin V/7-AAD (left graph) or active caspase-3 (right graph). Error bars represent the SD of  three 
replicates of  one independent experiment. (C) Sorted BM LSK from Apc WT and 15lox/ 15lox were transduced with 
Cre virus, cultured for 2 days and labeled with 5 mM proliferation dye EF670 or with DMSO. The left plot depicts 
representative histogram plots and the right graphs show the percentage of  non-proliferative cells (A), proliferative cells 
(B), and ratio of  A/B. Error bars represent the SD of  three samples from individual mice in one independent experi-
ment. Two independent experiments were done with similar outcome. *p < 0.05 and **p < 0.01 (Mann-Whitney U 
test).
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The finding that the Apc 15lox mutant leading to high
Wnt signaling levels is associated with increased numbers
of differentiated cells is not unprecedented. In the intes-
tine, Wnt signaling induces maturation of Paneth cells
that contain active b-catenin and Tcf4 (van Es et al.,
2005), confirming that highWnt signaling levels can drive
differentiation processes.
Other investigators have used a different system to in-
crease Wnt signals in HSCs, namely overexpression of an
oncogenic, constitutively active form of b-catenin (Ming
et al., 2012). They showed an increase in apoptosis using
annexin V/propidium iodide staining from 10% in WT
LSK cells to 35% in high Wnt LSK cells. The reasons for
the differences with our results could be due to differences
in the systems used, although both are expected to lead to
highWnt signaling levels. Possibly activated b-catenin also
negatively affects cell adhesion and homing properties
thereby decreasing exposure to important survival signals
leading to increased apoptosis. It is also noteworthy that
enhanced survival signals are needed to have HSCs survive
in the oncogenic b-catenin system. In addition, Li et al.
(2013) have shown that Apc regulates the function of
HSCs largely through b-catenin-dependent mechanisms,
thus demonstrating that, in both systems, canonical Wnt
signaling is the major factor.
Whatever the exact mechanism, it is clear that Wnt
signaling levels need to be strictly controlled. It is well
possible that somewhat higher Wnt levels, which are detri-
mental to stemness, can be tolerated if HSC survival is
enhanced, which then would lead to better self-renewal at
this somewhat higher Wnt signaling dose. For instance
PI3K/Akt signaling (Perry et al., 2011), as well as expression
of Bcl2 (Reya et al., 2003) can provide such signals. Appar-
ently, high Wnt signaling levels can be tolerated in HSC in
combination with activation of other survival pathways.
Intriguingly, thehighWnt levels in combinationwithonco-
gene activation in acute myeloid leukemia seem to allow
the Wnt pathway to function as a self-renewal factor for
leukemic stem cells (Wang et al., 2010), whereas high Wnt
levels cannot do so in normal HSCs. The different localiza-
tion of normal versus malignant HSCs in the bone marrow
niche (Lane et al., 2011)may also contribute to this differen-
tial outcomeofhighWntdosage andopensup a therapeutic
window targeting leukemic but not normal stem cells.
EXPERIMENTAL PROCEDURES
Mice
Mice were bred and maintained in the animal facilities of Leiden
University Medical Center, in accordance with legal regulations
in the Netherlands and with the approval of the Dutch animal
ethical committee.
Microarray Analysis
In this study, we measured the genome-wide gene expression pro-
files in 21 APC C57Bl/6 mouse samples using Affymetrix mouse
430 2 microarrays for four different conditions; six APCWT, three
APC 15lox/1572T, three APC 15lox/1638N, and three APC 15lox/
15lox mice. 40,000–70,000 sorted LSK cells were stimulated over-
night in serum-free medium (STEMCELL Technologies) supple-
mented with cytokines and transduced by spinoculation with
MSCV-Cre-IRES-GFP. Subsequently, Cre-GFP-expressing LSK cells
were isolated using flow cytometric cell sorting and collected for
RNA expression. RNA of more than 10,000 cells was amplified
and processed using the Encore Biotin module and hybridized to
Affymetrix mouse 430 2.0 Genechip arrays. Differential expressed
geneswere determined using Limma, and geneswere considered to
be differentially expressed ifmRNA levels differ with p% 0.05 after
multiple test correction using Holm.
Figure 4. High Levels of Wnt Signaling
Enhances Multilineage Differentiation
Transduced LSK cells from Apc WT and 15lox/
15lox were co-cultured with OP9 stromal
cell line for 14 days, then were harvested,
and assessed by flow cytometry for myeloid
(CD11b and Gr1+) and B cell development
(B220 and CD19+). Error bars represent the SD
of six samples from individual mice from two
independent experiments. Asterisks indicate
statistical significance as follows: *p < 0.05,
and **p < 0.01 (Mann-Whitney U test).
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Figure 4. High Levels of Wnt Signaling Enhances Multilineage Differentiation. 
Transduced LSK cells from Apc WT and 15lox/ 15lox were co-cultured with OP9 stromal cell line for 14 days, 
then were harvested, and assessed by flow cytometry for myeloid (CD11b and Gr1+) and B cell development (B220 
and CD19+). Error bars represent the SD of  six samples from individual mice from two independent experiments. 
Asterisks indicate statistical significance as follows: *p < 0.05, and **p < 0.01 (Mann-Whitney U test).
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Discussion
The Wnt signaling pathway has emerged as the dominant self-renewal pathway for vari-
ous adult-type stem cells and is required for maintenance of embryonic as well as induced 
pluripotent stem cells. In the hematopoietic system, only mild increased Wnt dosages result 
in higher stem cell activity; indeed the overall Wnt signaling levels in HSC are much lower 
than those found in intestinal, skin, or mammary gland stem cells. Nevertheless, complete 
loss of Wnt signaling leads to defective self-renewal as shown in secondary transplantations. 
This had led to interest in the use of Wnt signaling or factors that modulate Wnt signaling, 
such as prostaglandin E2 (PGE2) (Goessling et al., 2009) or GSK-3b inhibitors (Huang et al., 
2012), for expansion of HSCs ex vivo.
We previously demonstrated that Wnt signaling functions in a strictly controlled dosage-
dependent fashion (Luis et al., 2011). As also shown by several other laboratories (Kirstet-
ter et al., 2006; Ming et al., 2012) (Scheller et al., 2006), high Wnt levels in HSCs eventually 
lead to stem cell exhaustion and lack of reconstitution of irradiated recipients. In the cur-
rent study, we used gene expression profiling to understand why Apc mutations that lead 
to high Wnt signaling (among other defects) in HSCs would lead to loss of repopulating 
capacity. Our results show, both at the genetic level and in functional assays, increased 
differentiation, diminished proliferation, and no effects on apoptosis. The much stronger 
differentiation toward mature blood lineages coupled with loss of HSC proliferation (see 
also Figure S4) is expected to lead to lower reconstitution by HSCs. Collectively, these data 
explain the lack of maintaining bona fide stemness in Apc exon 15 deleted HSCs. Thus, 
instead of increased apoptosis of HSCs, here we offer another explanation for the loss of 
reconstitution capacity induced by high Wnt levels.
An alternative interpretation of our data is that the observed consequences of Apc mutant 
alleles are not Wnt but rather APC dependent. Apc encodes for a multifunctional protein 
involved in a broad spectrum of cellular functions (Gaspar and Fodde, 2004). To date, 
most Apc mutant mouse models are characterized by tumor phenotypes that depend 
completely on Wnt dosage. Apc1638T, the only targeted Apc mutation that does not 
affect Wnt signaling at all, results in homozygous viable and tumor-free animals, notwith-
standing the deletion of the C-terminal third of the protein containing many functional 
domains (Smits et al., 1999, 2000). Deletion of only a few amino acids encompassing 
crucial Axin-binding motifs results in Wnt signaling activation, tumor formation, and lack 
of reconstitution by HSCs, as we have shown before (Luis et al., 2011). Finally, mutations 
affecting other members of the Wnt pathway, such as Gsk3β and β-catenin, result in levels 
of signaling activation and hematopoietic defects that are fully in agreement with our 
results (Goes-sling et al., 2009; Huang et al., 2009, 2012; Lane et al., 2010). Therefore, the 
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most likely explanation is that specific levels of Wnt signaling are the major determinant 
of the observed differential effects on hematopoiesis. In addition, recent studies using 
recombinant Wnt3a also showed a dose dependent effect on HSC biology (Famili et al., 
2015) where high Wnt3a leads to loss of human HSC proliferation in vitro (Duinhouwer et 
al., 2015), underscoring the differential effects we also have observed with the different 
Apc alleles and correlating exactly with the Wnt dosages caused by these mutations.
The finding that the Apc 15lox mutant leading to high Wnt signaling levels is associated 
with increased numbers of differentiated cells is not unprecedented. In the intestine, Wnt 
signaling induces maturation of Paneth cells that contain active β-catenin and Tcf4 (van Es 
et al., 2005), confirming that high Wnt signaling levels can drive differentiation processes.
Other investigators have used a different system to increase Wnt signals in HSCs, namely 
overexpression of an oncogenic, constitutively active form of β-catenin (Ming et al., 2012). 
They showed an increase in apoptosis using annexin V/propidium iodide staining from 
10% in WT LSK cells to 35% in high Wnt LSK cells. The reasons for the differences with 
our results could be due to differences in the systems used, although both are expected 
to lead to high Wnt signaling levels. Possibly activated β-catenin also negatively affects 
cell adhesion and homing properties thereby decreasing exposure to important survival 
signals leading to increased apoptosis. It is also noteworthy that enhanced survival signals 
are needed to have HSCs survive in the oncogenic β-catenin system. In addition, Li et al. 
(2013) have shown that Apc regulates the function of HSCs largely through β-catenin-
dependent mechanisms, thus demonstrating that, in both systems, canonical Wnt signal-
ing is the major factor.
Whatever the exact mechanism, it is clear that Wnt signaling levels need to be strictly 
controlled. It is well possible that somewhat higher Wnt levels, which are detrimental to 
stemness, can be tolerated if HSC survival is enhanced, which then would lead to better 
self-renewal at this somewhat higher Wnt signaling dose. For instance PI3K/Akt signaling 
(Perry et al., 2011), as well as expression of Bcl2 (Reya et al., 2003) can provide such 
signals. Apparently, high Wnt signaling levels can be tolerated in HSC in combination with 
activation of other survival pathways. Intriguingly, the high Wnt levels in combination with 
oncogene activation in acute myeloid leukemia seem to allow the Wnt pathway to func-
tion as a self-renewal factor for leukemic stem cells (Wang et al., 2010), whereas high Wnt 
levels cannot do so in normal HSCs. The different localization of normal versus malignant 
HSCs in the bone marrow niche (Lane et al., 2011) may also contribute to this differential 
outcome of high Wnt dosage and opens up a therapeutic window targeting leukemic but 
not normal stem cells.




Mice were bred and maintained in the animal facilities of Leiden University Medical Center, 
in accordance with legal regulations in the Netherlands and with the approval of the Dutch 
animal ethical committee.
Microarray Analysis
In this study, we measured the genome-wide gene expression profiles in 21 APC C57Bl/6 
mouse samples using Affymetrix mouse 430 2 microarrays for four different conditions; 
six APC WT, three APC 15lox/1572T, three APC 15lox/1638N, and three APC 15lox/ 15lox 
mice. 40,000–70,000 sorted LSK cells were stimulated over-night in serum-free medium 
(STEMCELL Technologies) supplemented with cytokines and transduced by spinoculation 
with MSCV-Cre-IRES-GFP. Subsequently, Cre-GFP-expressing LSK cells were isolated using 
flow cytometric cell sorting and collected for RNA expression. RNA of more than 10,000 cells 
was amplified and processed using the Encore Biotin module and hybridized to Affymetrix 
mouse 430 2.0 Genechip arrays. Differential expressed genes were determined using Limma, 
and genes were considered to be differentially expressed if mRNA levels differ with p < 0.05 
after multiple test correction using Holm. The dataset associated with this study has been 
deposited at GEO: GSE79495.
Flow Cytometry
Cells were stained in fluorescence-activated cell sorting buffer at 4 ̊ C, washed, and measured 
either on a Canto I or an Aria (BD Biosciences). Data were analyzed using FlowJo software 
(Tree Star).
Proliferation, Apoptosis, and Differentiation Assays
For apoptosis, cells were harvested after 2 days (day 0) or 5 days (day 3) of culture, and 
stained with either 7-AAD/annexin V (BD Bioscience), or phycoerythrin-active caspase-3 
apoptosis kit (BD Pharmingen). For the proliferation assay, cells were labeled with 5 mM 
Cell Proliferation Dye eFluor 670 (eBioscience) at day 0. Subsequently, cells were harvested 
at day 3 and were assessed for proliferation. For differentiation assays, LSK cells were trans-
duced at day 0 and transferred onto confluent monolayers of OP9 WT. After 14 days, cells 
were harvested and assessed by flow cytometry for B and myeloid lineage differentiation.
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Mouse bone marrow (BM) cells were isolated from femurs and tibiae, which were crushed in 
a mortar and filtered through 70 µm filters. The cells were stained using biotinylated lineage 
antibodies (MAC-1/CD11b, B220/CD45R, CD3e, CD4, NK1.1, Gr1, Ter119), Streptavidin PE, 
CD117 APC and Sca1 PECy7. LSK cells were isolated using a BD Aria II SORP cell sorter (Beck-
ton-Dickinson) and were collected in Stemspan (Stem Cell Technologies), supplemented 
with mFlt3L (50 ng/ml), rmSCF (100 ng/ml) and rmTPO (10 ng/ml, all cytokines purchased 
from R&D sytems. The cells were incubated for 16 hr at 37°C and 5% CO2. LSKs from Apc 
15 Lox heterozygous mice with mildly elevated Wnt levels were shown to perform better 
in reconstitution experiments but are not integral part of the current study, as only subtle 
changes in gene expression were found.
Retroviral Production and  Transduction
MSCV-Cre-IRES-GFP plasmid was kindly provided by H. Nakauchi (Institute of Medical Sci-
ence, University of Tokyo, Japan) and viruses were generated with the Phoenix-packaging cell 
line. 40,000–70,000 sorted LSKs were stimulated overnight in serum-free medium (StemCell 
Technologies) supplemented with cytokines (100 ng/ml rmSCF, 10 ng/ml rmTPO, and 50 ng/
ml rmFlt3L; from R&D) and transduced by spinoculation (800 x g, 2 hours, 32°C) with titrated 
amounts of virus with Retronectin (Takara Bio Inc.). Cells were cultured for 2 additional days. 
Subsequently, Cre-GFP expressing LSK cells were isolated using flow cytometry cell sorting 
and collected for RNA expression. For in vitro assays including apoptosis, proliferation and 
differentiation assays bulk of transduced and un-transduced cells were used.
RNA amplification
RNA was isolated from the sorted transduced cells using Qiagen RNEasy micro columns 
(Qiagen, Hilden, Germany). RNA of more than 10,000 cells were then amplified using the 
Ovation RNA amplification system v2(Nugen Inc., San Carlos, CA, USA), processed using 
the Encore Biotin module (Nugen) and hybridized to Affymetrix mouse 430 2.0 Genechip 
arrays. Data is available at the NCBI Gene Expression Omnibus (GEO), accession number 
GSE79495.
Gene expression normalization. Gene expression data was measured in two batches. Raw 
data is normalized per batch with Robust Multi-Array Average (RMA), and batch correc-
tion is applied using Combat. Intensity values were mean centered per probe set. Gene 
symbols are mapped using MM9. As a result of the normalization, probe-intensity values 
follow a normal distribution for which intensities higher than 0 are up-regulated, and 
intensities lower than 0 are down-regulated. Principal component analysis and pairwise 
66 CHAPTER 2
correlations across the 21 samples showed the expected results; wild-type and mutants, 
t1572, n1638, and Knock-Out samples are different from each other in the PCA-space and 
correlation map.
Gene expression analysis. Differential expressed genes for the APC samples are deter-
mined by using Limma, and genes are considered to be differential expressed between 
the two selected groups if mRNA levels differ with P<0.05 after multiple test correction 
using Holm.
ChIP-Seq normalization. In this study we used massively parallel sequenced DNA-frag-
ments bound by the transcription factors, TCF1, TCF7, and β-catenin. All the sequencing 
data is aligned using Burrows-Wheeler transformation (BWA), according MM9. We used 
several literature sources (Li et al., 2013a; Steinke et al., 2014; Zhang and Li, 2008; Zhang 
et al., 2000) (Wu et al., 2012).
ChIP-Seq analysis. Binding of transcription factors is determined by utilizing Hypergeo-
metric Analysis of Tilling arrays (HATSEQ). A binding event was called when fragments are 
enriched based on default parameter settings, i.e., FWER significance level < 0.05, and a 
bandwidth (fragment size) of 300bp. We mapped the significantly detected binding sites 
to RefSeq genes in UCSC mm9 database (genome.ucsc.edu). A gene was designated as the 
target gene if the peak was present within 5000bp upstream of the transcription start site 
or inside of the gene.
For TCF1 (in mature CD8 T cells, accession number GSM1258235), we detected 591 signifi-
cantly enriched regions (ranges between 104bp-1048bp, median: 233bp) by comparing it 
to control IgG using sorted post- select DP and CD4+8lo thymocytes1 (accession number 
GSM1258236). The detected regions could subsequently be mapped to 116 unique genes. 
For the two TCF1 experiments in murine thymocytes (GSM1285796 for TCF1-CAT and 
GSM1133644 for TCF1), we detected 732 (size ranges between 102bp- 2632bp, median: 
237bp), and 2600 (102bp-2632bp, median: 237bp) significant binding regions respectively 
after comparing to control TCF1-CAT-INPUT (GSM1285797) and TCF1-INPUT (GSM1133645) 
respectively. The detected regions could subsequently be mapped to respectively 131, and 
653 unique genes (Table S2). The third analyzed ChIP-Seq data set was the binding of TCF7 
(GSM773994). For TCF7 we detected 6395 significant binding regions (size ranges between 
103bp-5840bp, median: 341bp) by comparing it to one control (input DNA of TCF7). These 
regions are subsequently mapped to 2015 genes (Table S2). The fourth public data set that 
we analyzed were three Beta-Catenin experiments, two with biotinylation and one based 
on FLAG-tag technology. As a background four different controls are used per experiment 
(2 with Beta-Catenin biotin without GSK and two GSK input samples). This resulted in 
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respectively 990, 385, and 671 significant binding regions for Beta-Catenin-Biotin-rep1, 
Beta-Catenin-Biotin-rep2, and Beta-Catenin- Flag-rep1 and were mapped to 121, 49, and 
79 genes (Table S2). Binding sites have median size of 336bp, 385bp, and 320bp.
To test the validity of the detected binding regions of each experiment, we expected an 
overrepresentation of WNT-associated genes. To test this, we overlaid the mapped genes 
with known WNT-associated genes (n=1136) from the Molecular Signature Database 
(MSigDB, v4.0), and detected that all seven ChIP-seq experiment showed a significant 
enrichment for binding in close vicinity of WNT-associated genes (P<0.05, Table S1) based 
on the hypergeometric test. As an example, all seven experiments showed binding of in 
the transcriptional start site of Axin2 (Figure S4A), whereas TCF1, and Beta-Catenin experi-
ments showed also binding for Lef1 (Figure S4A).
Pathway Analysis. Pathway analysis is performed by utilizing the Molecular Signature 
Database (MSigDB, v4.0) for the detection of enriched curated gene sets (C2), motif gene 
sets (C3), computational gene sets (C4), GO gene sets (C5), oncogenic signatures (C6), 
and immunologic signatures (C7). Gene sets and signatures are considered statistically 
significant when the P-value, derived from the hypergeometric test, is less or equal than 
0.05 after correcting for multiple testing using Holm.
Mice
Mice were bred and maintained in the animal facilities of Leiden University Medical Center, 
in accordance with legal regulations in The Netherlands and with the approval of the Dutch 
animal ethical committee. C57Bl/6-CD45.1 (Ly5.1) and C57Bl/6-CD45.2 (Ly5.2) mice were 
obtained from the Jackson Laboratory. Mice carrying targeted mutations on Apc were previ-
ously described (Fodde et al., 1994; Robanus-Maandag et al., 2010; Smits et al., 1999) and 
continuously backcrossed to C57Bl/6 background.
Flow Cytometry
The following antibodies were obtained from BD Biosciences (San Diego, CA): anti CD11b-PE 
(M1/70), anti CD19-APC (ID3) and anti CD117 (2B6). For Lineage depletion these markers 
were used: CD3 (145-2C11), CD4 (L3T4), CD8 (53-6.7), CD11b (M1/70), Gr1 (RB6-8C5), B220 
(Ra3-6B2), Ter119 (Ly76) and Nk1.1 (PK136) biotin and subsequently were stained with 
streptavidin eFluor 450 (48-4317) from eBioscience. The following antibodies were also 
purchased from eBiosiences: B220 PE-Cy7 (RA3-6B2), Gr1 eFluor 450 (RB6- 8C5) and Sca1 
PE-Cy7 (D7). Cells were stained in Fluorescence activated cell sorter (FACS) buffer (PBS, 2% 
bovine serum albumin, 0.1% sodium azide) for 30 min at 4 °C. Ultimately, Cells were washed 
and measured either on a Canto I, or an Aria (BD Biosciences). Data were analyzed using 
FlowJo software (Tree Star, Ashland, OR, USA).
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Proliferation, apoptosis and differentiation assays
5 × 104 sorted BM LSKs from APC WT and APC 15lox/15lox mice were transduced with 
titrated amount of CRE viruses in stemspan with FTS cytokines as previously described. For 
apoptosis assay harvested cells after 2 days (Day 0) or 5 days (Day 3) of culture, cells were 
stained with either 7AAD/AnnexinV (BD Bioscience), or PE-Active caspase-3 apoptosis kit (BD 
pharmingen) according to the manufacturer’s instruction. For proliferation assay, cells were 
labelled with 5 uM Cell Proliferation Dye eFluor® 670 (eBioscience) at Day 0. Subsequently, 
cells were harvested at Day 3 and were assessed by flow cytometry for proliferation.
For differentiation assay 2 × 104 BM LSKs were used and transduced cells at Day 0 were 
transferred onto confluent monolayers of OP9 WT and cocultured for additional 14 days 
with AlphaMEM 10% FCS containing 50 ng/ml rmSCF, 10 ng/ml rmFlt3L and 10 ng/ml 
rmIL-7 (all cytokines from R&D). After 7 days cells were harvested and transferred onto 
new monolayer of OP9 cells, and half of the medium were replaced every 3-4 days. Finally, 
after 14 days of coculture cells were harvested and assessed by flow cytometry for B and 
myeloid lineage differentiation.
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Suppl. Fig 1a: Validation of  differential gene expression by Q-PCR. Sorted LSK cells were cultured and transduced 
with CRE-GFP as described in the supplemental experimental procedures. RNA was isolated and used for analysis by 
Q-PCR for the indicated Wnt target genes.
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Di eren a on signatures as determined by Boiers (Cell Stem Cell 2013) and Chambers (Cell Stem Cell 
2007). 
Stem cell signature, such as proposed by Ivanova (Science 2002), Forsberg (PLoS One 2010), Chambers 
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Di eren a on signatures as determined by Boiers (Cell Stem Cell 2013) and Chambers (Cell Stem Cell 
2007). 
Stem cell signature, such as proposed by Ivanova (Science 2002), Forsberg (PLoS One 2010), Chambers 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Suppl. Fig 3: No differences in apoptosis and cell cycle in high Wnt signature when compared to published gene sets.
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Table S1
Gene-set Pathway PBY<0.05 Genes
All Curated gene sets MATSUDA_NATURAL_KILLER_DIFFERENTIATION 6.58E-06 ANXA1,APCDD1,CCR9,CD160,CDC23,GPR34,IL2RB,MYO5A,NTRK3,PDCD1,PLAGL1,PRSS23,PTP
RF,PVR,SH3BGRL2,SYTL2,TCF7,TULP3,XCL1,ZC3H12C
All Curated gene sets PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP 0.0002209 ANTXR1,CD93,CLU,DCLK1,FN1,FSTL1,IL18,LAMC1,PLA2G4C,RAI14,TMEM163,TNS1
All Curated gene sets LIU_PROSTATE_CANCER_DN 0.0002209 BEND5,CHST2,CLU,CRISPLD2,EPAS1,GPR155,ITGA2,PHLDA1,PLAGL1,PRSS23,RHOJ,ROBO1,TF
CP2L1,TMEM35,TNS1,WIF1,ZCCHC14
All Curated gene sets ONDER_CDH1_TARGETS_2_DN 0.0002209 ALDH1A3,CD83,CDK5R1,EPAS1,FGD6,FST,GJB5,IGSF3,IL18,ITGA2,KLF5,PTPRF,ROBO1,TFCP2L1
,THBD,TNFRSF25,TPD52L1
All Curated gene sets DELYS_THYROID_CANCER_UP 0.0006965 ALDH1A3,ANXA1,CHST2,DPP4,ENTPD1,FN1,IGSF3,ITGA2,MED13,NRP2,NT5E,P4HA2,PRSS23,PT
PRF,S100A5,STX3
All Curated gene sets ST_WNT_BETA_CATENIN_PATHWAY 0.001009 APC,AXIN2,DKK2,FSTL1,NKD1,WIF1
All Curated gene sets SANA_TNF_SIGNALING_DN 0.001009 ANTXR1,ANXA1,CLU,EPAS1,GIMAP6,NT5E,PHLDA1,RHOJ
All Curated gene sets GOZGIT_ESR1_TARGETS_DN 0.001305 ABHD2,CLU,DCLK1,FETUB,GFRA1,GPC4,MB21D2,MYO5A,PPAP2A,PRSS23,RASGRP1,RNF144B,
SDK1,SH3BGRL2,SHROOM3,SIPA1L2,SYTL2,THBD,THSD4
All Curated gene sets CUI_TCF21_TARGETS_2_UP 0.001305 ANTXR1,APCDD1,ARSB,BMP4,BMPER,CLU,DCLK1,EMID1,FN1,GAS2L3,HUNK,KLF5,LYPD6B,NKD
1,NRP2
All Curated gene sets GAVIN_PDE3B_TARGETS 0.001305 ENTPD1,IL18,LAMC1,NT5E,SYTL2
All Curated gene sets NABA_MATRISOME 0.003449 ADAM22,ANXA1,BMP4,BMPER,CRISPLD2,ELFN1,EMID1,FN1,FREM2,FST,FSTL1,GPC4,IL18,ISM1,
KY,LAMC1,P4HA2,S100A5,SCUBE3,THSD4,WIF1,XCL1
All Curated gene sets KEGG_WNT_SIGNALING_PATHWAY 0.00359 APC,AXIN2,CAMK2D,DKK2,LEF1,NFATC2,NKD1,TCF7,WIF1
All Curated gene sets CERVERA_SDHB_TARGETS_1_UP 0.00359 CAND2,CCDC109B,FSTL1,IL18,LYPD6B,PACSIN1,PRSS23,TNFRSF19
All Curated gene sets KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN 0.005222 CAMK2D,DCLK1,DLC1,FAM63A,FN1,FSTL1,LAMC1,MB21D2,NT5E,PHLDA1,PRSS23,SIPA1L2
All Curated gene sets CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN 0.005292 ADA,ALDH1A3,ANTXR1,ANXA1,CD14,FST,FSTL1,IL18,IL7R,KLF5,LAMC1,NT5E,PHLDA1,ZC3H12C
All Curated gene sets RIGGI_EWING_SARCOMA_PROGENITOR_DN 0.007768 ABHD2,ALDH1A3,BACE1,BMP4,CLU,FST,NRP2,PHLDA1,TNFRSF19
All Curated gene sets SANSOM_WNT_PATHWAY_REQUIRE_MYC 0.008652 AXIN2,LEF1,NKD1,TCF7,TNFRSF19,WIF1
All Curated gene sets PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP 0.008714 ADA,ANTXR1,ENTPD1,IRF4,NUDT4,OSBPL1A,PHLDA1,PVR,SH3BGRL2,SHROOM3,TULP3
All Curated gene sets BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS 0.008714 AXIN2,CD14,CHST2,EFHD1,EXTL3,FAM63A,GFRA1,GPC4,IL2RB,KIF5C,LEF1,MYO5A,PDCD1,STX3
,SULT1A1,TEK,TFCP2L1,THBD,TULP3,XCL1
All Curated gene sets GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP 0.009692 ARHGAP28,ARSB,BMP4,BMPER,FST,GPC4,IL18,NT5E,TEK
All Curated gene sets GAVIN_FOXP3_TARGETS_CLUSTER_P4 0.01055 CCDC109B,CD83,EPAS1,IL2RB,LYPD6B,PLAGL1,SH3BGRL2
All Curated gene sets KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 0.01299 CCR2,CCR9,EDAR,IL17RB,IL18,IL2RB,IL7R,TNFRSF19,TNFRSF25,XCL1




All Curated gene sets CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1 0.01646 BMPER,CCDC101,CRISPLD2,DLC1,EFHD1,FREM2,GFRA1,ITGA2,MB21D2,MYO5A,PRSS23,SYTL2,
THSD4,TPD52L1
All Curated gene sets SMID_BREAST_CANCER_NORMAL_LIKE_UP 0.01763 CCR2,CD3G,CLU,DPP4,GIMAP6,IL7R,LEF1,NT5E,SNCAIP,THBD,TNFRSF25,WIF1,XCL1
All Curated gene sets SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_UP 0.01851 B4GALT5,CD14,CD93,CLU,EPAS1,PRSS23,THBD,TNS1
All Curated gene sets WALLACE_PROSTATE_CANCER_RACE_UP 0.01852 CCDC109B,CD83,CD93,CLU,DLC1,GIMAP6,IL7R,RASGRP1,THBD,TMEM35
All Curated gene sets QI_PLASMACYTOMA_UP 0.02286 CARD11,CCR2,CD3G,CLU,DPP4,IL17RB,IL18,IL2RB,TUBB3,XCL1
All Curated gene sets AMIT_EGF_RESPONSE_480_HELA 0.02337 ABHD2,DCLK1,FST,ITGA2,NUDT4,PTPRF,PVR,TUBB3
All Curated gene sets NABA_MATRISOME_ASSOCIATED 0.03018 ADAM22,ANXA1,BMP4,ELFN1,FREM2,FST,FSTL1,GPC4,IL18,ISM1,KY,P4HA2,S100A5,SCUBE3,WI
F1,XCL1
All Curated gene sets REACTOME_IMMUNE_SYSTEM 0.03141 BTLA,CAMK2D,CARD11,CCR2,CD14,CD160,CD3G,CDC23,IL18,IL2RB,IL7R,IRF4,OSBPL1A,PDCD1,
PVR,RAP1GAP2,RASGRP1,RNF144B
All Curated gene sets FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP 0.03141 ABHD2,CD93,CHST2,FN1,IL7R,IRF4,MB21D2,MYO5A,NRIP3,P4HA2,PHLDA1,RAI14,RASGRP1,THB
D
All Curated gene sets SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP 0.03313 ALDH1A3,ANXA1,BDH1,CLU,CRISPLD2,EDARADD,GPR155,NT5E,PPFIBP2,SULT1A1,TFCP2L1,TP
D52L1,WIF1
All Curated gene sets KIM_MYC_AMPLIFICATION_TARGETS_DN 0.03336 DCLK1,GAS2L3,IL17RB,KLF5,NFATC2,SHROOM3
All Curated gene sets LIM_MAMMARY_STEM_CELL_UP 0.04392 ANTXR1,EDARADD,EPAS1,FST,ISM1,LAMC1,NRP2,NT5E,PPAP2A,RHOJ,THSD1,TNS1,WIF1
All Curated gene sets KEGG_BASAL_CELL_CARCINOMA 0.04862 APC,AXIN2,BMP4,LEF1,TCF7
All Curated gene sets TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN 0.04862 ANTXR1,CD14,CLU,ENTPD1,EPAS1,GPR34,IL7R,TMEM163
All Curated gene sets LINDGREN_BLADDER_CANCER_CLUSTER_2B 0.0488 CRISPLD2,EFHD1,ENTPD1,IL7R,LEF1,MYO5A,NRP2,TBC1D8,TCF7,THBD,TNS1
All Curated gene sets NUYTTEN_EZH2_TARGETS_UP 0.0488 ANXA1,AXIN2,B4GALT5,BACE1,CCDC109B,CD83,FGD6,FN1,GPR155,NT5E,P4HA2,PLAGL1,PRRG
1,PTPRF,ROBO1,STX3,TCF7,THSD1,ZC3H12C
All Curated gene sets SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN 0.0488 ANTXR1,CD83,CHDH,DKK2,GAS2L3,HUNK,LYPD6B,NRP2,P4HA2,PRTG,RHOJ,SIPA1L2
Computational gene sets MODULE_46 2.83E-06
ADA,CCR2,CCR9,CD14,CD3G,CD83,CDK5R1,CLU,DPP4,ENTPD1,FN1,IL18,IL2RB,IL7R,P4HA2,PDC
D1,XCL1
Computational gene sets MODULE_75 2.83E-06
ADA,CCR2,CCR9,CD14,CD3G,CD83,CDK5R1,CLU,DPP4,FN1,IL18,IL2RB,IL7R,P4HA2,PDCD1,TEK,
XCL1




















Gene ontology (GO) RESPONSE_TO_EXTERNAL_STIMULUS 0.01613 AHSG,ANXA1,CCR2,CCR9,CHST2,ENTPD1,ITGA2,PGLYRP2,SHROOM3,THBD,XCL1
Gene ontology (GO) RECEPTOR_ACTIVITY 0.01613 CD14,CD160,CD3G,GFRA1,GPR114,IL2RB,IL7R,MED13,NRP2,PGLYRP2,PTPRF,PVR,ROBO1,TEK,
TNFRSF25
Hallmark gene sets HALLMARK_ESTROGEN_RESPONSE_EARLY 0.004103 ABHD2,DLC1,FAM63A,GFRA1,IL17RB,PRSS23,RASGRP1,THSD4,TPD52L1
Hallmark gene sets HALLMARK_INFLAMMATORY_RESPONSE 0.006397 CD14,CHST2,IL18,IL2RB,IL7R,PVR,RASGRP1,RNF144B
Hallmark gene sets HALLMARK_COAGULATION 0.006397 ANXA1,CLU,DPP4,FN1,ITGA2,PRSS23,THBD
Hallmark gene sets HALLMARK_IL2_STAT5_SIGNALING 0.006397 CD83,IL2RB,IRF4,NT5E,PHLDA1,PLAGL1,PPAP2A,SH3BGRL2
Hallmark gene sets HALLMARK_WNT_BETA_CATENIN_SIGNALING 0.01107 AXIN2,LEF1,NKD1,TCF7
Hallmark gene sets HALLMARK_COMPLEMENT 0.01636 ACTN2,CDK5R1,CLU,DPP4,FN1,KCNIP2,RASGRP1
Immunologic signatures GSE20366_EX_VIVO_VS_DEC205_CONVERSION_NAIVE_CD4_TCELL_UP 0.001054 ACTN2,CCR2,CD160,EPAS1,GPR114,GPR34,IL17RB,RASGRP1,THBD,XCL1,XKRX
Immunologic signatures GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN2_THYMOCYTE_DN 0.001054 ADA,AXIN2,CCDC109B,CD3G,DPP4,EDARADD,IL17RB,IL7R,PDCD1,PTPRF,TUBB3
Immunologic signatures GSE7852_TREG_VS_TCONV_LN_UP 0.001054 CCR2,CD83,ENTPD1,FGD6,IRF4,LAMC1,NT5E,PLAGL1,PPAP2A,ZC3H12C,ZDHHC23
Immunologic signatures GSE10325_LUPUS_CD4_TCELL_VS_LUPUS_BCELL_UP 0.003344 ANXA1,CCDC109B,CD3G,DPP4,GIMAP6,IL7R,LEF1,TCF7,TNFRSF25,ZCCHC14
Immunologic signatures GSE30962_PRIMARY_VS_SECONDARY_CHRONIC_LCMV_INF_CD8_TCELL_ 0.003344 AHSG,ANXA1,CD93,ENTPD1,EPAS1,GPR114,GPR34,PRKAA2,RASGRP1,TMEM163
Immunologic signatures GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN2_THYMOCYTE_ADULT_D0.003403 AXIN2,CCDC109B,CD3G,EDARADD,IL17RB,IL7R,LEF1,PPAP2A,PTPRF,SYTL2
Immunologic signatures GSE7460_TCONV_VS_TREG_LN_DN 0.004089 CD83,DPP4,ENTPD1,IL2RB,IRF4,NT5E,PPAP2A,SH3BGRL2,ZC3H12C,ZDHHC23
Immunologic signatures GSE20366_EX_VIVO_VS_DEC205_CONVERSION_NAIVE_CD4_TCELL_DN 0.0137 ANXA1,CCDC109B,CD83,DCLK1,IL18,PLAGL1,RNF144B,SNX31,STX3
Immunologic signatures GSE10325_CD4_TCELL_VS_BCELL_UP 0.01559 ANXA1,CCR2,CD3G,DPP4,GIMAP6,IL2RB,LEF1,RASGRP1,TNFRSF25
Immunologic signatures GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_DN 0.01559 ADA,CCDC109B,GFRA1,IL7R,LEF1,PDCD1,PTPRF,TUBB3,TULP3
Immunologic signatures GSE39820_CTRL_VS_IL1B_IL6_IL23A_CD4_TCELL_UP 0.01559 CD83,GAS2L3,GPR34,LYPD6B,PACSIN1,PHLDA1,PLAGL1,RASGRP1,SYTL2
Immunologic signatures GSE7460_TCONV_VS_TREG_THYMUS_DN 0.01559 CCDC109B,CD83,IGSF3,IL2RB,KIF5C,NRP2,PLAGL1,PPAP2A,SH3BGRL2
Immunologic signatures GSE7852_TREG_VS_TCONV_THYMUS_UP 0.01634 CCDC109B,CCR2,CD83,IGSF3,KIF5C,PDCD1,PLAGL1,PPAP2A,SH3BGRL2
Immunologic signatures GSE24142_DN2_VS_DN3_THYMOCYTE_DN 0.01649 CCR9,CD3G,GFRA1,IRF4,LEF1,PHLDA1,PTPRF,TBC1D8,TULP3
Immunologic signatures GSE3982_BCELL_VS_CENT_MEMORY_CD4_TCELL_DN 0.03801 DLC1,DPP4,IL7R,ITGA2,PHLDA1,PRKAA2,TCF7,TNS1
Immunologic signatures GSE3982_MEMORY_CD4_TCELL_VS_BCELL_UP 0.04586 ANXA1,CAND2,CD3G,DPP4,GIMAP6,IL2RB,KIF5C,PHLDA1












Motif gene sets V$TCF4_Q5 0.009151 ABHD2,FAM63A,FST,GPC4,KY,NKD1,NRP2,SYTL2,TCF7,TNFRSF19
Oncogenic signatures CAMP_UP.V1_DN 1.97E-05 ANXA1,BACE1,CAMK2D,CCR9,CD160,CD83,CHST2,FSTL1,IL7R,NFATC2,TUBB3,ZCCHC14
Oncogenic signatures MEL18_DN.V1_UP 0.03587 CD83,CHST2,CRISPLD2,IL7R,NRP2,NT5E,TEK
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Table S3
Gene-set Pathway PBY<0.05 Genes
WNT gene sets WNT_BOIERS_2013_LYMPHOID 0.01053 CCR9,LEF1,TCF7
All Curated gene sets ST_WNT_BETA_CATENIN_PATHWAY 0.0001483 APC,AXIN2,DKK2,FSTL1,NKD1,WIF1
All Curated gene sets RIGGI_EWING_SARCOMA_PROGENITOR_DN 0.0006029
ALDH1A3,BACE1,BMP4,CLU,EBF1,FST,NRP2,PHLDA1,TNFR
SF19
All Curated gene sets SANSOM_WNT_PATHWAY_REQUIRE_MYC 0.001274 AXIN2,LEF1,NKD1,TCF7,TNFRSF19,WIF1
All Curated gene sets LIU_PROSTATE_CANCER_DN 0.001855
BEND5,CHST2,CLU,EPAS1,ITGA2,NDNF,PHLDA1,PRSS23,R
OBO1,TFCP2L1,WIF1,ZCCHC14
All Curated gene sets MATSUDA_NATURAL_KILLER_DIFFERENTIATION 0.001855
ANXA1,APCDD1,CCR9,CD160,EBF1,NTRK3,PDCD1,PRSS23
,SH3BGRL2,TCF7,TULP3,ZC3H12C
All Curated gene sets KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN 0.001979
DCLK1,EBF1,FAM63A,FSTL1,IL17RD,MB21D2,NT5E,PHLDA1
,PRSS23,SIPA1L2
All Curated gene sets KUMAR_TARGETS_OF_MLL_AF9_FUSION 0.001979
ANXA1,CCR9,CD83,EBF1,EXTL3,GPC4,IL7R,IRF4,LEF1,TCF7
,TNFRSF19
All Curated gene sets CUI_TCF21_TARGETS_2_UP 0.003067
ANTXR1,APCDD1,ARSB,BMP4,CLU,DCLK1,HUNK,KLF5,LYP
D6B,NKD1,NRP2
All Curated gene sets CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN 0.003672
ADA,ALDH1A3,ANTXR1,ANXA1,FST,FSTL1,IL7R,KLF5,NT5E,
PHLDA1,ZC3H12C




All Curated gene sets DELYS_THYROID_CANCER_UP 0.003672
ALDH1A3,ANXA1,CHST2,DPP4,IGSF3,ITGA2,MED13,NRP2,N
T5E,PRSS23,STX3
All Curated gene sets ONDER_CDH1_TARGETS_2_DN 0.004116
ALDH1A3,CD83,EPAS1,FST,IGSF3,ITGA2,KLF5,ROBO1,TFC
P2L1,THBD,WWC1
All Curated gene sets SANA_TNF_SIGNALING_DN 0.004116 ANTXR1,ANXA1,CLU,EPAS1,NT5E,PHLDA1
All Curated gene sets KEGG_WNT_SIGNALING_PATHWAY 0.004871 APC,AXIN2,DKK2,LEF1,NKD1,TCF7,WIF1
All Curated gene sets KEGG_BASAL_CELL_CARCINOMA 0.005932 APC,AXIN2,BMP4,LEF1,TCF7
All Curated gene sets CUI_TCF21_TARGETS_2_DN 0.006368
ANXA1,ARHGAP28,BACE1,DKK2,DPP4,EBF1,EPAS1,MED13,
NT5E,PPAP2A,SH3BGRL2,SHROOM3,SNCAIP,THBD
All Curated gene sets BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS 0.01287
AXIN2,CHST2,EFHD1,EXTL3,FAM63A,GPC4,KIF5C,LEF1,PD
CD1,STX3,SULT1A1,TFCP2L1,THBD,TULP3
All Curated gene sets GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP 0.0141 ARHGAP28,ARSB,BMP4,FST,GPC4,IL17RD,NT5E
All Curated gene sets CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN 0.01879
ANTXR1,ANXA1,CHST2,FST,FSTL1,IL7R,NT5E,PHLDA1,RAI1
4,ZC3H12C
All Curated gene sets GOZGIT_ESR1_TARGETS_DN 0.03962
CLU,DCLK1,FETUB,GPC4,MB21D2,PPAP2A,PRSS23,RASGR
P1,SH3BGRL2,SHROOM3,SIPA1L2,THBD
All Curated gene sets ENK_UV_RESPONSE_EPIDERMIS_DN 0.04184
ANXA1,APC,CD83,ITGA2,PHLDA1,PPAP2A,PRSS23,RAI14,R
OBO1,THBD
All Curated gene sets WNT_SIGNALING 0.04194 APC,LEF1,NKD1,TCF7,WIF1
All Curated gene sets PID_PS1_PATHWAY 0.04605 APC,DKK2,NKD1,WIF1
All Curated gene sets SENESE_HDAC1_AND_HDAC2_TARGETS_UP 0.04605 DCLK1,DKK2,EXTL3,IL7R,NRIP3,PHLDA1,WWC1
All Curated gene sets KIM_MYC_AMPLIFICATION_TARGETS_DN 0.04605 DCLK1,IL17RB,IL17RD,KLF5,SHROOM3














Motif gene sets V$TCF4_Q5 0.005048 FAM63A,FST,GPC4,KY,NKD1,NRP2,TCF7,TNFRSF19




Motif gene sets TATTATA,MIR-374 0.01408
ARHGAP28,BACE1,CHST2,EDAR,MED13,RNF214,UST,ZCC
HC14
Motif gene sets TGCCAAR_V$NF1_Q6 0.01468
AHSG,AXIN2,DCLK1,KY,LEF1,MB21D2,MED13,NRP2,NTRK3,
RAI14,ROBO1,XKRX
Motif gene sets RTAAACA_V$FREAC2_01 0.02911
AXIN2,BMP4,FST,FSTL1,IRF4,KY,NTRK3,ROBO1,SNCAIP,TC
F7,TNFRSF19,UNC45B,UST
Oncogenic signatures CAMP_UP.V1_DN 5.78E-06
ANXA1,BACE1,CCR9,CD160,CD83,CHST2,FSTL1,IL7R,TUBB
3,ZCCHC14
Oncogenic signatures AKT_UP.V1_DN 0.04519 AXIN2,EDARADD,TNFRSF19,TULP3,WIF1,ZC3H12C
Immunologic signature GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN2_THYMOCYTE_DN 0.001121
ADA,AXIN2,CCDC109B,DPP4,EDARADD,IL17RB,IL7R,PDCD
1,TUBB3
Immunologic signature GSE20366_EX_VIVO_VS_DEC205_CONVERSION_NAIVE_CD4_TCELL_UP 0.007534
ACTN2,CD160,EPAS1,GPR114,IL17RB,RASGRP1,THBD,XKR
X
Immunologic signature GSE10325_LUPUS_CD4_TCELL_VS_LUPUS_BCELL_UP 0.01556 ANXA1,CCDC109B,DPP4,IL7R,LEF1,TCF7,ZCCHC14
Immunologic signature GSE14350_IL2RB_KO_VS_WT_TREG_DN 0.01556 CCDC109B,CD160,CD83,KY,NT5E,PDCD1,ZC3H12C
Immunologic signature GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_DN 0.01556 ADA,CCDC109B,IL7R,LEF1,PDCD1,TUBB3,TULP3
Immunologic signature GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN2_THYMOCYTE_ADULT_DN 0.01556 AXIN2,CCDC109B,EDARADD,IL17RB,IL7R,LEF1,PPAP2A
Immunologic signature GSE26495_NAIVE_VS_PD1HIGH_CD8_TCELL_UP 0.01556 BDH1,BEND5,EDAR,EFHD1,LEF1,NT5E,PPAP2A
Immunologic signature GSE26495_NAIVE_VS_PD1LOW_CD8_TCELL_UP 0.01556 BDH1,BEND5,EDAR,EFHD1,LEF1,NT5E,PPAP2A
Immunologic signature GSE30962_PRIMARY_VS_SECONDARY_CHRONIC_LCMV_INF_CD8_TCELL_DN 0.01556 AHSG,ANXA1,EPAS1,GPR114,PRKAA2,RASGRP1,TMEM163
Immunologic signature GSE3982_BCELL_VS_CENT_MEMORY_CD4_TCELL_DN 0.01556 DPP4,IL7R,ITGA2,NDNF,PHLDA1,PRKAA2,TCF7
Immunologic signature GSE7460_TCONV_VS_TREG_LN_DN 0.01556 CD83,DPP4,IRF4,NT5E,PPAP2A,SH3BGRL2,ZC3H12C
Immunologic signature GSE7460_TCONV_VS_TREG_THYMUS_DN 0.01556 CCDC109B,CD83,IGSF3,KIF5C,NRP2,PPAP2A,SH3BGRL2
Immunologic signature GSE7852_TREG_VS_TCONV_THYMUS_UP 0.01556 CCDC109B,CD83,IGSF3,KIF5C,PDCD1,PPAP2A,SH3BGRL2
Hallmark gene sets HALLMARK_WNT_BETA_CATENIN_SIGNALING 0.002609 AXIN2,LEF1,NKD1,TCF7
Hallmark gene sets HALLMARK_COAGULATION 0.002609 ANXA1,CLU,DPP4,ITGA2,PRSS23,THBD
Hallmark gene sets HALLMARK_IL2_STAT5_SIGNALING 0.007102 CD83,IRF4,NT5E,PHLDA1,PPAP2A,SH3BGRL2
Hallmark gene sets HALLMARK_KRAS_SIGNALING_DN 0.007102 CHST2,CPB1,EDAR,EFHD1,PDCD1,TFCP2L1
Hallmark gene sets HALLMARK_ESTROGEN_RESPONSE_EARLY 0.04111 FAM63A,IL17RB,PRSS23,RASGRP1,WWC1
Hallmark gene sets HALLMARK_COMPLEMENT 0.04111 ACTN2,CLU,DPP4,KCNIP2,RASGRP1
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Abstract
The development of blood and immune cells requires strict control by various signaling 
pathways in order to regulate self-renewal, differentiation and apoptosis in stem and pro-
genitor cells. Recent evidence indicates critical roles for the canonical and non-canonical 
Wnt pathways in hematopoiesis. The non-canonical Wnt pathway is important for establish-
ment of cell polarity and cell migration and regulates apoptosis in the thymus. We here 
investigate the role of the non-canonical Wnt receptor Ryk in hematopoiesis and lymphoid 
development. We show that there are dynamic changes in Ryk expression during develop-
ment and in different hematopoietic tissues. Functionally, Ryk regulates NK cell develop-
ment in a temporal fashion. Moreover, Ryk-deficient mice show diminished, but not absent 
self-renewal of hematopoietic stem cells (HSC), via effects on mildly increased proliferation 
and apoptosis. Thus, Ryk deficiency in HSCs from fetal liver reduces their quiescence, leading 
to proliferation-induced apoptosis and decreased self-renewal.
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Introduction
In the bone marrow, blood cells develop from a small pool of hematopoietic stem cells 
(HSC).1 This rare population of cells is located in a specific microenvironment, the niche, and 
endows HSCs with the capacity to self-renew and provides signals to further differentiate 
HSCs into all blood cell lineages.2 A wide variety of signaling pathways regulate the fate 
of HSCs; in addition to these cells undergoing self-renewal or differentiation, they can also 
remain quiescent or undergo programmed cell death. These signaling pathways include 
Wnt, Notch, Hedgehog, BMP/SMAD, and many hematopoietic cytokines (SCF, TPO, angio-
poietins).3, 4 Defects in these pathways are implicated in the development of bone marrow 
failure syndromes and hematologic malignancies.5
Various subpopulations that are the progeny of stem cells can migrate from BM to thy-
mus, where they develop into the T-cell lineage.6 During thymic development, immature 
thymocytes gradually lose their proliferative and multi-lineage potential, and initiate a 
T-cell developmental program, a process called T-cell commitment.7 Early stages of T-cell 
development are phenotypically characterized by the absence of mature T-cell markers 
CD4 and CD8. These stages are therefore collectively referred to as Double Negative (DN). 
In mice, DN stages are subdivided into four subpopulations termed DN1: CD44+ CD25−, 
DN2: CD44+ CD25+, DN3: CD44− CD25+, and DN4: CD44− CD25−. Afterwards, thymocytes 
develop to immature single positive stage defined as CD3− CD8+ to initiate T-cell recep-
tor (TCR) rearrangement. Thymocytes with functional TCRs develop into the next stage, 
double positive for CD4 and CD8, and subsequently differentiate into either mature single 
positive (SP) CD4 or CD8 T cells,8 which have different functional properties. CD4T cells 
provide help to other cells and CD8 T cells are cytotoxic.
In order to better understand processes that underlie the development of HSC into T 
cells, we and others have performed gene expression profiling of sorted subsets of HSCs, 
progenitor cell, and stages of T-cell differentiation.9, 10, 11, 12 We focused on the Wnt signal-
ing pathway, as it is required for both self-renewal of HSCs as well as for proper T-cell 
development in the thymus.
Wnt signaling pathways have historically been characterized as either canonical (Wnt/β-
catenin pathway) or non-canonical pathways.13, 14, 15, 16, 17 In the absence of canonical Wnt 
ligands and receptors, cytoplasmic levels of β-catenin are kept very low through the action 
of a protein complex (the so-called destruction complex) that actively targets β-catenin 
for degradation. Activation of the pathway by Wnt leads to inactivation of the destruction 
complex allowing buildup of the dephosphorylated form of β-catenin and its migration 
to the nucleus. In the nucleus, β-catenin binds to members of the TCF/LEF transcription 
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factor family, thereby converting them from transcriptional repressors into transcriptional 
activators. In the non-canonical pathways, that use Ca2+ signals or JNK kinases, there are 
no increases in β-catenin levels but cell polarity or motility, as well as regulation of apop-
tosis are the main biological effects.
We previously observed that Wnt ligands and receptors are very dynamically expressed in 
HSCs, progenitors, and thymocytes.18 One of these genes encodes the non-canonical Wnt 
receptor Ryk. The Ryk (related to receptor tyrosine kinase), Ror (RTK-like orphan receptor), 
and MuSK (muscle-specific kinase) families of RTKs, which all have unexpected links to Wnt 
signaling, probably use a unique activation mechanism.19 Ryk contains a Wnt-inhibitory 
factor-1 domain in its extracellular region and was hypothesized to function as a receptor 
(or co-receptor) for Wnts, but lacks endogenous PTK activity owing to mutations in the 
kinase domain.20 The first function of Ryk was uncovered in a screen for genes involved 
in Drosophila CNS axon pathfinding21 and as a gene required for learning and memory in 
flies. A further breakthrough in understanding Ryk function came from the finding that 
Ryk is a axon-repulsive receptor for the WNT5 protein.22 Most of the fly and mammalian 
Ryk studies to date have focused on its role in aspects of the developing or regenerating 
nervous system (reviewed in ref. 23), although the Ryks also have roles in other tissues. 
Ryk directly binds Wnt-1 and Wnt3a via its WIF domain and forms a ternary complex with 
Frizzled required for the induction neurite outgrowth in dorsal root ganglia explants.24 The 
intracellular domain of Ryk binds to disheveled, which is required for TCF activation in 
response to Wnt3a activation.
There is only a handful of studies focused on the role of Ryk in hematopoiesis and thymo-
poiesis. More than 20 years ago, expression analyses revealed that Ryk is regulated during 
hematopoietic development and stages of maturation.25 More recently, it was proposed 
that Wnt5a regulates HSC quiescence and hematopoietic repopulation through the Ryk 
receptor and that this process is mediated by suppression of reactive oxygen species.26 We 
recently showed that canonical and non-canonical Wnt signaling have vastly different and 
contrasting roles in hematopoiesis and thymopoiesis, in part, by regulating cell survival 
and apoptosis.27
None of the few previous studies on Ryk function in hematopoiesis employed genetic loss-
of-function models, hence we explored the role of RYK1 using mice, which have a targeted 
mutation in Ryk1 generated by knocking a lacZ allele into the coding region.28 We analyzed 
the role of Ryk in four different experimental setups; (a) ex vivo functional gene expres-
sion analyses in neonatal mice and embryos, (b) in vitro assays for T-cell development 
in presence of the prototypical canonical and non-canonical Wnt ligands, Wnt3a, and 
Wnt5a, respectively,27, 29 (c) primary in vivo murine bone marrow transplantation assays 
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(for blood cell reconstitution), and (d) secondary transplantation reconstitution assays to 
address self-renewal. Only subtle differences between the Ryk mutant and controls were 
observed in the first three assays. However, the secondary transplantation assay revealed 
that lack of Ryk results in lower stem cell repopulation indicating a role for Ryk in stem 
cell self-renewal. Our studies indicate that this is likely due to the fact that Ryk knock-out 




In order to assess gene expression patterns of Ryk in the murine hematopoietic systems, in 
particular during T-cell development, quantitative PCR was performed. First, we quantified 
Ryk expression in embryonic thymic lobes and fetal livers (FLs). Brain tissues were used as a 
positive control, as brain provides a rich source of Wnts and their receptors. The expression 
of Ryk was ~12-fold higher in FL, the site of hematopoiesis in the embryo, relative to the thy-
mic lobes (Figure 1a). We also quantified Ryk expression during T-cell developmental stages 
in the adult murine thymus. The overall level of Ryk expression was much lower in the adult 
thymus compared with the embryonic thymic lobes. Nevertheless, the highest level of Ryk 
expression was observed at the most immature stage of DNs, and declined as thymocytes 
developed further. Notably, SP CD4+ T cells had a relatively higher Ryk expression compared 
with the SP CD8+ T cells (Figure 1b).
Wnt receptor Ryk. The Ryk (related to receptor tyrosine
kinase), Ror (RTK-like orphan receptor), and MuSK (muscle-
specific kinase) families of RTKs, which all have unexpected
links to Wnt signaling, probably use a unique activation
mechanism.19 Ryk contains a Wnt-inhibitory factor-1 domain
in its extracellular region and was hypothesized to function as
a receptor (or co-receptor) for Wnts, but lacks endogenous
PTK activity owing to mutations in the kinase domain.20 The
first function of Ryk was uncovered in a screen for genes
involved in Drosophila CNS axon pathfinding21 and as a gene
required for learning and memory in flies. A further break-
through in understanding Ryk function came from the finding
that Ryk is a axon-repulsive receptor for the WNT5 protein.22
Most of the fly and mammalian Ryk studies to date have
focused on its role in aspects of the developing or regenerating
nervous system (revi wed in ref. 23), although the Ryks also
have roles in other tissues. Ryk directly binds Wnt-1 and
Wnt3a via its WIF domain and forms a ternary complex with
Frizzled required for the induction neurite outgrowth in dorsal
root ganglia explants.24 The intracellular domain of Ryk binds
to disheveled, which is required for TCFactivation in response
to Wnt3a activation.
There is only a handful of studies focused on th role of Ryk
in hematopoiesis and thymopoiesis. More than 20 years ago,
expression analyses revealed that Ryk is regulated during
hematopoietic development and stages of maturation.25 More
recently, it was proposed that Wnt5a regulates HSC quies-
cence and hematopoietic repopulation through the Ryk
receptor and that this process is mediated by suppression of
reactive oxyge species.26We recently showed that canonical
and non-canonical Wnt signaling have vastly different and
contrasting roles in hematopoiesis and thymopoiesis, in part,
by regulating cell survival and apoptosis.27
None of the few previous studies on Ryk function in
hematopoiesis employed genetic loss-of-function models,
hence we explored the role of RYK1 using mice, which
have a targeted mutation in Ryk1 generated by knocking a
lacZ allele into the coding region.28 We analyzed the role of
Ryk in four different experimental setups; (a) ex vivo functional
gene expression analyses in neonatal mice and embryos, (b)
in vitro assays for T-cell development in presence of the
prototypical canonical and non-canonical Wnt ligands, Wnt3a,
and Wnt5a, respectively,27,29 (c) primary in vivo murine
bone marrow transplantation assays (for blood cell reconstitu-
tion), and (d) secondary transplantation reconstitution
assays to address self-renewal. Only subtle differences
between the Ryk mutant and controls were observed in the
first three assays. However, the secondary transplantation
assay revealed that lack of Ryk results in lower stem cell
repopulation indicating a role for Ryk in stem cell self-renewal.
Our studies indicat that this is likely due to the f ct that Ryk
knock-out (KO) stem cells have diminished quiescence,
leading to proliferation-induced apoptosis and decreased
self-renewal.
Results
In order to assess gene expression patterns of Ryk in the
murine hematopoietic systems, in particular during T-cell
development, quantitative PCR was performed. First, we
quantified Ryk expression in embryonic thymic lobes and fetal
livers (FLs). Brain tissues were used as a positive control, as
brain provides a rich source of W ts and their receptors. The
expression of Ryk was ~ 12-fold higher in FL, the site of
hematopoiesis in the embryo, relative to the thymic lobes
(Figure 1a). We also quantified Ryk expression during T-cell








































































































Figure 1 Gene expression analysis of Ryk in the murine hematopoietic system. RTq-PCR analysis was performed to determine the level of Ryk expression normalized to
ABL-2 expression as a housekeeping gene. The level of Ryk expression assessed in the thymic lobes and fetal liver E14 embryos (a) and adult T-cell developmental subsets in the
thymus (b). Brain tissue was used as a positive control. Data are mean±S.D. of six mice. Flow cytometric analysis performed in E14 thymocytes (c) and T-cell developmental
subsets of neonates (d) in Ryk WT, Het, and KO mice. Data are mean±S.D. of three mice per group (e) Frequency of non-T-cell lineages in cultured thymic lobes in fetal thymic
organ cultures
Ryk in hematopoiesis
F Famili et al
2
Cell Death and Disease
Figure 1. Gene expression analysis of Ryk in the murine hematopoietic system.
RT q-PCR analysis was perfor ed to determine the level of  Ryk expression normalized to ABL-2 expression s a 
housekeeping gene. The level of  Ryk expression assessed in the thymic lobes and fetal liver E14 embryos (a) and adult 
T-c ll developmental subsets in the thymus (b). Brain tissue was used as a positive control. Data are mean ± S.D. of  
six mice. Flow cytometric analysis performed in E14 thymocytes (c) and T-cell developmental subsets of  neonates (d) in 
Ryk WT, Het, and KO mice. Data are mean ± S.D. of  three mice per group (e) Frequency of  non-T-cell lineages in 
cultured thymic lobes in fetal thymic organ cultures.
Because this spatially and developmentally regulated expression pattern suggested a po-
tential functional the role for Ryk in thymopoiesis, we assessed thymic T-cell development 
phenotypically in Ryk-deficient neonates. However, no differences were observed in the 
T-cell developmental stages when we compared Ryk WT with Ryk/+ and Ryk −/− thymi in 
neonates (Figure 1c). We also looked into the thymocyte subsets in E14 thymic lobes and 
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again no difference was detected among different Ryk genotypes (Figure 1d). Yet, when 
thymic lobes were cultured in vitro, an increase in NK cells was observed.
It is known that Ryk can act as a co-receptor to induce Wnt signaling.30 In fact, it has shown 
that Ryk can bind to both Wnt3a and Wnt5a, and trigger canonical and non-canonical Wnt 
signaling pathways, respectively.24, 30, 31 To investigate the effects of Wnt signaling together 
with Ryk during T-cell development, we performed an in vitro T-cell development assay 
using E14 FL cells as a source of HSCs. In order to support multi-lineage differentiation, we 
mixed OP9 WT with OP9 DL1 (which induces T-cell development) in a 1:1 ratio as a control, 
and compared that with OP9 Wnt5a/DL1 1:1 and OP9 Wnt3a/DL1 1:1. T-cell development 
was assessed phenotypically at Day 7 and Day 14 post co-culture of FL cells with OP9 
cells. No difference was observed between Ryk WT and Ryk KO FL cells (Figures 2a and b). 
We also examined NK cells, early B cells and myeloid cells but no significant phenotypic 
differences were detected between Ryk WT and Ryk KO FL cells in any of the conditions 
(data not shown).
developmental stages in the adult murine thymus. The overall
level of Ryk expression was much lower in the adult thymus
compared with the embryonic thymic lobes. Nevertheless,
the highest level of Ryk expression was observed at the
most immature stage of DNs, and declined as thymocytes
developed further. Notably, SP CD4+ T cells had a relatively
higher Ryk expression compared with the SP CD8+ T cells
(Figure 1b).
Because this spatially and developmentally regulated
expression pattern suggested a potential functional the role
for Ryk in thymopoiesis, we assessed thymic T-cell develop-
ment phenotypically in Ryk-deficient neonates. However, no
differences were observed in the T-cell developmental stages
when we compared Ryk WTwith Ryk/+ and Ryk − /− thymi in
neonates (Figure 1c). We also looked into the thymocyte
subsets in E14 thymic lobes and again no difference was
detected among different Ryk genotypes (Figure 1d). Yet,
when thymic lobes were cultured in vitro, an increase in NK
cells was observed.
It is known that Ryk can act as a co-receptor to induce Wnt
signaling.30 In fact, it has shown that Ryk can bind to both
Wnt3a and Wnt5a, and trigger canonical and non-canonical
Wnt signaling pathways, respectively.24,30,31 To investigate
the effects of Wnt signaling together with Ryk during T-cell
development, we performed an in vitro T-cell development
assay using E14 FL cells as a source of HSCs. In order to
support multi-lineage differentiation, we mixed OP9 WT with
OP9 DL1 (which induces T-cell development) in a 1:1 ratio
as a control, and compared that with OP9 Wnt5a/DL1 1:1 and
OP9 Wnt3a/DL1 1:1. T-cell development was assessed
phenotypically at Day 7 and Day 14 post co-culture of FL
cells with OP9 cells. No difference was observed between Ryk
WTandRyk KOFL cells (Figures 2a and b).We also examined
NK cells, early B cells and myeloid cells but no significant
phenotypic differences were detected between Ryk WT and
Ryk KO FL cells in any of the conditions (data not shown).
In order to investigate the effect of Ryk deficiency during
hematopoiesis and lymphopoiesis in vivo we performed
competitive murine reconstitution assays. In such assays,
the test and competitor population differ only in alleles of CD45
namely, CD45.1 (Ly5.1 historically) and CD45.2 (Ly5.2
historically). These two alleles are believed to be functionally
identical, but can be readily discriminated by antibodies and
allow for tracking of various cell populations and their progeny.
LSK cells sorted from E14 FL Ryk WTor Ryk KO that bear the
Ly5.2 congenic marker weremixed in a 1:1 ratio withWT LSKs
from Ly5.1 congenic background. Next, the mixture of cells
was transplanted into irradiated Ly5.1 recipients. A marked
increase in CD3− NK1.1+ peripheral NK cells was observed
in the recipients reconstituted by Ryk KO LSKs at week 7 post
transplantation (Figure 3a). To follow-up on these observa-
tions, we analyzed the recipients every week. However, the
phenotype was not observed at later time points (only at week
7 and 8 with a slight increase at week 9). At the end of the
experiment we thoroughly examined NK cell development
in the thymus, spleen and BM of the recipients and did not
observe any differences between Ryk WT and Ryk KO
recipients (Figure 3b). We also analyzed the stem cell
reconstitution and LSK compartments in the BM of recipients.
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Figure 2 Phenotypic analysis of Ryk KOT cells developed in vitro in presence of prototype Wnt3a and Wnt5a. E14 FL cells were obtained from Ryk WTand Ryk KO embryos
and were co-cultured with mixture of OP9WT/DL1, OP9 Wnt3A/DL1, and OP9 Wnt5A/DL1 1:1. Cells were harvested 7 days (a) and 14 days (b) after co-culture and were
analyzed flow cytometric for DN stages of T-cell development. The plots are pre-gated for Thy1+ and LIN− markers. The representative plots of two independent experiments are
shown. Three mice per experiment were used
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Figure.2 Phenotypic analysis of Ryk KOT cells developed in vitro in presence of prototype Wnt3a 
and Wnt5a. 
E14 FL cells were obtained from Ryk WT and Ryk KO embryos and were co-cultured with mixture of  OP9WT/
DL1, OP9 Wnt3A/DL1, and OP9 Wnt5A/DL1 1:1. Cells were harvested 7 days (a) and 14 days (b) after 
co-culture and were analyzed flow cytometric for DN stages of  T-cell development. The plots are pre-gated for Thy1+ 
and LIN− markers. The representative plots of  two independent experiments are shown. Three mice per experiment 
were used.
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In order to investigate the effect of Ryk deficiency during hematopoiesis and lymphopoiesis in 
vivo we performed competitive murine reconstitution assays. In such assays, the test and 
competitor population differ only in alleles of CD45 namely, CD45.1 (Ly5.1 historically) and 
CD45.2 (Ly5.2 historically). These two alleles are believed to be functionally identical, but 
can be readily discriminated by antibodies and allow for tracking of various cell populations 
and their progeny. LSK cells sorted from E14 FL Ryk WT or Ryk KO that bear the Ly5.2 con-
genic marker were mixed in a 1:1 ratio with WT LSKs from Ly5.1 congenic background. Next, 
the mixture of cells was transplanted into irradiated Ly5.1 recipients. A marked increase in 
CD3− NK1.1+ peripheral NK cells was observed in the recipients reconstituted by Ryk KO LSKs 
at week 7 post transplantation (Figure 3a). To follow-up on these observations, we analyzed 
the recipients every week. However, the phenotype was not observed at later time points 
(only at week 7 and 8 with a slight increase at week 9). At the end of the experiment we thor-
oughly examined NK cell development in the thymus, spleen and BM of the recipients and 
did not observe any differences between Ryk WT and Ryk KO recipients (Figure 3b). We also 
analyzed the stem cell reconstitution and LSK compartments in the BM of recipients. The 
Ly5.2 to Ly5.1 ratio of LSK (Figure 3c), LSK Flt3−, and LSK Flt3+ (Figure 3d) were not altered 
in the Ryk-deficient chimeric BMs. However, when thymic lobes were cultured in vitro, in a 
so-called fetal thymic organ culture, an increase in NK cells was observed consistent with the 
temporal increase in NK cells observed after transplantation. Hence, the mild phenotypic 
difference in NK cells may result from the mild block at DN stages, where NK cells in the 
thymus split off from the T-cell lineage.
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LSK Flt3+ (Figure 3d) were not altered in the Ryk-deficient
chimeric BMs. However, when thymic lobes were cultured
in vitro, in a so-called fetal thymic organ culture, an increase in
NK cells was observed consistent with the temporal increase
in NK cells observed after transplantation. Hence, the mild
phenotypic difference in NK cells may result from the mild
block at DN stages, where NK cells in the thymus split off from
the T-cell lineage.
Although, no significant alteration was observed owing to
Ryk deficiency at the level of stem cells in BM, there seemed to
be a trend of fewer stem cells in Ryk KO BMs (Figure 3d). As
we detected high levels of Ryk gene expression in FL cells and
most immature thymocytes, we hypothesized that Ryk might
be involved in stem cell repopulation or self-renewal of HSCs.
To further investigate this hypothesis, we performed second-
ary transplantation assay with chimeric BMs obtained from the
primary recipients. This assay is the gold standard for
investigating self-renewal properties of HSCs.32 Three out of
four mice reconstituted with Ryk KO primary chimeric BM
showed lower reconstitution of Ly5.2+ cells compared with the
recipients reconstituted with RykWT primary BMs (Figure 4a).
Further analysis revealed that lower reconstitution in Ryk KO
group was caused by fewer Ly5.2+ LSK cells relative to Ryk
WT group (Figure 4b). In contrast to the stem cell-mediated
phenotype, no significant differences were observed during
T-cell developmental stages in the thymus (Figure 4c).
To study the mechanisms underlying reduced stem cell
repopulation in the absence of Ryk, we performed apoptosis
and proliferation analyses. E14 FL cells were obtained from
RykWTand Ryk KO embryos, stained for LSK ex vivo, and the
apoptosis and proliferation status of the cells was analyzed by
flow cytometry. FL LSKs derived from Ryk KO embryos were
more apoptotic showed by higher percentage of AnnexinV
compared with the Ryk WT LSK cells (Figures 5a and c).
However, the percentage of AnnexinV+ 7AAD+ dead cells
were not altered in the Ryk KO LSK cells (Figures 5b and c). In
addition, proliferation analysis of FL LSKs using the Ki67
marker revealed that the percentage of proliferative LSK cells
is around twofold higher in Ryk KO FLs compared with the
controls. (Figure 5d). This was confirmed using cell cycle
analysis on FLs from Ryk KO and wt littermate controls
(Table 1) showing that wild-type cells are much more in G1
(resting) than Ryk-deficient stem/progenitor cells, where
almost twice as many cells are actively cycling indicating a
loss of quiescence. Thus, a combined increase in apoptosis
and proliferation explains the lower self-renewal of Ryk-
deficient LSK cells.
Discussion
In this study we used a full Ryk loss-of-function model for the
first time to investigate the role of this non-canonical Wnt
receptor during hematopoiesis and lymphopoiesis. The model
represents the null allele of Ryk generated by homologous
recombination in which 14.5 kb of genomic DNA including
exons encoding 495% of the Ryk extracellular domain and
the entire transmembrane domain are deleted.28,33 Our data
suggest that Ryk as a co-receptor has a marginal role in
hematopoiesis, possibly owing to a redundant role with other
tyrosine kinase receptors including Ror,34,35 or Wnt signaling
receptors such as FRZ 2,30,36 and or FRZ8 in combination with
Flamingo.37 During neurogenesis, Ryk’s function is vital,





































































































Figure 3 Peripheral NK cells analysis in recipient mice reconstituted by Ryk-deficient LSKs. Lin− Sca1+ Kit+ (LSK) cells were sorted from E14 FL Ryk WT and Ryk KO
embryos and were transplanted intravenously into the Ly5.1-irradiated recipients. Peripheral blood analysis performed at 7, 8, and 9 weeks post transplantation. (a) The ratio of
Ly5.2/Ly5.1 NK1.1+ CD3− cells in the recipient mice reconstituted with Ryk WTand Ryk KO LSKs is depicted. The recipients were killed 16 weeks after transplantation and the
thymus, spleen, and BM were analyzed for NK cells. (b) The ratio of Ly5.2/Ly5.1 of NK1.1+ CD3− cells is depicted. The Ly5.2/Ly5.1 ratio of LSK compartments in the BM of
recipient mice after 16 weeks of transplantation is shown (c and d). Data are mean±S.D. of five mice per group. *Po0.05 and **Po0.01
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Figur  3. Periphe al NK cells analysis in recipient mice reconstituted by Ryk-deficien  LSKs. 
Lin− Sca1+ Kit+ (LSK) cells were sorted from E14 FL Ryk WT and Ryk KO embryos and were transpl nted 
intravenously into the Ly5.1-irradiated recipients. Peripheral blood analysis performed at 7, 8, and 9 weeks post trans-
plantation. (a) The ratio of  Ly5.2/Ly5.1 NK1.1+ CD3− cells in the recipient mice reconstituted with Ryk WT and 
Ryk KO LSKs is depicted. The recipients were killed 16 weeks after transplantation and the thymus, spleen, and BM 
were analyzed for NK cells. (b) The ratio of  Ly5.2/Ly5.1 o  NK1.1+ CD3− cells is depicted. The Ly5.2/Ly5.1 
ratio of  LSK compartments in the BM of  recipient mice after 16 weeks of  transplantation is shown (c and d). Data 
are mean ±S.D. of  five mice per group. *P < 0.05 and **P < 0.01.
Although, no significant alteration was observed owing to Ryk deficiency at the level of stem 
cells in BM, there seemed to be a trend of fewer stem cells in Ryk KO BMs (Figure 3d). As 
we detec ed high levels of Ryk gene expression in FL cells and most immature thymocytes, 
we hypothesized that Ryk might be involved in stem cell repopulation or self-renewal of 
HSCs. To further investigate this hypothesis, we performed secondary transplantation assay 
with chimeric BMs btain  from the primary recipients. This assay is the gold standard for 
investigating self-renewal properties of HSCs.32 Three out of four mice reconstituted with 
Ryk KO primary chimeric BM showed lower reconstitution of Ly5.2+ cells compared with 
the recipients reconstituted with Ryk WT primary BMs (Figure 4a). Further analysis revealed 
that lower reconstitution in Ryk KO group was caused by fewer Ly5.2+ LSK cells relative to 
Ryk WT group (Figure 4b). In contrast to the stem cell-mediated phenotype, n  significant 
differences were observed during T-cell developmental stages in the thymus (Figure 4c).
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which is consistent with its high level of gene expression in
neural tissues.36 The importance of Ryk during embryogen-
esis is well studied.23 38 Indeed, we also observed that in
hematopoietic tissues the level of Ryk expression is higher in
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Figure 4 LSK and T-cell development analysis in secondary recipient. Primary BMs were obtained from the recipients reconstituted with Ryk WT and Ryk KO LSKs and
transplanted into the L5.1-irradiated secondary recipient. Twelve weeks after transplantation, the secondary recipients were killed and BM and thymus were analyzed by flow
cytometry. The ratio of Ly5.2/Ly5.1 (a) BM LSKs (b) and T-cell developmental subsets in the thymus (c) are depicted. Data are mean±S.D. of four mice per group. *Po0.05



















































Figure 5 Apoptosis and proliferation analysis of E14 FL LSKs ex vivo. The percentage of AnexinV+ apoptotic cells (a) and AnexinV+ 7AAD+ dead cells (b) of Ryk KO and Ryk
WT E14 FL LSKs are depicted. The representative plot of three mice per group is shown (c). The proliferation status of cells was assessed by Ki67 staining. The representative
plot of three mice per group is shown (d). Data are mean± S.D. of three mice per group. *Po0.05
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Figure 4. LSK and T-cell dev l pment analysis in secondary recipi nt.
Primary BMs were obtained from the recipients reconstituted with Ryk WT and Ryk KO LSKs and transplanted into 
the Ly5.1-irradiated secondary recipient. Twelve weeks after transplantation, the secondary recipients were killed and 
BM and thymus were analyzed by flow cytometry. The ratio of  Ly5.2/Ly5.1 (a) BM LSKs (b) and T-cell develop-
mental subsets in the thymus (c) are depicted. Data are mean ±S.D. of  four mice per group. *P<0.05.
To study the mechanisms underlying reduced stem cell repopulation in the absence of Ryk, 
we performed apoptosis and proliferation analyses. E14 FL cells were obtained from Ryk 
WT and Ryk KO embryos, stained for LSK ex vivo, and the apoptosis and proliferation status 
of the cells was analyzed by flow cytometry. FL LSKs derived from Ryk KO embryos were 
more apoptotic showed by higher percentage of AnnexinV compared with the Ryk WT LSK 
cells (Figures 5a and c). However, the percentage of AnnexinV+ 7AAD+ dead cells were not 
altered in the Ryk KO LSK cells (Figures 5b and c). In addition, proliferation analysis of FL 
LSKs using the Ki67 marker revealed that the percentage of proliferative LSK cells is around 
two fold higher in Ryk KO FLs compared with the controls. (Figure 5d). This was confirmed 
using cell cycle analysis on FLs from Ryk KO and WT littermate controls (Table 1) showing 
that wild-type cells are much more in G1 (resting) than Ryk-deficient stem/progenitor cells, 
where almost twice as many cells are actively cycling indicating a loss of quiescence. Thus, 
a combined increase in apoptosis and proliferation explains the lower self-renewal of Ryk-
deficient LSK cells.
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which is consistent with its high level of gene expression in
neural tissues.36 The importance of Ryk during embryogen-
esis is well studied.23 38 Indeed, we also observed that in
hematopoietic tissues the level of Ryk expression is higher in
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Figure 4 LSK and T-cell development analysis in secondary recipient. Primary BMs were obtained from the recipients reconstituted with Ryk WT and Ryk KO LSKs and
transplanted into the L5.1-irradiated secondary recipient. Twelve weeks after transplantation, the secondary recipients were killed and BM and thymus were analyzed by flow
cytometry. The ratio of Ly5.2/Ly5.1 (a) BM LSKs (b) and T-cell developmental subsets in the thymus (c) are depicted. Data are mean±S.D. of four mice per group. *Po0.05



















































Figure 5 Apoptosis and proliferation analysis of E14 FL LSKs ex vivo. The percentage of AnexinV+ apoptotic cells (a) and AnexinV+ 7AAD+ dead cells (b) of Ryk KO and Ryk
WT E14 FL LSKs are depicted. The representative plot of three mice per group is shown (c). The proliferation status of cells was assessed by Ki67 staining. The representative
plot of three mice per group is shown (d). Data are mean± S.D. of three mice per group. *Po0.05
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Figure 5. Apoptosis nd proliferation analysis of E14 FL LSKs ex vivo
The percentage of  AnexinV+ apoptotic cells (a) and AnexinV+ 7AAD+ dead cells (b) of  Ryk KO and Ryk WT 
E14 FL LSKs are depicted. The representative plot of  three mice per group is shown (c). The proliferation status of  
cells was assessed by Ki67 staining. The representative plot of  three mice per group is shown (d). Data are mean ±S.D. 
of  three mice per group. *P<0.05.
It has previously been shown that Ryk’s function, similar to
other receptors, is context and tissue dependent.23,34 Most
probably, this is determined by several factors, including
abundancy of specific triggers in various tissues, or the
expression of distinct co-receptors by neighboring cells. Ryk
can bind to both the Wnt3a canonical ligand,24 and Wnt5a
non-canonical ligand26 depending on the context and type of
tissue, suggesting that different experimental settings might
result in different outcomes. Our data do not support an
important specific role for Ryk during T-cell development as no
differences betweenmutant and control were observed in vitro
in presence of both the Wnt3a and Wnt5a ligands.
We showed that Ryk has a role in stem cell repopulation
when we performed secondary transplantations. Ryk KO stem
cells undergo more apoptosis and are more proliferative
compared with wild-type cells. Nemeth and co-workers have
proposed that Ryk, by binding Wnt5a, can suppress prolifera-
tion of LSK cells.25,39 In these studies on Ryk’s function in
hematopoiesis, anti-Ryk polyclonal antibodies that presum-
ably block the receptor have been employed.24,26 These
investigators showed that by adding polyclonal antibodies to
the Ryk receptor a modest decrease in cells in G0 (from 29 to
22%) was observed, which was interpreted as a loss-of-
function effect, in which blocking Ryk would increase
proliferation; this in line with our observation on genetically
deficient Ryk stem cells. However, polyclonal antibodies have
variable effects and could include both stimulating and
inhibitory antibodies. In addition, structural and functional
studies have shown high levels of redundancy between Ryk
and other members of tyrosine kinase receptors, in particular
the ROR non-canonical Wnt receptors, making the study of
each receptor specifically cumbersome.34 Given these struc-
tural similarities, it is even possible that an anti-Ryk polyclonal
antibody could cross react with other non-canonical receptors.
Thus, it is uncertain if all effects attributed to blocking Ryk,
could be assigned to Ryk, Ror or perhaps other receptors. A
clear loss-of-function model as we employed here allows a
more direct interpretation of the role of Ryk in hematopoiesis,
although molecular redundancy by the related Ror receptors
could also play a role here. The effects of treatment with
polyclonal Ryk antibodies on long-term hematopoietic recon-
stitution were similar to ours results, that is, lower reconstitu-
tion when Ryk’s function was lost. We have chosen to
use competitive transplantation, as this reduces mouse to
mouse variability and possible effects of an antibody treatment
on non-hematopoietic cells can be excluded, for instance on
niche cells that express Ryk. Using this system, we
here provide definitive proof for Ryk’s functional role in HSC
self-renewal via competitive secondary transplantation, the
gold standard assay to assess HSC self-renewal. Thus, Ryk
deficiency in HSCs reduces their quiescence, leading
to proliferation-induced apoptosis and decreased self-
renewal.
Our data also suggest that a timing–dependent role for Ryk
in hematopoietic tissues. We observed that peripheral NK
cells are temporary higher in initial assays of recipients
transplanted with Ryk KO FL cells compared with wild-type
group. One possible explanation is that Ryk is only important
in a certain stage of NK cell development, as a default pathway
during thymic T-cell development when TCR rearrangements
cannot successfully be accomplished and multipotent cells
choose a NK cell fate. As the cells pass that specific stage and
a critical number of T cells have been generated, the role of
Ryk would become less important.
Concluding, besides a developmental window of time for NK
lineage development, the effects of Ryk on thymopoiesis are
apparently limited. The combined increases in apoptosis and
loss of quiescence in HSCs, likely underlie the lower self-
renewal of Ryk-deficient LSK cells. The roles of canonical and
non-canonical Wnts and potential cross-talk between the
pathways, clearly require more research, particularly, as Wnts
are being employed in stem cell expansion protocols,40,41
including those employing designer nucleases for therapeutic
gene editing.42 Finally, increasing evidence indicates the
involvement of both canonical and non-canonical Wnts in
hematological malignancies (e.g., reviewed in ref. 13). As we
showed previously, the dosage of canonical Wnt signaling is
critical in determining the functional outcome on hematopoie-
tic cells43,44 and investigating Wnt proteins for HSC expansion
will require good in vivo reporter systems and well-
characterized reagents to take effects on apoptosis as well
as on cell proliferation into account. Collectively, such tools
would help capitalizing on the inherent power of the canonical
and non-canonical Wnt pathway to regulate apoptosis and
self-renewal of stem cells.
Materials and Methods
Mice. Mice were bred and maintained in the animal facilities of Leiden University
Medical Centre, in accordance with legal regulations in The Netherlands and with
the approval of the Dutch animal ethical committee. C57Bl/6-CD45.1 (Ly5.1) and
C57Bl/6-CD45.2 (Ly5.2) mice were obtained from the Jackson Laboratory, and Ryk
KO mice were kindly provided by Dr. S Stacker.28
Flow cytometry. The following antibodies were obtained from BD Biosciences
(San Diego, CA, USA): anti-CD3-APC (145-2C11), anti-cKit-Pe-Cy7 (2B8), and anti
CD11b-PE (M1/70). For Lineage depletion these markers were used: CD3
(145-2C11), CD4 (L3T4), CD8 (53-6.7), CD11b (M1/70), Gr1 (RB6-8C5), B220
(Ra3-6B2), Ter119 (Ly76) and Nk1.1 (PK136) biotin and subsequently were stained
with streptavidin eFluor 450 (48-4317) from eBioscience (Vienna, Austria). The
following antibodies were also purchased from eBioscience: Ly5.1-PE-Cy7 (A20),
Ly5.2 Alexa Fluor 780 (104), B220 PE-Cy7 (RA3-6B2), Gr1 eFluor 450 (RB6-8C5)
and Sca1 PE-Cy7 (D7). Cells were stained in fluorescence activated cell sorter
(FACS) buffer (PBS, 2% bovine serum albumin, 0.1% sodium azide) for 30 min at
4 °C. Ultimately, cells were washed and measured either on a Canto I, or an Aria
(BD Biosciences) FACS. For FL LSK, Mac1 was precluded from the lineage gate, as
FL LSK express Mac1.45 For apoptosis analysis, E14 FL cells were stained with
7AAD/AnnexinV kit (BD Bioscience) in combination with LSK staining. For
proliferation analysis E14 FL cells were stained with PE mouse anti-Ki67 set (BD
Pharmingen, San Diego, CA, USA) in combination with LSK staining or for cell cycle
analysis with an adapted protocol for combined LSK and propidium iodide
staining.46 Data were analyzed using FlowJo software (Tree Star, Ashland,
OR, USA).
Table 1 Cell cycle analysis of Ryk-deficient vs wild-type fetal liver stem/
progenitor cells
Genotype G1 (%) S (%) G2/M (%) Resting/cycling
wt 41 48 12 0.68
wt 39 48 15 0.62
Ryk− /− 23 56 20 0.30
Ryk− /− 22 60 14 0.29
Ryk in hematopoiesis
F Famili et al
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Discussion
In this study we used a full Ryk loss-of-function model for the first time to investigate the role 
of this non-canonical Wnt receptor during hematopoiesis and lymphopoiesis. The model 
represents the null allele of Ryk generated by homologous recombination in which 14.5 kb 
of genomic DNA including exons encoding >95% of the Ryk extracellular domain and the 
entire transmembrane domain are deleted.28, 33 Our data suggest that Ryk as a co-receptor 
has a marginal role in hematopoiesis, possibly owing to a redundant role with other tyro-
sine kinase receptors including Ror,34, 35 or Wnt signaling receptors such as FRZ 2,30, 36and or 
FRZ8 in combination with Flamingo.37 During neurogenesis, Ryk’s function is vital, which is 
consistent with its high level of gene expression in neural tissues.36 The importance of Ryk 
during embryogenesis is well studied.23 38 Indeed, we also observed that in hematopoietic 
tissues the level of Ryk expression is higher in FL or fetal thymic lobes compared with the 
adult tissues (Figure 1).
It has previously been shown that Ryk’s function, similar to other receptors, is context 
and tissue dependent.23, 34 Most probably, this is determined by several factors, including 
abundancy of specific triggers in various tissues, or the expression of distinct co-receptors 
by neighboring cells. Ryk can bind to both the Wnt3a canonical ligand,24 and Wnt5a non-
canonical ligand26 depending on the context and type of tissue, suggesting that different 
experimental settings might result in different outcomes. Our data do not support an im-
portant specific role for Ryk during T-cell development as no differences between mutant 
and control were observed in vitro in presence of both the Wnt3a and Wnt5a ligands.
We showed that Ryk has a role in stem cell repopulation when we performed secondary 
transplantations. Ryk KO stem cells undergo more apoptosis and are more proliferative 
compared with wild-type cells. Nemeth and co-workers have proposed that Ryk, by bind-
ing Wnt5a, can suppress proliferation of LSK cells.25, 39 In these studies on Ryk’s function 
in hematopoiesis, anti-Ryk polyclonal antibodies that presumably block the receptor have 
been employed.24, 26 These investigators showed that by adding polyclonal antibodies 
to the Ryk receptor a modest decrease in cells in G0 (from 29 to 22%) was observed, 
which was interpreted as a loss-of-function effect, in which blocking Ryk would increase 
proliferation; this in line with our observation on genetically deficient Ryk stem cells. 
However, polyclonal antibodies have variable effects and could include both stimulat-
ing and inhibitory antibodies. In addition, structural and functional studies have shown 
high levels of redundancy between Ryk and other members of tyrosine kinase receptors, 
in particular the ROR non-canonical Wnt receptors, making the study of each receptor 
specifically cumbersome.34 Given these structural similarities, it is even possible that an 
anti-Ryk polyclonal antibody could cross react with other non-canonical receptors. Thus, 
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it is uncertain if all effects attributed to blocking Ryk, could be assigned to Ryk, Ror or 
perhaps other receptors. A clear loss-of-function model as we employed here allows a 
more direct interpretation of the role of Ryk in hematopoiesis, although molecular redun-
dancy by the related Ror receptors could also play a role here. The effects of treatment 
with polyclonal Ryk antibodies on long-term hematopoietic reconstitution were similar to 
ours results, that is, lower reconstitution when Ryk’s function was lost. We have chosen to 
use competitive transplantation, as this reduces mouse to mouse variability and possible 
effects of an antibody treatment on non-hematopoietic cells can be excluded, for instance 
on niche cells that express Ryk. Using this system, we here provide definitive proof for 
Ryk’s functional role in HSC self-renewal via competitive secondary transplantation, the 
gold standard assay to assess HSC self-renewal. Thus, Ryk deficiency in HSCs reduces their 
quiescence, leading to proliferation-induced apoptosis and decreased self-renewal.
Our data also suggest that a timing–dependent role for Ryk in hematopoietic tissues. 
We observed that peripheral NK cells are temporary higher in initial assays of recipients 
transplanted with Ryk KO FL cells compared with wild-type group. One possible explana-
tion is that Ryk is only important in a certain stage of NK cell development, as a default 
pathway during thymic T-cell development when TCR rearrangements cannot successfully 
be accomplished and multipotent cells choose a NK cell fate. As the cells pass that specific 
stage and a critical number of T cells have been generated, the role of Ryk would become 
less important.
Concluding, besides a developmental window of time for NK lineage development, the ef-
fects of Ryk on thymopoiesis are apparently limited. The combined increases in apoptosis 
and loss of quiescence in HSCs, likely underlie the lower self-renewal of Ryk-deficient LSK 
cells. The roles of canonical and non-canonical Wnts and potential cross-talk between the 
pathways, clearly require more research, particularly, as Wnts are being employed in stem 
cell expansion protocols,40, 41 including those employing designer nucleases for therapeu-
tic gene editing.42 Finally, increasing evidence indicates the involvement of both canonical 
and non-canonical Wnts in hematological malignancies (e.g., reviewed in ref. 13). As we 
showed previously, the dosage of canonical Wnt signaling is critical in determining the 
functional outcome on hematopoietic cells43, 44 and investigating Wnt proteins for HSC 
expansion will require good in vivo reporter systems and well-characterized reagents to 
take effects on apoptosis as well as on cell proliferation into account. Collectively, such 
tools would help capitalizing on the inherent power of the canonical and non-canonical 




Mice were bred and maintained in the animal facilities of Leiden University Medical Centre, 
in accordance with legal regulations in The Netherlands and with the approval of the Dutch 
animal ethical committee. C57Bl/6-CD45.1 (Ly5.1) and C57Bl/6-CD45.2 (Ly5.2) mice were 
obtained from the Jackson Laboratory, and Ryk KO mice were kindly provided by Dr. Stacker.28
Flow cytometry
The following antibodies were obtained from BD Biosciences (San Diego, CA, USA): anti-CD3-
APC (145-2C11), anti-cKit-Pe-Cy7 (2B8), and anti CD11b-PE (M1/70). For Lineage depletion 
these markers were used: CD3 (145-2C11), CD4 (L3T4), CD8 (53-6.7), CD11b (M1/70), Gr1 
(RB6-8C5), B220 (Ra3-6B2), Ter119 (Ly76) and Nk1.1 (PK136) biotin and subsequently were 
stained with streptavidin eFluor 450 (48-4317) from eBioscience (Vienna, Austria). The fol-
lowing antibodies were also purchased from eBioscience: Ly5.1-PE-Cy7 (A20), Ly5.2 Alexa 
Fluor 780 (104), B220 PE-Cy7 (RA3-6B2), Gr1 eFluor 450 (RB6-8C5) and Sca1 PE-Cy7 (D7). 
Cells were stained in fluorescence activated cell sorter (FACS) buffer (PBS, 2% bovine serum 
albumin, 0.1% sodium azide) for 30 min at 4 °C. Ultimately, cells were washed and measured 
either on a Canto I, or an Aria (BD Biosciences) FACS. For FL LSK, Mac1 was precluded from 
the lineage gate, as FL LSK express Mac1.45 For apoptosis analysis, E14 FL cells were stained 
with 7AAD/AnnexinV kit (BD Bioscience) in combination with LSK staining. For proliferation 
analysis E14 FL cells were stained with PE mouse anti-Ki67 set (BD Pharmingen, San Diego, 
CA, USA) in combination with LSK staining or for cell cycle analysis with an adapted protocol 
for combined LSK and propidium iodide staining.46 Data were analyzed using FlowJo software 
(Tree Star, Ashland, OR, USA).
Co-culture of FL cells with OP9 cell lines and fetal thymic organ cultures (FTOC)
In total, 50 000 total FL cells were obtained from Ryk WT and Ryk KO mice and were co-
cultured on confluent layers of OP9 WT/DL1, OP9 Wnt3a/DL1, or OP9 Wnt5a/DL1 mixed in 
a 1:1 ratio as described previously27 with Alpha MEM 10% FCS containing 50 ng/ml rmSCF, 
10 ng/ml rmFlt3L and 10 ng/ml rmIL-7 (all cytokines from R&D Systems, Abinsdon, UK) in 
24-well plates. Cells were harvested after 7 and 14 days of co-culture and assessed for T-cell 
development by flow cytometric analysis. FTOC were done as described before47 using fetal 
thymic lobes from E14 embryos, which were genotyped for the status of the Ryk deficiency. 
Thymic lobes were cultured on a nitrocellulose filter on air/medium interphase for 7–14 
days, dispersed, and analyzed by flow cytometry.
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Ryk gene expression analysis
Total RNA was extracted using Qiagen RNeasy mini or micro columns. One mirogram of total 
RNA was used as a template for cDNA synthesis, using Superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA), Oligo dT, and random hexamer primers. The RT-PCR reaction 
was performed using TaqMan Universal Mastermix (Applied Biosystems, Foster City, CA, USA) 
and was run on a PRISM 7700 sequence detection system containing a 96-well thermal cycler 
(Applied Biosystems). The following primers were used in combination with FAM-labeled 
probes from the universal probe library (Roche, Almere, Netherlands): mouse Ryk forward 
primer: 5′-CAAGCTTCGAGGTCTGCAC-3′ reverse primer: 5′-ACCATGGGCTTTTCTCCTTC-3′. RQ-
PCR results were normalized to Abl expression in the same sample: forward primer: 5′-TG-
GAGATAACACTCTAAGCATAACTAAAGGT-3′ reverse primer: 5′-GATGTAGTTGCTTGGGACCCA-3′ 
and probe: 5′-FAM-CCATTTTTGGTTTGGGCTTCACACCATT- NFQ-3′.
Competitive transplantation assay
Primary transplantation assays were performed with the Ly5.1/Ly5.2 system. LSK cells were 
sorted from Ryk WT and Ryk KO (Ly5.2 background) and Ly5.1 WT FLs. In total, 2 × 103 Ryk WT 
or Ryk KO LSKS were mixed 1:1 with Ly5.1 WT LSKs, and were transplanted intravenously into 
lethally irradiated (8 Gy) Ly5.1 (9–12 weeks) mice together with 3 × 105 Ly5.1 splenic support 
cells. Chimeras were analyzed at 4, 8, and 12 weeks after transplantation in peripheral blood, 
and mice were killed for analysis at 16 weeks post transplantation except where otherwise 
indicated. Mice were considered repopulated when>1% multi-lineage Ly5.2 cells could be 
detected in nucleated peripheral blood cells 3 months after transplantation. For secondary 
transplantation, equal numbers of total BM cells from primary recipients that received Ryk 
WT or Ryk KO LSKs were pooled and transplanted into lethally irradiated Ly5.1 secondary 
recipients. Peripheral blood from secondary transplanted mice was analyzed at 4, 8, and 12 
weeks post transplantation. Thirteen weeks after transplantation mice were killed and BM, 
thymus, and spleen were analyzed.
Statistical analysis
Statistical analysis was performed using the Mann–Whitney U-test (Prism GraphPad Soft-
ware, San Diego, CA, USA). P<0.05 was considered statistically significant.
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Abstract
The mechanisms that regulate proliferation, fate decisions and differentiation of hematopoi-
etic stem cells (HSC) and thymic stem cells are highly complex. Several signaling pathways 
including Wnt signaling have important roles during these processes. Both canonical and 
non-canonical Wnt signaling are important in normal and malignant hematopoiesis and lym-
phoid development, yet their precise roles are controversial. In a side-by-side comparison, 
we investigated the roles of the canonical and non-canonical Wnt pathway in hematopoiesis 
and thymopoiesis. As complete loss-of-function models for non-canonical Wnt signaling 
are not yet available and highly complex for canonical Wnt signaling, we decided to use a 
gain-of-function approach. To this end, Wnt3a and Wn5a, two well-known prototypical ca-
nonical and non-canonical Wnt ligands were produced in hematopoiesis supporting stromal 
assays. High levels of Wnt3a signaling blocked T-cell development at early stages, whereas 
intermediate levels accelerated T-cell development. In contrast, Wnt5a signaling prompted 
apoptosis in developing thymocytes, without affecting differentiation at a particular stage. 
To explore the role of Wnt3a and Wnt5a in vivo, we transduced HSCs isolated from fetal 
liver, transduced with Wnt3a and Wnt5a vectors, and performed reconstitution assays in 
irradiated C57Bl/6 mice. Wnt3a overexpression led to increased lymphopoiesis, whereas 
Wnt5a augments myelopoiesis in the bone marrow (BM) and spleen. Thus, the canonical 
and non-canonical Wnt signaling have discrete roles in hematopoiesis and thymopoiesis, and 
understanding their right dose of action is crucial for prospective translational applications.
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Introduction
The development of blood and immune cells are highly complex and regulated processes. A 
wide variety of signaling pathways has been implicated in these processes. Several develop-
mental signals have key roles in both the bone marrow (BM) and thymus, such as BMP, Wnt 
and Notch signaling.1, 2 Hematopoietic stem cells (HSC) are rare BM-residing cells with the 
capacity to self-renew and differentiate into all blood cell lineages. All blood cells, except T 
lymphocytes, develop within the BM. Different types of progenitor cells migrate from BM to 
thymus where they develop to mature T cells.3, 4 The nature of these cells is still subject of 
debate. As only few early thymic progenitors (ETPs) arrive in the thymus (<10/day), massive 
proliferation is necessary to establish a pool of T-cell progenitors.5 During development, 
these immature thymocytes gradually lose their proliferative and multilineage potential, 
and initiate a T-cell developmental program, a process termed T-cell commitment. Notch 
signaling has been shown to have an important role during T-cell commitment by directly 
or indirectly upregulation of T-cell-specific genes including Ptcra, Cd3e and Zap 70.6, 7 Other 
soluble factors including Wnt ligands might also be crucial for T-cell proliferation and com-
mitment.8, 9, 10
Early stages of T-cell development are phenotypically characterized by absence of the ma-
ture T-cell markers CD4 and CD8 and referred to as double negative (DN).11 DN stages are 
subdivided into four stages. DN1: CD44+ CD25–, DN2: CD44+ CD25+, DN3: CD44− CD25+ 
and DN4: CD44– CD25–.8, 12 It is believed that T-cell commitment occurs at the transition 
of DN2 to DN3 stages.13, 14 Afterwards, thymocytes develop to the immature single positive 
(ISP) stage defined as CD3− CD8+. Thymocytes with functionally rearranged T-cell recep-
tors (TCRs) develop to next stage, which is double positive (DP) for CD4 and CD8 and finally 
they become mature single positives (SP)12 either CD4 or CD8.7, 8, 9
Thymic epithelial cells (TECs) provide a unique environment for ETPs to develop towards T 
cells.15, 16TECs also express high levels of Notch ligands including Delta like ligands 1 and 4, 
soluble Wnt ligands and IL-7, which all are crucial for early stages of T-cell development.17
The Wnt signaling pathway is subdivided into canonical (β-catenin dependent) and non-
canonical (β-catenin independent) pathways. Binding of different Wnt proteins to frizzled 
(Fzd) receptors can trigger different Wnt pathways. The diversity of ligands and receptors 
makes the study of Wnt signaling from point of view of cell surface receptors and ligands 
challenging. Wnt proteins function as proliferation-inducing growth factors but may also 
affect cell-fate decisions, apoptosis and quiescence.18 Canonical Wnt proteins bind to their 
receptors, thereby preventing proteosomal degradation of the Wnt-mediator β -catenin. 
Subsequently, β -catenin trans locates to the nucleus where it will form an active transcrip-
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tion complex with one of the four transcription factors downstream of the Wnt pathway: 
Tcf1, 3 or 4 (T-cell Factor 1, 3, 4) or Lef1 (lymphocyte-enhancer-binding factor). Upon 
transcriptional activation, several target genes will be activated including Axin2, c-fos, 
c-myc and many others, which are important for proliferation and/or cell-fate decisions. 
Non-canonical Wnt signaling involves recognition of distinct Wnt ligands by a cognate Frz-
LRP receptor complex, heterotrimeric G protein activation of phospholipase C as well as 
the release of intracellular Ca2+ ions. Non-canonical Wnt signaling also regulates cellular 
polarization and migration (the so-called planar-cell-polarity pathway).9, 10, 18, 19, 20, 21
A large body of evidence has shown the significance of canonical Wnt signaling during 
T-cell development. Generation of Tcf1 KO mice provided the first evidence of a Wnt 
signaling effect during T-cell development.22 Tcf1 deficiency partially blocks T-cell develop-
ment at various early DN stages, resulting in fewer mature T cells and smaller thymus. In 
addition, Tcf1/Lef double KO mice have a complete block at the ISP stage, which indicates 
redundancy between these factors during thymocyte development.23
Similar to Tcf1 deficiency, fetal thymic organ cultures using Wnt3a-deficient progenitors 
exhibited progressively impaired T-cell development caused to an ISP block.24 Several loss-
of-function and gain-of-function studies have targeted the core Wnt-mediator β-catenin 
in thymocytes. Conditional β-catenin deletion using Lck-Cre impaired β-selection of 
TCR,25 whereas β-catenin overexpression regulates positive selection and generation 
of SP CD4/ CD8.26 Inhibiting the interaction between β-catenin and Tcf1 also blocks the 
DN to DP transition.27 Wnt signaling is active at various stages of T-cell development but 
most predominantly at DN stages. Indeed, inhibiting Wnt signaling by using Dickkopf 
(DKK1) as Wnt sequestering molecule, blocks the development at the most immature 
DN1 stage.21 Finally, genetic proof that canonical Wnt signaling is crucial for normal T-cell 
development stems from complementation studies in which only the large form of Tcf1 
that can interact with β-catenin and transduce Wnt signals was capable to restore T-cell 
development, whereas the short form that lack the β-catenin domain could not.28
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On contrary, there are only a handful of studies focused on the role of non-canonical 
Wnt signaling in T-cell development. Liang et al.29 showed that Wnt5a deficiency protects 
against apoptosis in DP stage, but it was proposed to be irrelevant at early stages of 
T-cell development. Another series of studies revealed that Wnt4 induces expansion of 
Lin- Sca1+ Kit+ (LSKs) in BM, which subsequently causes ETP expansion in thymus.30 Wnt4 
regulates ETP expansion via a TEC-dependent mechanism.31 Whether Wnt4 functions as a 
canonical or non-canonical ligand is still debatable, in particular in gain-of-function studies 
in which thymopoiesis was increased. Perreault and colleagues showed that Wnt4 binds 
to Fzd6 and activates JNK kinase via PCP pathway,32 strongly suggesting that Wnt4 signals 
in a non-canonical fashion.
Loss-of-function approaches using β-catenin and γ-catenin have often not revealed thymic 
phenotypes,33most likely because Wnt signaling is still present at appreciably levels in 
these models.34 In addition, during T-cell development canonical and non-canonical Wnt 
signaling have only been studied in isolation but not together. Here, we aimed to side-
by-side compare the two prototypical canonical and non-canonical Wnt ligands, that is, 
Wnt3a (canonical) and Wnt5a (non-canonical).
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Results
OP9-based in vitro assays for T-cell development
To study the role of canonical and non-canonical Wnt signaling during T-cell development in 
vitro, we generated two diff erent OP9-based assays. First, we transduced OP9-WT cell line with 
Wnt3a and Wn5a constructs linked to an IRES-GFP cassett e, mixed the transduced cell lines 
with the OP9-Dl1 cell line in 1:1 rati o to support T-cell development (Figure 1a). Initi ally, we 
examined effi  ciency of the OP9 cell mixtures for support of T-cell development in comparison 
with OP9-Dl1 cell line alone. The aim of mixing Wnt3a- and Wnt5a-producing OP9 cells with 
OP9-DL11 was (a) supporti ng T-cell development in contrasti ng situati on of abundant Wnt3a 
vs Wnt5a (b) creati ng an culture system to study T and B lymphoid as well as myeloid develop-
ment simultaneously. Although there was a slight delay in T-cell development at 14–21 days, 
the mixture could also effi  ciently support T-cell development up to the DP stages, whereas 
OP9-WT did not induce T-cell development (See Supplementary Figure 1).
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Figure 1. Canonical Wnt3a overexpression blocks T-cell development at early stages. 
(a) Experimental design. OP9-WT cell lines were transduced with pRRL-SFFV-Wnt3a-GFP or pRRL-
SFFV-Wnt5a-GFP lentiviral constructs, selected by cell sorting on high GFP expression and for experiments mixed 
with OP9-Dl1-GFP. Stem cells from E14 fetal liver cells were co-cultured with OP9-WT/Dl1 mixed 1:1 as a 
control, or OP9-Wnt3a/Dl1 1:1, or OP9-Wnt5a/Dl1 1 : 1 for 14–21 days in aMEM 10% FCS in presence of  
IL-7, SCF and Flt3 L cytokines. (b) Experimental design. OP9-Dl1-GFP cell lines were transduced with pRRL-
SFFV-Wnt3a-tomato (DLW3A) or pRRL-SFFV-Wnt5a-Tomato (DLW5A) and selected by cell sorting on high 
GFP expression. Stem cells from E14 fetal liver cells were co-cultured with OP9-Dl1 as a control, OP9-DLW3A 
or OP9-DLW5A for 14 days in aMEM 10% FCS in presence of  same cytokines. (c) RTq-PCR analysis was 
performed to determine overexpression of  Wnt3a (left bar), Wnt5a (middle bar) and Dl1 gene (right bar) in transduced 
OP9 cell lines. The levels of  expression are normalized by ABL-2 expression and presented as fold induction relative 
to untransduced OP9 cell line. 
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Figure 1. Canonical Wnt3a overexpression blocks T-cell development at early stages. (continued)
(d) The overexpression of  Dl1 gene (gray bars), Wnt3a gene (white bars) and Wnt5a gene (black bars) in untransduced 
OP9DL1 cell line (left), OP9-DLW3A cell line (middle) and OP9-DLW5A (right) are shown. The levels of  expres-
sion are normalized by ABL-2 expression and presented as fold induction relative to untransduced OP9 cell line. (e) 
Total fetal liver cells were co-cultured with OP9-WT/DL1 : 1 as control (top row), OP9-Wnt5a/DL1:1 (middle row) 
or OP9-Wnt3a/DL1 : 1 (bottom row). Cells were harvested 4 days and 14 days after co-culture and were analyzed 
flow cytometric for DN stages of  T-cell development. The plots are pre-gated for Thy1+ and LIN- markers. Lineage 
markers include CD3e, CD4, CD8a, CD11b, Gr1, B220, NK1.1 and Ter119. The percentage of  each population 
is indicated. (f) Collective data of  total experiments from (e) are depicted. Total fetal liver cells are co-cultured with 
OP9-WT/DL1 : 1 as control (white bars) or with OP9-Wnt3a/DL11 : 1 (Black bars). Cells were harvested at day 
4 and day 14 of  co-culture and were assessed by FACS for DN stages of  T-cell development. The percentage of  each 
stage is shown within Thy1+ Lin– population. Data are mean ±S.D. of  nine control and eight Wnt3a samples from 
three independent experiments. *P<0.05; **P<0.01; ***P<0.001
We also generated another OP9-based assay in which we directly transduced OP9- Dl1-GFP 
cell line with Wnt3a and Wnt5a-tomato constructs, and assessed in vitro T-cell development 
(Figure 1b). We quantified relative expression of Wnt3a, Wnt5a and Dl1 using Q-PCR. Wnt3a 
had over 1000-fold higher expression compared with OP9-WT, whereas Wnt5a had ~500-
fold and Dl1 remained to be expressed at levels over 700-fold (Figure 1c). In OP9-DLWnt3a-
tomato (DLW3A) and OP9-DLWnt5a-tomato (DLW5A) Wnt3a and Wnt5a were expressed as 
high as in the OP9-Wnt3a-GFP and OP9-Wnt5a-GFP, respectively, and Dl1 expression was not 
altered compared with the OP9-Dl1-GFP (Figure 1d).
Canonical Wnt3a overexpression blocks T-cell development at early stages, thereby 
favoring development of alternative lineages
We cultured fetal liver cells (as these provide a good source of both T-cell progenitors 
and stem cells) either with the mixture of OP9-WT/Dl1 in 1:1 ratio as a control, or with 
OP9-Wnt3a/Dl1 or OP9-Wnt5a/Dl1 with the same ratio for 14 days. Wnt3a overexpression 
blocked T-cell development at the DN1 stage (Figures 1e and f).
The mixture of OP9-WT and OP9-Dl1 provides a means to study development of B, T, 
NK and myeloid lineages simultaneously.35 DN1 and DN2 immature thymocytes have the 
potential to develop towards other lineages. Consistently, in the Wnt3a-overexpressing 
cultures, non T cells, such as B and myeloid cells developed more efficiently compared 
with the control (Figures 2a and b). The difference was not only observed in proportion of 
each lineage, but also in the absolute numbers (Figure 2c).
Similar data were observed when Wnt3a and Wnt5a were expressed in the OP9-Dl1 cells 
themselves (supplementary Figure 2). Therefore, we conclude that canonical Wnt3a 
signaling has the capacity to inhibit T-cell development at early DN2-DN3 stages, and to 
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increase alternati ve (myeloid and B cell) development. Wnt5a overexpression in neither of 
assays did show any phenotypic diff erence regarding T-cell development (data not shown).
Figure 2. Wnt3a overexpression favors alternati ve lineages development.
(a) Total fetal liver cells were co-cultured with OP9-WT/DL1 : 1 (top row) or with OP9-Wnt3a/DL11 : 1 (bottom 
row). Cells were harvested after 14 days of  co-culture and were analyzed by FACS for B cells (B220 and CD19) and 
myeloid cells (CD11b and Gr1). The plots are pre-gated on CD45+ cells. Representative plots of  two independent 
experiments are shown. (b) Collective data of  all experiments are depicted. OP9-WT/DL (Ctrl) are depicted in white 
bars and OP9-Wn3a/Dl (Wnt3a) in black bars. The left bar graphs present percentage of  B cells (B220+ CD19+) 
within the CD45+ gate, and right bar graphs present percentage of  myeloid cells (CD11b+ Gr1+) within the CD45+ 
g ate. (c) Absolute number of  total CD45+ life cells after 14 days of  co-culture are depicted. Data are mean ±S.D. of  
six controls and fi ve Wnt3a samples from two independent experiments. *P<0.05; **P<0.01; ***P<0.001
Wnt5a overexpression results in increased apoptosis in developing thymocytes, 
whereas Wnt3a does not
Further analysis revealed that total percentage of lymphocytes was around fourfold lower 
in the Wnt3a-overexpressing group at various ti me points aft er co-culture (4, 7 and 14 days) 
(Figure 3a). This could be caused by increased apoptosis in the Wnt3a-expressing cultures. 
We performed apoptosis assays by using AnexinV and 7AAD in combinati on with the Thy1 
marker to separate T cells from non-T cells. In the Wnt3a-overexpressing cultures total 
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Thy1+thymocytes and specifi cally DN thymocytes were not undergoing any a signifi cant level 
of apoptosis (Figure 3a). There is an increase in apoptosis in non T cells, yet not to the extent 
that non T cells would decrease in numbers in comparison with thymocytes (see Figures 2b 
and c). Thus, we concluded that inhibiti on of diff erenti ati on toward T lineage due to Wnt3a 
overexpression causes low cellularity in this culture.
Figure 3. Wnt5a overexpression results in apoptosis in developing thymocytes.
(a) Total fetal liver cells were co-cultured with OP9-WT/DL1 : 1 (Ctrl) or with OP9-Wnt3a/DL1 : 1 (Wnt3a) or 
with OP Wnt5a/Dl1 (Wnt5a). In the left graph, the percentage of  total CD45+ life cells were assessed by FACS 
after 4 days, 7 days and 14 days of  co-culture. The averages are indicated by a dash. Each dot represents one mouse. 
In the right graph, the percentage of  AnexinV+ apoptotic cells is shown in specifi ed populations after 14 days of  co-
culture with OP9-WT/DL (white bars) or with OP9-Wnt3a/DL (black bars). Error bars represent mean±S.D. 
from two independent experiments (each in triplicates). (b) In the left graph, the absolute number of  life cells is shown 
after 14 days of  co-culture. Error bars represent mean±S.D. from two independent experiments (each in triplicates). 
In the right graph, the percentage of  AnexinV+ apoptotic cells is shown in specifi ed populations after 14 days of  co-
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culture with OP9-WT/DL (white bars) or with OP9-Wnt5a/DL (black bars). Error bars represent mean±S.D. 
from two independent experiments each in triplicates. (c) Percentage of  AnexinV+AAD7+ cells representing dead 
cells in the culture gated on tall thymocytes, DN thymocytes and non-T lineage cells in thymic cultures with Wnt3a or 
Wnt5a expressed in OP9-DL1 cells. *P<0.05; **P<0.01; ***P<0.001.
Although the Wnt5a-overexpressing cultures did not show any phenotypic differences 
compared with the controls, the absolute numbers were around three- to fivefold lower 
(Figure 3b). Lack of Wnt5a promotes Bcl-2 expression and inhibits apoptosis of DP thymo-
cytes.29 Our analysis showed that both Thy1+ and Thy1– co-cultured cells were undergoing 
more apoptosis. Thus, this gain-of-function approach showing more apoptosis is consistent 
with the loss-of-function Wnt5a experiments reported before. The effect of apoptosis in 
thymocytes (DN and Thy1+) by Wnt5a was much stronger than Wnt3a, which was similar to 
controls. Interestingly, for non T cells, similarly high apoptosis was found. The strong effects 
of Wnt5a on cell death are also reflected in the strong increase in 7AAD+AnnexinV+ DP cells 
(Figure 3c).
Optimal dosage of Wnt3a signaling accelerates T-cell development
Gene expression analysis revealed that Wnt3a was very highly expressed in our transduced 
OP9 cells (Figures 1c and d). This is 500-fold higher than the physiological level, for example, 
as found in fetal thymus,21 which we used as comparison. We have previously shown that 
canonical Wnt signaling functions in a dosage-dependent fashion during HSC reconstitution 
and T-cell development using Apc hypomorphic models.19 We hypothesized that the same 
would hold true with the Wnt3a gain-of-function model. We modified the Wnt3a concentra-
tion in the culture by serially mixing OP9-DL with OP9-DLW3a at various ratios.
After 14 days of co-culture, the majority of cells developed into DN3 and DN4 with 32% of 
DN4 thymocytes. Interestingly, the co-cultured cells with 1% DLW3A (which has fivefold 
higher overexpression relative to the physiological level, supplementary Figure 3), showed 
an accelerated T-cell development with 50% DN4 thymocytes development. However, T-
cell development was inhibited again by increasing the concentration of DLW3A (10% and 
50% Wnt3a), and was completely blocked at the DN3 stage with 100% OP9-DLW3A alone 
(Figure 4a).
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Figure 4. Opti mal dosage of canonical Wnt signaling accelerates T-cell development. 
(a) Total FL cells were co-cultured for 14 days with OP9-DL1, or different ratios of  OP9-DLW3A/ OP9-Dl1 
mixture as indicated. Cells were then harvested and were analyzed by FACS for DN stages of  T-cell development. 
The percentage of  CD44− CD25− DN4 is indicated. The plots are pre-gated on Thy1+ LIN– markers. Error 
bars represent mean ±S.D. of  one independent experiment in triplicates. Below the bar graphs Wnt3a gene overex-
pression relative to the physiological levels are indicated. (b) Total FL cells from Axin2 LacZ (wnt reporter mice) 
were co-cultured with OP9-DL1 and different ratios of  OP9-DLW3A as previously indicated. Cells were harvested 
and β-galactosidase (LacZ) activity in Thy1+ cells was measured. Quantifi cation of  the mean fl uorescence intensity 
(MFI) of  Thy1+ cells is shown (left). Quantifi cation of  the frequency of  LacZ+ cells is shown (right). Littermate 
mice not carrying the reporter transgene (Axin2 +/+) were used to defi ne the LacZ– population. Data represent four 
Axin2 +/− mice and two Axin2 +/+ control mice. Error bars represent mean ±S.D. *P<0.05; **P<0.01; 
***P<0.001.
To determine the Wnt signaling acti vity, we performed the same experiment using Axin-
2LacZ heterozygous reporter cells, a well-established Wnt reporter mouse model.36 Phenotypic 
analysis of the co-cultured cells exhibited similar T-cell development potenti al at diff erent 
dosages of Wnt3a (data not shown). Importantly, the actual Wnt signaling acti vity of total 
Thy1+ cells correlated with the increasing concentrati on of Wnt3a (Figure 4b). Therefore, our 
data suggest that Wnt3a canonical Wnt signaling functi ons in a dosage-dependent fashion, 
in accordance with the diff erenti al Wnt signaling acti vity of the cells.
Wnt3a overexpression enhances B lymphopoiesis and Wnt5a overexpression 
augments myelopoiesis in vivo
To study the role of Wnt3a and Wnt5a signaling in vivo we carried out reconsti tuti on assays 
in which we sorted CD45.2 LSK cells from fetal liver, transduced them with lenti viral vectors 
encoding Wnt3a, Wnt5a in combinati on with GFP, and transplanted them into irradiated 
CD45.1 B6-recipient mice (Figure 5a). At week 16 post transplantati on we analyzed spleen, 
thymus and BM of the recipients. In the spleens of Wnt3a-overexpressing mice the percent-
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age of B220+ CD19+ B cells was around twofold higher compared with the control mice 
within the GFP+ transduced compartment. In contrast, Wnt5a-overexpressing mice had 
around twofold higher percentage of CD11b+ Gr1+ myeloid cells relati ve to the control. 
Therefore, the rati o of B cells versus myeloid cells was in favor of B cells in the Wnt3a group, 
and in favor of myeloid cells in the Wnt5a group (Figures 5b and c).
Figure 5. Wnt3a overexpression enhances lymphopoiesis, whereas Wnt5a overexpression aug-
ments myelopoiesis in vivo. 
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Figure 5. Wnt3a overexpression enhances lymphopoiesis, whereas Wnt5a overexpression aug-
ments myelopoiesis in vivo. (continued)
(a) Experimental design. Lin– Sca1+ Kit+ (LSK) cells were sorted from E14 WT FL and were stimulated overnight 
in medium with SCF, TPO and Flt3-L cytokines. Next day, the cells were transduced with pRRL-SFFV-GFP 
(Ctrl), pRRL-SFFV-Wnt3a-GFP (Wnt3a) or pRRL-SFFV-Wnt5a-GFP (Wnt5a). Bulk of  transduced cells 
were transplanted intravenously into CD45.1 8 Gy irradiated recipients. At week 16 post transplantation, the mice 
were killed and blood, spleen, BM and thymus were harvested and were assessed by FACS. Each group consists of  five 
mice. (b) Representative FACS plots of  B cell (B220+ CD19+) and myeloid cells (CD11b+ G1+) in the spleen of  
a recipient mouse 16 weeks after transplantation. The cells are pre-gated on CD45.2+ CD45.1− and GFP+. The 
numbers indicate percentage of  cells within the gate. (c) Collective data represent the percentage of  GFP+ B cells (left 
graph), myeloid cells (middle graph), and the ratio of  B cells versus myeloid cells in the spleen of  each group. Data are 
mean ±S.D. of  five mice per group. *P<0.05; **P<0.01; ***P<0.001
In the BM, the ratio of B cells versus myeloid cells was around threefold lower in the Wnt5a 
group, whereas there was no statistically significant difference between the control and 
Wnt3a group. MPPs (LSK Flt3+) were around threefold higher in the Wnt5a group compared 
with the control (Figure 6a). In the thymus, T-cell development was clearly blocked at early 
stages in the transduced compartment of the Wnt3a group, and to some extend with Wnt5a 
(as characterized by higher percentage and MFI of GFP in DN and ISP stages). However, 
the blocks did not affect the absolute number of mature T cells or total thymic cellularity 
(Figures 6b and c). Thus, Wnt3a overexpression induces B lymphopoiesis in spleen and BM 
whereas Wnt5a overexpression induces increased myelopoiesis in these organs.
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Figure 6. Wnt3a overexpression blocks T-cell development at early stages in the thymus.
(a) At week 16 post transplantation, BM and Thymus are harvested and assessed by FACS Collective data depict the 
ratio of  GFP+ B cells versus myeloid cells (Left), percentage and absolute number of  LSKs (Middle), and percentage 
of  LSK Flt3+46 in the BM. Data are mean ±S.D. of  fi ve mice per group (right). (b) Collective data show percentage 
(left), or mean fl uorescent intensity (MFI) (right) of  GFP within each T-cell developmental stage for Ctrl group (White 
bar), Wnt3a group (Black bars) and Wnt5a group (gray bars). Data are mean ±S.D. of  fi ve mice per group. (c) Bar 
graph depict absolute number of  total thymus (thymic cellularity) within each group. Data are mean ±S.D. of  fi ve mice 
per group. *P<0.05; **P<0.01; ***P<0.001
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Discussion
Canonical Wnt signaling has a well-established role in T-cell development in the thymus; yet 
only a few reports deal with non-canonical Wnt signaling. A side-by-side comparison of the 
effects of these interacting pathways has not been performed, in contrast to for instance 
B-cell development20 and HSC biology.37 We therefore set out to compare the prototypical 
canonical Wnt ligand Wnt3a with the prototypical non-canonical Wnt ligand Wnt5a. We 
demonstrated that the induction of canonical Wnt signaling via Wnt3a is first, important for 
T-cell development, and second functions in dosage-dependent fashion. Although interme-
diate-to-low doses of canonical Wnt signaling is beneficial for thymopoiesis, higher doses 
support B lymphopoiesis in vivo. On the other hand, Wnt5a non-canonical Wnt signaling 
induces myelopoiesis in vivo and it does not appear to function in a strict dosage-dependent 
fashion. Moreover, Wnt5a signaling induces apoptosis in developing thymocytes, in line with 
the diminished apoptosis observed in Wnt5a-deficient thymi.
Previous studies in our laboratory and many others revealed that canonical Wnt signaling 
is crucial for T-cell development, and it functions in a dosage-dependent fashion.19 In the 
current study we used Wnt3a, a natural ligand of canonical Wnt signaling, and we obtained 
similar data. This shows that Wnt3a triggers canonical Wnt signaling via the β-catenin and 
TCF/LEF-dependent pathway in the thymus,34 and that it is possible to modulate canonical 
Wnt signaling via differential concentration of Wnt3a physiologically. It is very likely that 
in the thymus, developing thymocytes are exposed to different types and concentrations 
of Wnt ligands. It is likely that thymocytes express different FZD receptors with various 
binding affinity to the existing Wnt proteins within the thymic microenvironment. Previous 
Q-PCR data suggest that this might be the case,21 although experimental proof awaits the 
development of specific antibodies for each Frizzled receptor suitable for flow cytometry. 
As a result, developing thymocytes would undergo different levels of Wnt signaling owing 
to the accumulation of different amounts of β-catenin proteins in the cytoplasm.
Another possibility is that the interaction of canonical and non-canonical Wnt signaling 
might be important for control of β-catenin dosage in the cytoplasm. Sugimura et al.37 el-
egantly described a situation where canonical and non-canonical Wnt signaling interact 
with each other in the hematopoietic system. Non-canonical Wnt maintains quiescent 
long-term HSCs through Flamingo and Frizzled 8 receptor on HSCs. Under stress, non-
canonical Wnt is attenuated and canonical Wnt is enhanced, which results in the activation 
of HSC. The same might be true during T-cell development in the thymus under stress, 
which could be a fascinating issue for future studies.
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Previously, Malhorta et al.20 used a similar OP9-based Wnt3a/Wnt5 gain-of-function ap-
proach to study B lymphopoiesis. There are several differences between these two stud-
ies. (i) Their study is restricted to lympho-hematopoiesis of the BM and not thymopoiesis 
in the thymus.34 Their study was confined to in vitro work using FACS-purified stem cells. 
Importantly, using a β-catenin overexpression approach, Kincade and coworkers38 showed 
that committed B-cell progenitors gained myeloid lineage potential. Although we did not 
observe such phenomena in the T-cell lineage, Wnt3a clearly could maintain cells in an 
immature stage, at which thymocytes can still develop into alternative lineages. Thus, 
despite these differences, both studies suggest distinctive roles of Wnt family proteins 
during hematopoiesis and lymphopoiesis, and Wnt3a inhibits progenitor cell differentia-
tion. However, the effect of Wnt5a on B-cell development is controversial. Malhorta et 
al.39 showed that it induces B lymphopoiesis, whereas Liang et al. showed inhibition of 
B-cell proliferation. We did not observe any effect of Wnt5a on B-cell development even 
at higher doses (data not shown) which could be due to the difference in timing, source of 
stem cells or concentration of Wnt proteins.
Khoo et al.40 have demonstrated that human aged HSCs have a reduced canonical Wnt 
signaling activity, and as a result impaired or delayed T-cell development, which is re-
stricted to the T-cell progenitors, indicating the significance of Wnt signaling in human 
T-cell development during senescence. The notion that non-canonical Wnt signaling mim-
ics murine HSC ageing has been put forward by Florian et al.41They reported that a shift 
from canonical to non-canonical Wnt signaling occurs during HSC ageing. Wnt5a treat-
ment of young HSCs induced ageing associated stem cell apolarity, and an lymphoid to 
myeloid differentiation skewing, which is observed normally during ageing. We performed 
similar experiments in which we transduced HSC with Wnt3a and Wnt5a, rather than ex 
vivo treatment. Similarly, myelopoiesis was enhanced in Wnt5a-overexpressing HSC, and 
B lymphopoiesis in Wnt3a-overexpressing HSC (Figures 5 and  and6).6). Therefore, Wnt3a 
treatment of stem cells before transplantation could be considered a promising approach 
to improve lymphopoiesis.
A series of studies in the laboratory of Perreault and coworkers30, 31, 32 suggest that Wnt4 
is a non-canonical Wnt ligand, enhances MPP expansion in the BM and ETP proliferation 
in the thymus, which results in increased thymic cellularity. We have also shown that 
Wnt5a overexpression induces MPP expansion, and DN expansion in thymus (Figure 6). 
However, this did not affect the total cellularity of the organs. This suggests specific roles 
of various Wnt family members during different stages of thymopoiesis, probably due to 
their differential expression throughout the thymus and/or differential responsiveness of 
developing thymocytes. For instance, Wnt4 has been proposed to function as a canonical 
Wnt in inducing FoxN1 expression in TEC,42 but seems to act as a non-canonical Wnt in 
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studies aimed at improving thymic reconstitution from hematopoietic rather than thymic 
stromal cells.30
Previous studies indicate that deregulation of Wnt signaling occurs in leukemia.43 We have 
also shown that deregulation of Wnt signaling due to the absence of Tcf1, induces lym-
phomas in mice.44 Independent of our study, Yu et al.11 also reported similar results and 
showed similarities of Tcf1 lymphomas with human ETP-ALL cases. In addition, Martins et 
al.45 recently suggested that natural cell competition between young and old thymic pro-
genitors is crucial for inhibition of T-ALL development. Therefore, thymic progenitor fitness 
is necessary for normal T-cell development. Our gain-of-function Wnt3a model preserves 
thymocytes in an immature state without inducing any malignancy. It is therefore intrigu-
ing to speculate that canonical Wnt signaling may be involved in regulating stemness of 
thymic stem cells.
Concluding, our work and that of others referred to above show discrete effects of 
Wnt3a and Wnt5a treatment on hematopoietic cells, both in vitro and in vivo. These at-
tempts might lead to application of Wnt ligands as therapeutic candidates to improve 
HSC repopulation and T-cell reconstitution after SCT. However, the challenge and focus of 
future studies should be on determining the ‘right concentration’ of Wnt proteins to avoid 
deregulated Wnt signaling.
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Materials and Methods
Lentiviral production and transduction
Wnt3a and Wnt5a gene transfer plasmids individually cloned into the multiple cloning 
sites of pRRL-SFFV-IRES-GFP lentiviral vector by restriction digestion and ligation reactions. 
293 T cells were transiently transfected with either the genes transfer or empty control 
constructs together with helper plasmids using X-TremeGENE9 transfection reagent (Roche, 
Basel, Switzerland). Virus containing supernatants were harvested 20 h and 40 h after 
transfection in Iscove’s Modified Dulbecco’s Medium supplemented with 10% fetal bovine 
serum, l-glutamin, 100 U/ml penicillin and 100 mg/ml streptomycin and used immediately 
for transduction, or stored at –80 °C for later use.
For transduction of OP9 stromal cells, 150 000 OP9-WT or OP9DL1 cells were seeded into 
a well of six-well plates with alpha MEM (Lonza, Verviers, Belgium) supplemented with 
20% FCS-HI, l-glutamin and penicillin/streptomycin. The following day, OP9 cells were 
transduced with fresh or frozen viral supernatant containing 4 μg/ml proteamine sulfate 
(Sigma-Aldrich, St. Louis, MO, USA). After few days of culture transduced GFP+ cells were 
sorted, and stable OP9-pRRL-GFP (empty vector transduced), OP9-(DL1)- W3A (Wnt3a-
transduced) and OP9-(DL1)-W5A (Wnt5a-transduced) cell lines were generated. Overex-
pression of the genes were then confirmed by Q-PCR gene analysis. The overexpression 
of DL1 gene was not altered in the transduced cell lines compared with untransduced or 
transduced with empty vector.
Coculture of fetal liver cells with OP9 cell lines
For different experiments various conditions of OP9 co-cultures were used as follows: 
OP9-WT, OP9-DL1-GFP, OP9-WT/DL1 (1 : 1), OP9-DLW3A, OP9-DLW5A, OP9-DLW3A/DL1 
(1:1), OP9-DLW3A/DL1 (1 : 10) and OP9-DLW3A/DL1 (1 : 100). In all conditions 50 000 total 
fetal liver cells were cultured on confluent layers of OP9 cells, with AlphaMEM 10% FCS 
containing 50 ng/ml rmSCF, 10 ng/ml rmFlt3L and 10 ng/ml rmIL-7 (all cytokines from R&D 
systems, Minneapolis, MN, USA) in a well of 24-wells plate. For different purposes, cells were 
harvested after 6 h, 24 h, 3, 7 or 14 days of culture and stained for flow cytometric analysis.
In vivo transplantation assay
Transplantation assays were performed with the CD45.1/CD45.2 system. LSK cells were sort-
ed from CD45.2 WT fetal liver mice, overnight stimulated in stemspan in presence of Flt3-L 
(50 ng/ml), TPO (10 ng/ml) and SCF (100 ng/ml). Next day, sorted LSKs were transduced by 
means of Retronectin (Takara Bio Inc., Kusatsu, Japan) with SFFV-IRES-GFP or SFFV-Wnt3a-
IRES-GFP or SFFV-Wnt5a-IRES-GFP. The viral supernatants were titrated in advance to obtain 
equal transduction efficiency (~50%). One day after transduction 5 × 103 bulk transduced 
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LSK cells were transplanted intravenously into lethally irradiated (8 Gy) CD45.1 (9–12 weeks) 
mice together with 5 × 105 CD45.1 spleen support cells. Chimeras was analyzed at 4, 8 and 12 
weeks after transplantation in peripheral blood, and mice were killed for analysis at 16 weeks 
post transplantation. Mice were considered repopulated when >1% multilineage CD45.2 
cells could be detected in nucleated peripheral blood cells 3 months after transplantation.
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Mice were bred and maintained in the animal facilities of Leiden University Medical Cen-
ter, in accordance with legal regulations in The Netherlands and with the approval of the 
Dutch animal ethical committee. C57Bl/6-CD45.1 (Ly5.1) and C57Bl/6-CD45.2 (Ly5.2) mice 
were obtained from the Jackson Laboratory, and Conductin (Axin2)-LacZ mice were kindly 
provided by B. Jerchow and W. Birchmeier  (Max Delbruck Center for Molecular Medicine, 
Berlin, Germany) and have been described previously 35.  
Flow Cytometry
The following antibodies were obtained from BD Biosciences (San Diego, CA): anti-CD3-APC 
(145-2C11), anti-CD4-PeCy7 (RM4-5), anti-CD8-PerCP(53-6.7), anti-CD25-PE (PC61), anti- 
CD44-APC-Cy7 (IM7), anti-cKit-PeCy7 (2B8), anti CD11b-PE (M1/70), anti CD19-APC (ID3) . 
For Lineage depletion these markers were used: CD3 (145-2C11), CD4 (L3T4), CD8 (53-6.7), 
CD11b (M1/70), Gr1 (RB6-8C5), B220 (Ra3-6B2), Ter119 (Ly76) and Nk1.1 (PK136) biotin and 
subsequently were stained with streptavidin eFluor 450 (48-4317) from eBioscience. The 
following antibodies were also purchased from eBioscience: CD45.1-PE-Cy7 (A20), CD45.2 
Alexa Fluor 780 (104), B220 PE-Cy7 (RA3-6B2), Thy1.2 APC (53-2.1), Gr1 eFluor 450 (RB6-8C5) 
and Sca1 PE-Cy7 (D7). Cells were stained in Fluorescenceactivated cell sorter (FACS) buffer 
(PBS, 2% bovine serum albumin, 0.1% sodium azide) for 30 min at 4 °C. Ultimately, Cells were 
washed and measured either on a Canto I, or an Aria (BD Biosciences). For apoptosis analysis 
cells were stained with 7AAD/AnnexinV (BD Bioscience). Data were analyzed using FlowJo 
software (Tree Star, Ashland, OR, USA).
Intracellular β-galactosidase activity was measured by staining cells with 2 mM fluorescein 
di-b-D-galactopyranoside (FDG) substrate (Molecular Probes). FDG was loaded into the 
cells by hypotonic shock at 37 °C for 1 min, prior to cell surface antibody staining. The 
β-galactosidase reaction was stopped with 1 mM phenylethyl b-D-thiogalactopyranoside 
(PETG, from Molecular Probes) after 3 hours as described before and optimized for use in 
thymocytes 36. 
Gene expression analysis
Total RNA was extracted using Qiagen RNeasy mini or micro columns. One ug of total RNA 
was used as a template for cDNA synthesis, using Superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA), Oligo dT, and random hexamer primers. The RQPCR reac-
tion was performed using TaqMan Universal mastermix (Applied biosystems, Foster City, 
CA, USA) and was run on a PRISM 7700 sequence detection system containing a 96-well 
thermal cycler (Applied Biosystems). The following primers were used in combination 
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with FAM-labelled probes from the universal probe library (Roche): Delta Like-1 forward 
primer: 5’- GGGGAGAGAGGGGAGAAGAT - 3’; reverse primer: 5’- ACAGCCTGGCAGACAAATG 
-3’; Wnt3a  forward primer: 5’- CTTAGTGCTCTGCAGCCTGA -3’; reverse primer: 5’- GAGT-
GCTCAGAGAGGAGTACTGG -3’; Wnt5a  forward primer: 5’- ATGAAGCAGGCCGTAGGAC 
-3’; reverser primer: 5’- CTTCTCCTTGAGGGCATCG -3’; Axin2 forward primer: 5’-GCAG-
GAGCCTCACCCTTC-3’; reverse primer: 5’- TGCCAGTTTCTTTGGCTCTT-3’. RQ-PCR results were 
normalized to Abl expression in the same sample: forward primer: 5’-TGGAGATAACACTC-
TAAGCATAACTAAAGGT-3’; reverse primer: 5’-GATGTAGTTGCTTGGGACCCA-3’; and probe: 
5’-FAM-CCATTTTTGGTTTGGGCTTCACACCATT- NFQ-3’.
Statistical analysis
Statistical analysis was performed using the Mann–Whitney U test (Prism GraphPad 
Software, San Diego, CA, USA). P < 0.05 was considered statistically significant. Asterisks 
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Supplementary Figure 1. Comparison of OP9WT/DL and OP9 Dl1 for T cell development support. 
(A) Total fetal liver cells were cocultured with OP9 WT (top row), OP9 DL1-GFP (middle row) or mix of  OP9 
WT and OP9 DL 1:1(bottom row). Cells were harvested after 4 days, 7 days and 14 days of  coculture and were 
analysed by FACS for T cell development. The plots are pre-gated on Thy1+ LIN- markers and depict DN1-DN4 
T cell developmental stages. The numbers represent percentage of  each stage. (B) The cells were harvested 14 days and 
21 days after coculture and were assessed by FACS for late stages of  T cell development. The plots are pre-gated on 
Thy1+ marker.  The numbers represent percentage of  each population. Representative FACS plots of  one independent 
experiment in triplicates are shown.
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Supplementary Figure 2. Canonical Wnt3a overexpression blocks T cell development at early 
stages.
Total fetal liver cells were cocultured with OP9 DL1 as control (white bar) or with OP9 DLW3A (black bars). Cells 
were harvested 14 days after coculture and were analysed by FACS for DN stages of  T cell development. The percent-
age of  DN stages are shown within Thy1+ LIN- populations. Error bars represent mean ± SD of  two independent 
experiments, each in triplicates.
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Supplementary Figure 3. In vivo measurement of canonical Wnt signaling acti vity in thymocytes 
and non-T cells within the Thy us. 
Activation of  the canonical Wnt signaling pathway was measured using the Axin2/conductinLacZ/+ Wnt-reporter 
mice by FACS. (A) Quantifi cation of  frequency, and (B) the mean fl uorescence intensity (MFI) of  the LacZ+ 
populations for each subset in the thymus are depicted. Littermate mice not carrying the reporter transgene (Axin2/
Conductin+/+) were used to defi ne the LacZ+ population. For each subset, MFI of  the LacZ+ population was 
normalized for the MFI of  corresponding LacZ- population (MFI LacZ+/MFI LacZ-) in order to correct for dif-
ferences in background staining between different hematopoietic populations. Data represent results from three Axin2/
conductinLacZ/+ mice and two Axin2/Conductin+/+ control mice, from one independent experiment. Error bars 
represent mean ± SD. 
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T cell factor 1 (Tcf1) is the first T cell‒specific protein induced in multipotent progenitors 
following Notch signaling in the thymus, leading to the activation of its two target genes, 
Gata3 and Bcl11b. Tcf1 deficiency results in partial arrest in T cell development at various 
stages, high apoptosis, and increased development of B cells and myeloid cells. Phenotypi-
cally, fully T cell‒committed Tcf1-deficient thymocytes have promiscuous gene expression 
and de-differentiate into immature thymocytes and non-T cells. Expressing Bcl11b in Tcf1-
deficient cells rescues T cell development, but does not suppress the development of non-T 
cells; in contrast, expressing Gata3 suppresses the development of non-T cells, but does not 
rescue T cell development. These results reveal that T cell development is controlled by a 
minimal transcription factor network  involving Notch signaling, Tcf1, and the subsequent 
division of labor between Bcl11b and Gata3, thereby ensuring a properly regulated T cell 
gene expression program. 
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Introduction
T cells are disease-fighting leukocytes that—similar to all blood cells—originate from 
hematopoietic stem cells (HSCs). However, whereas all other blood cell lineages develop 
in the bone marrow in specific niches , T cells develop in the thymus, a specialized organ 
located in the chest where progenitor cells migrate from the bone marrow and definitively 
commit to the T cell lineage, ultimately forming mature T cells 1. The development of T 
cells within the thymus is a highly complex process involving successive stages in which 
the expression of CD4 and CD8 co-receptors occurs in distinct microenvironments 2. Via a 
series of progressive developmental stages, T cell precursors (i.e., thymocytes) differentiate 
from double-negative (DN; CD4-CD8-) cells into intermediate immature single-positive (ISP; 
CD8+CD3-CD4-) cells, then into double-positive (DP; CD4+CD8+) cells, and finally into single-
positive (SP; CD8+CD4-CD3+ or CD4+CD8-CD3+) cells. In the DN stage, developing thymocytes 
can be further subdivided into four stages of differentiation based on their expression levels 
of CD44 and CD25: DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-CD25+), and DN4 
(CD44-CD25-). Early stages are not committed to the T cell lineage (i.e., fate restricted), allow-
ing alternate lineages to develop 3. Indeed, B cells, dendritic cells, myeloid cells, and natural 
killer (NK) cells can all be generated from CD44+CD25-c-kithi early thymic progenitors (ETPs) 
4,5, DN1 cells, and—albeit to a lesser extent—DN2 cells 6. These multipotent cells, which 
can enter a number of differentiation programs, are directed towards the T cell lineage via 
a process called specification. The irreversible capacity to develop solely into T cells occurs 
somewhat later and is referred to as T lineage commitment; this process also involves the 
active repression of non-T cell lineages 7-9.
The microenvironment of the thymus provides a cellular context that drives T cell devel-
opment. This process is initially driven by the expression of Notch ligands, particularly 
delta-like protein 4 (DLL4) 10, and later in the DP stage by providing the signals required to 
control positive selection (for self-MHC) and negative selection (against autoreactive T cell 
clones).  The various stages in T cell development have been investigated in great detail 
using flow cytometry and genomic analyses; thus, T cell development serves as a paradigm 
for the molecular regulation of cell fate 11,12. The fact that T cell development occurs in 
an anatomically separate niche has allowed researchers to study the detailed successive 
steps that underlie lineage specification and commitment. All of the events that establish 
the identity of T cell precursors are driven by Notch signalling 13, involving binding of the 
transcription factor RBP-J (also known as CBF1) to intracellular Notch ligands, thereby 
forming an active transcription factor complex in ETPs.
The subsequent stages in T cell development are governed by several key transcription 
factors that form an intricate gene regulatory network 14. The core set of transcription 
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factors in the early phases of T cell development are Tcf1 (encoded by the gene confus-
ingly termed  Tcf7 ), Gata3, Bcl11b, and two members of the E2A family, Ikaros and Runx1 
14-17. Importantly, the Tcf7 gene is direct Notch signaling target and the first T cell‒specific 
transcription factor induced by Notch signaling 18; in contrast, Bcl11b drives T cell com-
mitment by limiting the NK cell fate and activating the T cell developmental gene program 
at the DN2-DN3 stage 19, leading to expression of the fully rearranged TCR-beta gene in 
the DN3 stage. Rothenberg and colleagues showed that four transcription factors—Tcf1, 
Gata3, Notch/RBP-J, and to a lesser extent Runx1—are required for the timed expression 
of Bcl11b 14. Of these four transcription factors, Tcf1 is the most complex, as it can act as 
both a transcriptional repressor (e.g., when bound by a co-repressor such as Groucho)or a 
transcriptional activator by binding β-catenin in order to respond to canonical Wnt signals 
20. Interestingly, Tcf1 also acts as a tumor-suppressor gene 21,22, and it can be functionally 
replaced—at least partially—by Lef1, a related transcriptional regulator expressed at ap-
proximately  50-fold lower levels than Tcf1 23.
The precise role that Tcf1 plays in regulating T cell specification and commitment, and its 
interaction with other core regulatory factors in T cell development, is poorly understood. 
Therefore, we examined the role of Tcf1 in the earliest stages of T cell development, focus-
ing primarily on fully committed DN3 cells. We found that Tcf1 is necessary for driving 
thymocytes down the T cell developmental path even after the T cell commitment stage, 
as Tcf1-deficient DN3 thymocytes can de-differentiate into DN1-like cells that can then 
develop into the myeloid and B cell lineages. In addition, we found that Tcf1 supports this 
“lineage fidelity” via two direct—and functionally complementary—target genes, Gata3 
and Bcl11b. An epistasis analysis using retroviral gene complementation in Tcf1-deficient 
stem cells revealed that the role of Gata3 in immature T cells is to repress B cell and 
myeloid fate, whereas Bcl11b establishes the T cell lineage program, and its expression 
can fully overcome the defect in T cell development inTcf1 deficient thymocytes. 
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Results
Tcf1 deficiency leads to several arrests in T cell development with increased non-T cells 
Tcf1 deficiency results in multiple incomplete blocks in T cell development that vary from 
mouse to mouse (Fig 1A). While the block at the ISP stage is well described24-26, the earlier 
blocks have not been well documented. We therefore set out to better characterize these 
blocks and noticed developmental arrests at DN1, DN2, DN3 and ISP stages. (Fig. 1A). Al-
though the block at the ISP stage has been well described 24-26, arrests at the earlier stages 
have not been reported in detail.. In addition to the partial blocks in development shown 
in Fig. 1A, we also observed increased percentages of non-T cell lineages, most notably B 
cells and myeloid cells (Fig. 1B). ln contrast, Tcf1 deficiency did not affect the development 
of NK cells (Fig. 1C), consistent with previous reports that the development of NK cells is 
independent of the effect of Tcf1 on T cell lineage 27,28. Consistent with T cell developmental 
arrest, loss of Tcf1 significantly impaired ɑβ T cell development (Fig. 1C). 
In contrast to these partial arrests in developing mice, transplanting Tcf1-deficient stem 
cells into adult recipient mice led to a complete block in T cell development at the DN1-







































































































Fig 1 Famili et, al.
Figure 1. Tcf1 deficiency results in several incomplete blocks in T cell development and increased 
numbers of thymic B and myeloid cells 
A: Tcf1 deficient thymi can show different developmental arrests: DN1, DN2, DN3 or ISP. B: increased percentages 
of  B  cells and myeloid cells in Tcf1 -/- thymi. C: decreased numbers of  αβT cells in Tc f1-/- thymi. D: Complete 
block at the DN1 to DN2 transition in the thymus of  bone marrow chimeras generated from Tcf1 deficient stem cells.
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DN2 transition (Fig. 1D), presumably of an insufficient compensatory expression of Lef1 in 
these cells 29. Moreover, we cultured Tcf1-deficient stem cells on OP9-DL1 cells and found 
a similar DN1-like arrest, with increased numbers and relative percentages of non-T cell 
lineages (data not shown, but see Figs. 5 and 6).
Tcf1 deficiency leads to high levels of apoptosis
Developmental arrest in the thymus is often accompanied by an increase in apoptosis. To 
examine the role of apoptosis in Tcf1-deficient thymocytes, we measured apoptosis and 
proliferation of various developmental stages in the thymus of Tcf1-deficient mice and wild-
type littermates. Compared to wild-type cells, we found increased levels of apoptosis in 
Tcf1-deficient cells at nearly every stage (Fig. 2), as well as decreased cell proliferation in the 
DN2 and DN4 stages (not shown).Taken together, these results explain the decrease in T cells 
in Tcf1-deficient mice; however, they do not explain the increased numbers of non-T cells.
Fig 2 Famili et, al.
Figure 2: Increased apoptosis in Tcf1-/- thymocytes. 
Ex vivo Thymocytes were analysed by flow cytometry for various developmental subsets in combination with 
AnnexinV/7AAD. (n=4 or 5 per group) 
Phenotypically, fully committed DN3 TCF1-deficient thymocytes have promiscuous 
gene expression and more open chromatin
 Next, to better understand the role of Tcf1 in T cell commitment, we compared gene expression 
profiles between Tcf1-deficient thymocytes and wild-type thymocytes. The T cell commitment 
process starts at the DN2 stage and continues to the DN3a (CD25+CD44-CD27-) stage in which 
a rearranged Tcrb gene is expressed in combination with pTA to form the pre-TCR complex in 
a process known as β-selection. After β-selection, the cells rapidly proliferate, express CD27, 
and are fully T cell committed based on expression of a functional, rearranged Tcrb gene 30. 
We therefore performed whole-transcriptome RNA-Seq analysis on DN3b cells obtained from 
Tcf1-deficient and wild-type littermates (Fig 3A). For visualization the  top 50 differentially ex-
pressed genes are shown and confirm absence of  expression for Tcf7, but also that there were 
many fewer rearranged Tcrb genes than in wildtype control DN3b thymocytes, as indicated 
for the Trbj expressed gene segments(Fig. 3A). We used the genes differentially expressed 
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between Tcf1 deficient and wild type DN3b cells in a Gene Set Enrichment analysis (GSEA). We 
used published gene sets of T cell developmental stages to establish a DN2 signature 31. The 
genes highly expressed in Tcf1-/- DN3b clustered strongly with DN2 cells, indicating that they 
share many characteristics of  earlier developmental stages that are less T cell committed (Fig 
3A). The RNA-seq data also indicated that many of the T cell commitment genes were low or 
not expressed while genes involved in for instance non T cell lineages (Pax5, Pu.1, Blc11a) were 
highly expressed. Based on these data we validated the expression of a number of important 
T cell developmental genes by Q-PCR on sorted DN1, DN2, DN3 and DN4 thymocytes. These 
results validated the RNA-Seq data and showed much lower expression of the T cell specific 
transcription  factors Gata3 and Bcl11b (with higher expression of its functional counterpart 
Bcl11a) while the B cell commitment factor Pax5 and the myeloid associated factor Pu.1 were 
significantly higher expressed in the Tcf1 deficient thymocytes (Fig 3B). In addition, genes more 
associated with stem/progenitor cells (sometimes referred to as legacy genes1) such as c-kit 
were also significantly higher expressed(Fig 3B), while both Wnt and Notch target genes were 
decreased. Collectively, these data showed that while in some regards Tcf1-/- DN3 thymocytes 
were T cell committed, they also showed lineage infidelity, with expression of master regula-
tory genes from non-T cells. This notion was further substantiated by investigating the chro-
matin status of Tcf1 vs wildtype thymocytes using ATAC-Seq (Assay for Transposase-Accessible 
Chromatin sequencing) as discussed below.
Gata3 and Bcl11b are direct targets of Tcf1 and downregulated in Tcf1 deficient 
thymocytes
The downregulated mRNA expression levels of the transcription factors Gata3 and Bcl11b in 
various DN thymocyte stages in Tcf1 deficient mice, suggested that these factors may be di-
rect target genes of Tcf1. In accordance, the Bcl11b and Gata3 enhancers contain conserved 
Tcf/Lef binding sites (see M&M). To check whether in DN thymocytes these promoters are 
regulated in a Tcf-dependent manner, we performed chromatin immune precipitation (ChIP) 
using a monoclonal antibody specific for Tcf1 (Fig 4A) followed by Q-PCR. This revealed 
binding of Tcf1 to the Gata3 and Bcl11b promoter sequences in wild type DN thymocytes 
but not in  Tcf1 deficient thymocytes, showing that both genes are direct target genes of 
Tcf1. This finding was further substantiated by ATAC-Seq (Assay for Transposase-Accessible 
Chromatin) data which indicates chromatin accessibility Although in general, chromatin 
was less condensed in DN3b thymocytes lacking Tcf1 compared to wildtype DN3b cells, in 
certain specific areas the chromatin was more condensed. Focusing on the Bcl11b and Gata3 
promoter/enhancer sequences, the chromatin in these promoters was less accessible com-
pared to wild type littermate control DN3b cells (Fig 4B). Similarly, the TCRB loci were much 
less accessible in accordance with the RNA-Seq data. Interestingly, no major differences in 
chromatin accessibility were found at genes involved in alternative lineages, indicating that 
expression of these genes was not regulated at the level of chromatin opening.
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Fig 3B Famili et, al.
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B
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Phenotypically, fully committed DN3 Tcf1-deficient thymocytes de-differentiate into 
DN1 thymocytes, B cells, and myeloid cells
Based on the hypothesis derived from these results, that Tcf1 deficient DN3 thymocytes 
may not be T cell committed, we sought to better investigate the differentiation capacity of 
Tcf1-/- DN3 thymocytes. Therefore, DN3 cells were sorted and cultured under conditions 
with strong T cell inducing capacity. Indeed the majority of wild type DN3 thymocytes dif-
ferentiated further into DN4 cells, with a smaller part remaining DN3 (Fig 5A). Unexpectedly, 
most Tcf1-/- DN3 thymocytes dedifferentiated into DN1 and DN2 cells, with extensive B 
and myeloid development while only a minority of cells remained DN3 without any further 
Figure 3: Tcf1 deficient DN3b cells show promiscuous gene expression and more open chromatin 
loci compared to wild type littermate controls (continued)
A: Heat map of  the top 50 differentially expressed gene as determined by RNA-SEq of  sorted DN3b cells from wild 
type and Tcf1 deficient thymi, with an extra focus on rearranged TCR products on the right. GSEA of  the differentially 
expressed genes (Tcf1-/- over wild type for DN3b) are enriched for DN2 genes. B: Q-PCR validation of  RNA-Seq 
data for selected T cell specific genes, genes expressed in non-T cells and legacy genes whose expression is inherited from 
stem cells/ multipotent progenitors 
Fig 4 Famili et, al.
A B
Figure 4: Chromatin analysis in Tcf1 deficient vs. wild type DN thymocytes.
A. Chromatin immune precipitation with an antibody specific for Tcf1 revealed that the Gata3 and Bcl11b promoters 
are occupied by Tcf1 in vivo, whereas in Tcf1-/- DN thymocytes no binding can be detected. Negative controls with IgG 
instead of  anti-Tcf1 showed no enrichment. B. ATAC-Seq data mined for the Bcl11b, Gata3 and TRB-J genomic 
regions. Per locus the relative abundance of  transposase accessible regions is indicated. In blue the fold enrichment(FE) 
of  wildtype over Tcf1-/- DN3b cells are indicated, blue bars underneath show the significant peaks called by MACS2. 
In black the individual ATAC-seq profile from each genotype is shown. Data are shown as normalized read density. 
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development along the T cell lineage (Fig 5A). Especially development into B cells was ex-
tensive, with up to 60% of DN3 thymocytes developing into B cells (Fig 5B).These DN1 and 
DN2  cells were not a contaminating fraction that grew out, as intracellular staining for Tcrb 
revealed high Tcrb expression in these DN1/2 cells at similar levels as wild type DN3 and 
DN4 cells (Fig 5B). We conclude that Tcf1KO cells dedifferentiate to less committed cells 
and exhibit lineage infidelity with significant development into alternative (non-T) lineages. 
When ETP cells rather than DN3 cells were seeded on OP9-DL1, as expected Tcf1 deficient 
cells were arrested in development at DN1, with abundant B and myeloid development, 
whereas wild type stem cells differentiated along the T cell lineage with many fewer non-T 
cells (Suppl Fig 1)
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De-differentiation into alternate lineages can be prevented by expressing Gata3 in 
Tcf1 deficient thymocytes 
Epistasis analysis is a powerful genetic tool, often used in model organisms such as Dro-
sophila to investigate hierarchical relationships between genes32.  It can be more complex to 
perform in mammals such as mice, where not only expression per se but also gene dosage 
is important. For instance, while complete loss of Gata3 blocks T cell development at the 
earliest stages,  transgenic overexpression of Gata3 can lead to development of mast cells in 
the thymus33-36. We therefore expressed Gata3 and Blc11b using recombinant retroviruses as 
they have a broad range of expression that would allow different phenotypes to be selected 
under the strong developmental pressure of the thymic microenvironment. We used retrovi-
ruses encoding GFP and Gata3 or Bcl11b together with GFP to investigate complementation 
of the Tcf1 phenotype by either Gata3 or Bcl11b(Fig 6A,7A). We used retroviruses solely 
encoding GFP as negative controls.
Expression of Gata3 could partially rescue the development of Tcf1-/- thymocytes from 
a DN1 arrest to DN2 but not further(Fig 6B). Strikingly, Gata3 strongly suppressed the 
enhanced development of B and myeloid cells (granulocytes as well as monocytes) from 
Tcf1-/- as well as the less prominent non T development from wild type thymocytes (Fig 6C). 
The suppression of B cell development was also observed in vivo when Gata3 completed 
Tcf1-deficient stem cells were transplanted in irradiated recipient mice (Fig 6D, right and 
supplemental Fig 2A). However, thymic T cell development again was arrested at a DN1/2 
transition, barely different than GFP control transduced cells (Fig 6D, left; supplemental fig 
2B). Thus, the major role of Gata3 in earliest DN development is the suppression of non T 
cell development with only a minor feed forward role into the T cell program.
Figure 5: Tcf1 deficient DN3 cells de-differentiate into DN1/2 cells with multipotent lineage ca-
pacity (continued)
A: wild type DN3 cells sorted and seeded on OP9-Dl1 cells develop largely further into DN4 or remain DN3, while 
Tcf1 deficient cells develop into DN1 and DN2 cells with prominent B cell and myeloid cell development B: Quantifica-
tion of  the developmental plasticity nad de-differentaion effcts of  DN3 Tcf1 deficient thymocytes into DN1, DN2, 
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The T cell lineage-specifi c defects caused Tcf1 defi ciency can be rescued by 
expressing Bcl11b
Bcl11b(Fig 7A) in contrast rescued the T cell development of Tcf1 defi cient cells virtually 
completely. Bcl11b transduced Tcf1 defi cient stem cells developed readily into Thy1 posi-
ti ve (Fig 7B) cells, and could develop into DN2 and DN3 thymocytes to a similar degree as 
wild type thymocytes (Fig 7C). However, overexpression of Bcl11b did not infl uence B and 
myeloid development from Tcf1 defi cient cells. 
Figure 6: Re-expression of Gata3 suppresses B and myeloid development in Tcf1 defi ciency. 
(Conti nued)
A:layout of  retroviral complementation experiments with GFP and/or Gata3 
B: Gata3 expression partially overcomes the DN1 thymocyte block and suppressed the enhanced non-T cell lineages 
after 7 days in the OP9-Dl1 culture system (Two-way ANOVA) Error bars represent the SD from two independent 
experiments. C: in vivo complementation reveals suppression of  B cell development also in the spleen, but minimal and 
partial rescue of  T cell development in the thymus (D)(two-way ANOVA) Error bars represent the SD from 3-4 
individual mice per group.
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Fig 7C Famili et, al.




















Fig 7A,B Famili et, al.
Figure 7: Re-expression of Bcl11b rescues T cell development from Tcf1 defi cient stem cells. 
A: layout of  retroviral complementation experiments with Bcl11b. B: Thy1 expression is rescued in Tcf1 defi ciency by 
expression of  Bcl11b after 14 days in OP9-Dl1 culture. C: Bcl11b fully rescues T cell development from Tcf1 -/- stem 
cells that otherwise are arrested in DN1. D: Bcl11b overexpression does not affect myeloid and B cell development. 
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Discussion
T cell development has been used as a classic example of a relatively ordered pathway to 
study cell fate determination 16, thereby giving the impression that transcriptional regulation 
during T cell development is a well-understood process. Despite this general belief, however, 
and compared to other developmental processes (for example, B cell development, which has 
similar requirements in terms of proliferation, lineage restriction, immune receptor rearrange-
ment, and checkpoints for premature and mature immune receptors), the roles of the major 
transcription factors in T cell development are rather poorly understood. In B cell develop-
ment, a clearly defined linear hierarchical relationship exists between E2A, EBF1, and Pax5 37-44. 
However, with respect to early T cell development, whether the Notch (RBP-J), Gata3, Bcl11b, 
Runx1, E2A, Tcf1/Lef1, Ikaros, and/or Hox genes play unique, redundant, or synergistic roles 
remains unclear and is the subject of intense research that focuses largely on either individual 
factors or the collective activity of these factors using computational biology. Considering that 
Notch signaling is required for T cell development, and given that the first T cell‒specific target 
gene is Tcf7 18, which encodes Tcf1, we investigated the process of T cell lineage commitment 
in Tcf1-deficient mice.
Although Tcf1-deficient mice have been studied extensively, a comprehensive description 
of developmental arrest in these mice is currently lacking. Here, we report that developing 
thymocytes in adult Tcf1-deficient mice have incomplete arrest at several stages, including 
the previously reported ISP block 26. 
The study of Tcf1-deficient mice is generally complicated by three factors. First, in the 
absence of Tcf1, the HMG box transcription factor Lef1—which is expressed in the thymus, 
albeit at much lower levels than Tcf1—plays a compensatory role 23,29,45. This low-level 
expression of Lef1 causes incomplete penetrance of the Tcf1-deficient phenotype. How-
ever, if Tcf1-deficient stem cells are either transplanted into recipient mice or cultured on 
OP9-DL1 cells to induce T cell differentiation, complete block occurs at the DN1 stage (see 
Fig. 1D). Therefore, in our experiments we used bone marrow-derived cells obtained from 
Tcf1-deficient mice. Second, Tcf1-deficient mice are prone to developing T cell lymphomas 
in the thymus 22, which is similar to T-cell acute lymphoblastic leukemia (T-ALL) in patients. 
As discussed above, this issue can be overcome by using Tcf1-deficient stem cells instead 
of thymocytes. The third issue associated with studying Tcf1-deficient mice is that Tcf1 
functions as both a transcriptional repressor and a transcriptional activator (for example, 
when bound to the Wnt mediator β-catenin). Indeed, when Tcf1-dependent promoters 
were tested using in vitro reporter systems, transcription occurred only when β-catenin 
was also expressed 46,47. Consistent with this notion, Tcf1 binds to the promoter/enhancer 
regions of the target genes Gata3 and Blcl11b, and we found evidence that Tcf1 binds to 
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β-catenin at these promoter regions (data not shown). In addition, DN stages of T cell 
development show high canonical Wnt signaling, which is driven by β-catenin and Tcf/Lef 
48. On the other hand, some of Tcf1’s functions in the earliest stages of T cell development 
are independent of β-catenin 18, possibly due to the redundant role of Lef1.
A seminal study by Busslinger and colleagues revealed that Pax5 is a major lineage com-
mitment factor in the development of B lymphocytes 42,43,49. Thus, B cells that lack Pax5 can 
de-differentiate into multipotent progenitor cells that can replenish all hematopoietic lin-
ages, even in vivo. In this respect, our findings are somewhat analogous, as Tcf1-deficient 
DN3 cells—which should be fully committed—have promiscuous gene expression and can 
de-differentiate into immature cells that can give rise to non-T cell lineages, including B 
cells and myeloid cells. Indeed, key transcription factors that drive alternate lineages (e.g., 
the transcription factors Bcl11a, Pax5, and Pu.1) are robustly expressed in Tcf1-deficient 
DN3 and DN4 cells, but not in wild-type cells. In contrast to wild-type cells—in which 
global chromatin accessibility is restricted in order to ensure that only T cell lineage genes 
are expressed—Tcf1-deficient cells have many more accessible loci, thereby explaining 
their functional role as multipotent progenitor cells. In contrast with Pax5-deficient cells, 
however, only a small number of Tcf1-deficient cells survive the de-differentiation process, 
which is likely due to the high level of apoptosis in Tcf1-deficient thymocytes.
Given that both Bcl11b and Gata3 are key target genes for Tcf1, we expressed these 
transcription factors in Tcf1-deficient cells in an attempt to rescue the thymic pheno-
type. Similar analyses of epistasis have been used previously in model organisms (e.g., 
Drosophila) to delineate both hierarchical and functional relationships. The expression 
of exogenous Gata3 has been shown to suppress B cell development in the wild-type 
thymus 50; however, we found that Gata3 also suppresses myeloid fate in DN thymocytes. 
Interestingly, Gata3 does not suppress myeloid fate in the bone marrow, even though the 
effect on B cell development occurs outside of the thymus. 
Our finding that the constitutive expression of Bcl11b in Tcf1-deficient cells fully rescued T cell 
development suggests a division of labor between Bcl11b and Gata3, with Gata3 suppressing 
non-T cell lineages and Bcl11b inducing the expression of T cell‒specific genes. Taken together, 
the data from our group and others indicate a gene network in which Notch signaling via RBP-Jk 
drives the expression of Tcf1, which in turn activates Gata3 and Bcl11b, most likely in collabora-
tion with Notch signals that can also act directly on these genes’ promoters. Interestingly, in 
addition to its requirement for initiating the T cell commitment process, Tcf1 expression is also 
required to maintain lineage fidelity. In skin stem cells, lineage infidelity increases the likelihood 
of malignancy 51. Thus, given that loss of Tcf1 leads to the rapid development of T cell lympho-
mas, lineage infidelity may also serve as a previously unrecognized factor in leukemogenesis.




C57Bl/6 TCF-1 -/- ΔVII/ΔVII mice were originally described by Verbeek et al (1995) and 
C57Bl/6-Ly5.1 mice were purchased form Charles Rivers Laboratories. Mice were bred and 
maintained in the animal facility of Leiden University Medical Center. All animal experiments 
were performed in accordance with legal regulations in The Netherlands and with approved 
protocols of the Dutch animal ethical committee.  
Mice used for transplantation assay were kept in specified pathogen-free section and 
were fed with special food and antibiotic water. Genotyping assay of newborn Tcf1 mice 
was performed with DNA samples from earpieces using GoTaq Flexi DNA polymerase kit 
(Promega) according to manufacturer’s instructions.
Flow cytometry and cell sorting
Single cell suspensions from thymus, spleen, BM and blood were stained with monoclonal 
antibodies against CD3e, CD4, Cd8a/Ly-2, CD11b/Mac-1, CD19, CD25, CD27, , CD44/Ly-24, 
CD45.1/Ly-5.1, CD45.2/Ly-5.2, B220/CD45R, CD90.2/Thy1.2, CD117/c-kit, CD135/Flt3, Gr1/
Ly-6G-6C, NK1.1, Sca1/Ly-6A, TCRβ,  and Ter-119/Ly-76 (See STAR Table_ Antibodiesfor ad-
ditional antibody information). All antibodies used were directly conjugated to biotin, fluo-
rescein isothiocyanate (FITC), phycoerythrin (PE), Peridinin Chlorophyll-a Protein (PerCP), 
PE-Cy7, allophycocyanin (APC), APC-Cy7 or efluor450. Biotinylated antibodies were revealed 
with streptavidin conjugated antibodies (PE, efluor450, APC-Cy7, APC or Pe-Cy7) (all anti-
bodies were purchased from BD or eBioscience). 
Cells were blocked with normal mouse serum (NMS, Invitrogen) for 10min at room 
temperature and subsequently cell surface staining was performed in two steps. Firstly, 
cells were incubated for 30min at 4°C in the dark with the antibody-mix solution including 
directly conjugated antibodies at the optimal working solution in FACS buffer (PBS pH7.4, 
0.1% azide, 0.2% BSA). After washing with FACS buffer, a second 30min incubation step at 
4°C was performed with the streptavidin conjugated antibodies mix.
Cell apoptosis was assessed by AnnexinV and 7AAD staining, which was performed 
following the PE AnnexinV Apoptosis detection Kit protocol (BD Pharmingen) after the 
cell surface staining. Proliferation assay was done by intracellular Ki67 staining (mIgG as 
control) with PE Mouse anti-human Set protocol (BD Pharmingen). For that purpose, cells 
were initially stained for cell surface markers as described previously and subsequently 
fixated and permeabilized by using fixation/permeabilization buffer (eBiosience) for an 
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hour at 4°C. Cells were then washed with permeabilization (eBiosience) buffer with 2% 
NMS and stained with Ki67 or IgG1 solution for 30min at 4°C in the dark.
Double positive CD4&CD8 cells before DN cell sorting and lineage positive cells before 
LSK/LK sorting were depleted using magnetic-activated cell sorting, autoMACS (Miltenyi 
Biotec). For DNs sorting, thymocytes were first stained with anti-CD4 and CD8-biotin, fol-
lowing by Streptavidin microbeads staining according to manufacturer instruction (Miltenyi 
Biotec). For LSK/LK cell sorting, lineage depletion kit (Miltenyi Biotec) was used according 
to manufacturer instruction. Subsequently, depleted cells were stained again for DNs or 
LSKs as described before. Cell sorting was performed on FACSAria II (BD Biosciences) or 
stained cells were measured with FACS-CantoII (BD Bioscience). Data was analysed using 
FlowJO (Tree Star). All different hematopoietic populations were defined as described in 
Table S2_Appendix.
Cell culture
Bone-marrow-derived stromal cell line OP9 and OP9-DL1 cells which ectopically ex-
press the Notch ligand Delta-Like 1 (DL1) were used as described by J.C. Zuñiga-Pflucker. 
Sorted DN cells were cultured on OP9  or OP9 WT/OP9-DL1 (10:1) confluent monolayers in 
αMEM (Lonza)-10%FCS, 1% P/S (Life Technologies) and GlutaMAX (Life Technologies) me-
dium complemented with 50 ng/ml rmFlt3L, 50 ng/ml rmSCF, 10 ng/ml rmIL-7, and 50μM 
β-mercaptoethanol (β-ME; Sigma-Aldrich). (all cytokines purchased from R&D). Cells were 
harvested after 7 to 14 days of coculture and were analysed by flow cytometry. 
Transduced LSK and LK with LZRS-ires-eGFP (control), LZRS-Gata3-eGFP or LZRS-Bcl11b-
GFP vector were cultured on OP9-DL1 monolayer for 6 to 14 days in αMEM-10%FCS 
complemented with rmIL7 (10 ng/ml),rm Flt3L (50 ng/ml), rmSCF (10 ng/ml) and β-ME 
(50μM). Harvested cells were analysed by flow cytometry or sorted. 
Retroviral production
LZRS-Gata3 and Bcl11b plasmids were obtained from Addgene and cloned into LZRS-
ires-eGFP vector (Addgene, control vector). Control, Gata3 and Bcl11b retroviruses were 
generated using Phoenix ecotropic  packaging cell line (ATTC). Cells were cultured in IMDM 
(Lonza)-10%FCS-1% Penicillin/Streptomycin -1%Glutamine and transfected with plasmids 
using X-treme Gene9 DNA transfection reagent (Roche) protocols. Selection of transfected 
cells was performed with 1mg/mL puromycin (Sigma-Aldrich) for a week and viral superna-
tant was harvested at 24h and 48h. 
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Retroviral transduction
LSK and LK sorted cells were stimulated overnight in StemSpan serum-free expansion me-
dium (StemCell Technologies) supplemented with 10ng/ml rmTPO (R&D) , 50ng/ml rmFlt3L 
(R&D) and 100ng/ml rmSCF (R&D). Antibiotic mix with polymixine B sulphate, kanamycin, 
penicilin/streptomycin and amphotericin B was added to prevent bacterial infections. He-
matopoietic progenitors were transduced using RetroNectin (Takara Bio Inc) coated wells 
according to the manufacturer’s instructions. Non-tissue culture plates were coated with 
RetroNectin overnight at 4ºC and then blocked with 2% bovine serum albumin (BSA) in PBS 
for 30min. Retroviral supernatant (24h or 48h) was centrifuged at 1500xg for 2h at 32ºC 
and incubated an extra hour at 37ºC. After coating, viral supernatant was removed and 
stimulated cells were immediately added on the virus-coated plates. Cells were cultured in 
StemSpan medium supplemented with rmTPO (10 ng/ml), rmFlt3L (50 ng/ml) and rmSCF 
(100 ng/ml) and transduced overnight at 37ºC. LZRS-ires-eGFP,LZRS-Gata3-ires-eGFP and 
LZRS-Bcl11b-ires-eGFP transduced cells were used for in vitro and in vivo approaches.
Quantitative real time (rt)-PCR
RNA from sorted cells was purified using Micro RNeasy kit (Qiagen) and reverse transcribed 
into cDNA using Superscript III kit (Invitrogen). RT-PCR was performed using TaqMan Uni-
versal Master Mix II in combination with specific probes for indicated genes from Universal 
Probe Library (Roche).  Specific primers for ABL-2, Bcl11a, Bcl11b, Gata3, Pax5, PU.1/Spfi1, 
IL-7Ra, CD117/c-kit, ID2, Axin-2 and Hes1. were designed and purchased from Sigma-Aldrich 
(See specific gene sequences on Table 3_Appendix). Samples were analyzed by StepOne-
Plus RT-PCR system (Life Technologies). Relative transcript abundance was determined by 
ΔCt and expression levels were normalized for the endogenous reference gene ABL-1. All 
samples were run in at least in  duplicates.
RNA-SEQ
RNA from sorted DN3b cells (Lin-CD25+CD44-CD27+) from Tcf1-/- and wild type littermates 
thymi was isolated using the Mini RNeasy Kit (Qiagen) The integrity (scores > 9.0) of the 
RNA was determined on the Agilent 2100 Bioanalyzer (Agilent). Total RNA enrichment for 
sequencing poly(A) RNAs was performed with the TruSeq mRNA sample preparation kit (Il-
lumina). 1μg of total RNA for each sample was used for poly(A) RNA selection using magnetic 
beads coated with poly-dT, followed by thermal fragmentation. The fragmented poly(A) RNA 
enriched samples were subjected to cDNA synthesis using Illumina TruSeq preparation kit. 
cDNA was synthesized by reverse transcriptase (Super-Script II) using poly-dT and random 
hexamer primers. The cDNA fragments were then blunt-ended through an end-repair reac-
tion, followed by dA-tailing. Subsequently, specific double-stranded bar-coded adapters 
were ligated and library amplification for 15 cycles was performed. The pooled cDNA library 
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consisted of equal concentration bar-coded samples. The pooled library was sequenced in 
one lane, 36 bp single read on the HiSeq2500 (Illumina). 
RNaseq data were aligned to the mm10 genome using the STAR aligner (Dobin et al., 
2013) and quantified using featureCounts . The raw counts data were processed using the 
“voom” function (Law et al., 2014) in the limma R package which normalizes the data and 
assigns a weight for each measurement for subsequent linear model fitting.. Differential 
expression was assessed using the limma moderated T statistic.. Normalization for rep-
licate number and technical parameters was also applied directly to the voom result to 
obtain “normalized counts,” which were used for data visualization. Geneset enrichment 
was performed using the “RankSumWithCorrelation” function in the limma R package, 
which automatically corrects enrichment statistic inflation due to correlation among genes 
ATAC-SEQ  
15,000 sorted DN3b Cells were washed 1 time with cold PBS. Pellets were spun down at 
500 g for 5 min at 4°C, and the supernatant was removed carefully. 20 µl of transposase mix 
(10µl 2xTD buffer, 1 µl TDE (Nextera DNA Library Prep Kit; Illumina), 0.2 µ digitonin (G9441, 
Promega), 8.8 µl nuclease-free water) was added to the cells. Reactions were incubated 
at 37°C for 30 min. Transposed DNA was purified using the MinElute Reaction Cleanup Kit 
(28204, Qiagen), amplified, and again purified according to published protocols (Buenrostro 
et al 2015, CurrProtocMolBiol). Size selection was done using Low Range Ultra Agarose (161-
3107, Bio-Rad). Fragments between 150-600 bp in size were used for further analysis. Qual-
ity and quantity of the libraries was assessed by Bioanalyzer High Sensitivity DNA Analysis Kit 
(Agilent) before sequencing. Libraries were sequenced 50 bp, paired-end, on a HiSeq4000.
Reads were mapped to mm10 using bwa mem(Li H et al 2010, Bioinformatics) with default 
settings. Only reads with high mapping quality (Q>10) were used for further analysis, and 
DNA duplicates were removed using samtools(Li H et al 2009, Bioinformatics). Data were 
aggregated by each unique genotype and subsampling was done to correct for sequencing 
depth(about 23million reads). Differential peaks(in bed file format) between WT and Tcf1 
KO cells were called using MACS2 with the following parameters: -g mm -B –nomodel 
(q-value <0.05). BigWig-tracks were generated by MACS2 using WT as input and Tcf1 KO 
as control. The track of Fold Enrichment (WT over KO) was generated using the bdgcmp 
function in MACS2 with the following settings: -m FE.
Chromatin immunoprecipitation 
DN thymocytes (CD8-CD4-) from Tcf1-/- and wildtype littermates were sorted and subse-
quently crosslinked with formaldehyde (Sigma). Crosslinking was quenched with Glycine and 
after cell lysis chromatin was sonicated into fragments. Sonicated chromatin was precleared 
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and incubated with antibodies. TCF-1 (C46C7; #2206 Cell Signalling Technologies). Immuno 
precipated chromatin complexes were purified and quantified by real-time PCR using Fast-
start Universal Sybr Green Master mix (Roche) 
Competitive transplantation assay
Competitive transplantation assay is used to determine HSC development and functionality 
in vivo by measuring multi-lineage reconstitution of hematopoiesis in irradiated transplanted 
mice. This assay was performed with the Ly5.1/Ly5.2 (CD45.1/CD45.2) system. 12.5000 trans-
duced LSK and 40.000 transduced LK cells from Ly5.2 mice were transplanted into lethally 
irradiated (8.07Gy) Ly5.1 mice (8-12 weeks), together with 300.000 spleenocytes (Ly5.1) as 
support cells. Chimerism and peripheral T cell were analysed at week 6 after transplanta-
tion in peripheral blood. Mice were sacrificed for analysis 7 weeks after transplantation 
to evaluate hematopoietic system repopulation. Mice were considered repopulated when 
≥1% multi-lineage Ly5.2 cells could be detected. Single cell suspension from the thymus, 
spleen and bone marrow (BM), as well as lysate blood were analysed by flow cytometry as 
described previously.
Statistical methods
All statistics were calculated and all graphs were generated using GraphPad Prism6 (Graph-
Pad Software). Statistical significance was determined by standard two-tailed  Student t test 
t student (*p<0.05) or ANOVA. 
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Abstract
The HMG-box factor Tcf1 is required during T-cell development in the thymus and mediates 
the nuclear response to Wnt signals. Tcf1−/− mice have previously been characterized and 
show developmental blocks at the CD4−CD8− double negative (DN) to CD4+CD8+ double 
positive transition. Due to the blocks in T-cell development, Tcf1−/− mice normally have a 
very small thymus. Unexpectedly, a large proportion of Tcf1−/− mice spontaneously develop 
thymic lymphomas with 50% of mice developing a thymic lymphoma/leukemia at the age 
of 16 wk. These lymphomas are clonal, highly metastatic, and paradoxically show high Wnt 
signaling when crossed with Wnt reporter mice and have high expression of Wnt target 
genes Lef1 and Axin2. In wild-type thymocytes, Tcf1 is higher expressed than Lef1, with a 
predominance of Wnt inhibitory isoforms. Loss of Tcf1 as repressor of Lef1 leads to high 
Wnt activity and is the initiating event in lymphoma development, which is exacerbated by 
activating Notch1 mutations. Thus, Notch1 and loss of Tcf1 functionally act as collaborating 
oncogenic events. Tcf1 deficiency predisposes to the development of thymic lymphomas 
by ectopic up-regulation of Lef1 due to lack of Tcf1 repressive isoforms and frequently by 
cooperating activating mutations in Notch1. Tcf1 therefore functions as a T-cell–specific 
tumor suppressor gene, besides its established role as a Wnt responsive transcription factor. 
Thus, Tcf1 acts as a molecular switch between proliferative and repressive signals during 
T-lymphocyte development in the thymus.
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Introduction
Cancers often develop as consequence of deregulated expression of key factors that operate 
during normal development. Deregulation of the Wnt signaling pathway has been implicated 
in many types of malignancies, especially in solid tumors (reviewed in [1]–[3]). Mutations in 
different components of the Wnt pathway are found to contribute to carcinogenesis [3]. 
During normal development, Wnt proteins function as proliferation-inducing growth factors 
and may also affect cell-fate decisions [4]–[6]. Wnt proteins bind to their Frizzled receptors, 
thereby preventing proteosomal degradation of the Wnt mediator β-catenin. Subsequently, 
β-catenin is translocated to the nucleus, where it forms an active transcription complex with 
the nuclear proteins downstream of the Wnt pathway: TCF1 (T-cell factor 1, the product 
of the Tcf7 gene, referred to as Tcf1 throughout this article), LEF1 (Lymphocyte-Enhancer-
binding Factor), or the homologous factors TCF4 and TCF3. All TCF/LEF factors belong to a 
family of high-mobility-group (HMG) proteins that utilize the HMG box for sequence-specific 
DNA binding. The HMG boxes of these factors are virtually identical and likely display indistin-
guishable DNA-binding specificities [7],[8]. TCF/LEF nuclear proteins exist as transcriptional 
repressors and only upon binding to β-catenin will form an active transcription complex. For 
TCF1, at least eight isoforms have been identified with different capacities to bind β-catenin, 
thereby influencing the responsiveness of cells toward Wnt signals [9]. The long isoforms of 
TCF1 contain the amino-terminal β-catenin-binding domain, whereas the shorter isoforms 
lack this domain and will therefore function as the naturally occurring repressors of the 
pathway.
A large body of evidence has shown that canonical Wnt signaling is essential for thymocyte 
proliferation and normal T-cell development [10]–[16]. Among the Wnt proteins, specifi-
cally Wnt1 and Wnt4 are essential for thymocyte proliferation [11], which is reflected in 
mice deficient for Wnt1 and Wnt4 that display low thymic cellularity [15]. In addition, 
overexpression of Wnt4 selectively expands thymic output from transduced hematopoietic 
stem cells [17]. Recently, we showed that another Wnt protein, Wnt3a, plays a crucial role 
in fetal thymopoiesis, with Wnt3a−/− thymi showing severely reduced numbers of DP and a 
block of the preceding CD8+ Immature Single Positive (ISP) stage [18], thereby displaying 
an exact phenocopy of fetal thymi in Tcf1−/− mice.
Studies on mice deficient for the Wnt-responsive nuclear proteins reveal crucial roles 
for Tcf1 in T-cell development and Lef1 in B-cell development [19],[20]. Tcf1−/− mutant 
mice have a severe reduction of thymic cellularity and a partial block in thymocyte dif-
ferentiation at the transition from the CD8+ ISP stage to the CD4+CD8+ double positive 
(DP) stage [19]. Thymocytes of Tcf1−/− mice do not proliferate as strong as their wild-type 
counterparts [21]. These data indicate that lack of Tcf1 mainly results in lack of prolifera-
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tion and therefore expansion of the thymocytes. Although Lef1−/− mice have normal T-cell 
development, mice deficient in both Lef1 and Tcf1 have a complete block in T-cell differen-
tiation at the ISP stage, which indicates redundancy between these two factors [22]. The 
block in T-cell development in Tcf1-deficient mice was shown to be caused by lack of Wnt 
mediated signals, as Tcf isoforms without the β-catenin binding domain could not restore 
T-cell development, but Tcf isoforms containing the interaction domain with the Wnt me-
diator β-catenin fully reconstituted T-cell development [23]. In addition, soluble Frizzled 
receptors acting as inhibitors of Wnt signaling [11], or overexpression of an inhibitor of 
the interaction between β-catenin and Tcf/Lef factors, ICAT [13], inhibited T-cell develop-
ment at the same stages as Tcf1 KO mice. Recent studies by the laboratories of Bhandoola 
and Gounari further emphasize the importance of Tcf1 as a critical regulator of T-lineage 
specification and differentiation. These investigators demonstrate that Tcf1 is critical for 
induction of a T-cell-specific gene program in stem cells and uncommitted progenitors [16]. 
In addition, the Gounari lab showed that ETPs lacking Tcf1 fail to develop normally [10]. 
Together, these studies conclusively point to Tcf1 as an essential transcriptional regulator 
of T-cell specification, commitment, and lineage determination [24]. Here we report that 
Tcf1, besides acting as a Wnt responsive transcription factor, also has an important other 
function, namely as tumor suppressor for the development of T-cell lymphomas.
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Results
Lack of Tcf1 Induces Thymic Lymphomas with High Frequency
The generation of mice lacking the Wnt-responsive factor Tcf1 revealed a crucial role for Tcf1 
in T-cell development [19]. Tcf1−/− mice have thymi characterized by low cellularity (fewer 
than 107 cells at 6–8 wk of age, compared to >108 cells in littermates [19]), which is due 
to the blocks at the DN and ISP developmental stages. Strikingly, over time an increasing 
number of Tcf1−/− mice were found with an extremely enlarged thymus (example in Figure 
1A). The occurrence of these enlarged thymi in Tcf1−/−mice was not a rare finding. Study-
ing the thymi of 150 Tcf1−/− mice showed a clear bimodal distribution in thymic cellularity 
(Figure 1B). A threshold in thymocyte numbers occurs at 18×106 thymocytes. A cellularity 
of <18×106 cells can therefore be regarded as a normal size Tcf1−/− thymus, whilst a thymus 
with a cellularity >18×106 cells can be regarded as an abnormal enlarged thymus. The right 
graph of Figure 1B demonstrates an increasing percentage of Tcf1−/− mice with a hyperplastic 
thymus with increasing age. This hyperproliferation could be caused by increased normal 
proliferation or by the presence of a clonal population of tumor cells. Results described 
below collectively demonstrate that these cells are neoplastic in nature and represent 
thymic lymphomas (Figures 1C and 2). Immunohistochemical analysis shows that neoplastic 
cells completely disrupted the thymic architecture (Figure 1C), and loss of corticomedullary 
demarcation was evident. Neoplastic cells invaded the thymic capsule, neighboring adipose 
tissue, thoracic organs, liver, kidney, spleen, and lymph nodes. Abdominal organs (liver and 
kidney) and lymphatic tissues (spleen and lymph nodes) have been shown to be preferential 
sites for metastasis of systemic lymphomas [25].
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Figure 1. Tcf12/2 mice develop thymic lymphomas. (A) Heart with thymus and spleen of one Tcf1+/2 and three Tcf12/2 mice are shown. The
number of thymocytes of the mice is from top to bottom: 79, 9, 110, and 3556106 cells. (B) Tcf12/2 mice are sacrificed at a certain age (8–10, 10–15,
15–18, or .18 wk), and according to the bimodal distribution of the thymus size, mice were considered to have a tumor when the thymus contains
Tcf1 is a T-Cell-Specific Tumor Suppressor Gene
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ure 1. Tcf1−/− mice develop thy ic lymphomas. 
(A) Heart with thymus and spleen of  one Tcf1+/− and three Tcf1−/− mice are shown. The number of  thymocytes of  
the mice is from top to bottom: 79, 9, 110, and 355×106 cells. (B) Tcf1−/− mice are sacrificed at a certain age (8–10, 
10–15, 15–18, or >18 wk), and according to the bimodal distribution of  the thymus size, mice were considered to have 
a tumor when the thymus contains >18×106 cells. In total 150 Tcf1−/− mice were analyzed. The percentage of  mice 
categorized to have a tumor is shown for each age group in the right panel. (C) Histopathology of  normal tissue compared 
to tumors from Tcf1−/− mice. Paraffin sections of  thymus, liver (Tcf1+/+ and Tcf1−/−), and heart (Tcf1−/− only) were 
stained with hematoxylin and eosin (HE). The HE sections of  the Tcf1−/− mouse show neoplastic cells arranged in 
cords and sheets in the thymus that infiltrate in the liver and the heart; final magnification, 100×.
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Figure 2. Tcf12/2 thymic lymphomas are phenotypically heterogeneous, malignant, and oligoclonal. (A) Thymocytes, bone marrow
(BM) cells, splenocytes, and lymphocytes obtained from lymph nodes (LN) were stained for CD4, CD8, CD44, and CD25. The CD4/CD8 and CD44/CD25
plot is shown for lineage negative cells for all the different organs. Results are shown for one Tcf1+/2 mouse and three representative Tcf12/2 mice.
Tcf1 is a T-Cell-Specific Tumor Suppressor Gene
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Figure 2. Tcf1−/− thymic lymphomas are phenotypically heterogeneous, malignant, and oligo-
clonal. 
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Figure 2. Tcf1−/− thymic lymphomas are phenotypically heterogeneous, malignant, and oligo-
clonal. (continued)
(A) Thymocytes, bone marrow (BM) cells, splenocytes, and lymphocytes obtained from lymph nodes (LN) were stained 
for CD4, CD8, CD44, and CD25. The CD4/CD8 and CD44/CD25 plot is shown for lineage negative cells for 
all the different organs. Results are shown for one Tcf1+/− mouse and three representative Tcf1−/− mice. (B) Left panel, 
genomic DNA was prepared from thymocytes derived from a Tcf1+/− mouse (Lane 1, showing the germline band and a 
faint pattern of  additional bands) and four different Tcf1−/− mice with thymic lymphomas (DN3 tumor, Lane 2; DP 
tumors, Lanes 3 and 4) and an ISP tumor (Lane 5). The asterisk indicates the fragment expected for the germ-line 
(g.l.) TCRβ gene configuration. On the left side, a size marker (M) was included of  which the sizes are indicated in the 
figure (kD). Right panel, genomic DNA was prepared from different organs, T (thymus), B (bone marrow), S (spleen), 
LN (lymph nodes), and Liv (liver) of  one control Tcf1+/− mouse and four different Tcf1−/− mice. The phenotype of  
the lymphoma as determined by FACS analysis is shown for each mouse. The first lane includes a size marker (M) of  
which the sizes (kD) are indicated in the figure. (C) Tcf1−/− tumor cells characterized by an intermediate expression of  
CD3 and CD25 were injected into sublethally irradiated Rag1−/− mice by tail vein injection. Mice were bled at the time 
of  injection, 4 and 6 wk after injection. The presence of  CD3+CD25+ tumor cells in blood is indicated per mouse 
(n = 8). (D) Six weeks after transfer of  the cells, the mice were sacrificed and the thymus, bone marrow, and spleen were 
analyzed for the presence of  tumor cells. Cell suspensions were stained for lineage markers (Mac1, Gr1, B220, Ter119, 
and NK1.1) and CD4, CD8, CD3, CD44, and CD25. An example of  the gating strategy is shown for a bone 
marrow sample. The percentage of  CD3+CD25+ tumor cells is shown per mouse per organ.
Tcf1−/− Induced Thymic Lymphomas Are Clonal and Highly Metastatic
The lymphomas have different phenotypic characteristics that to some extend reflect the 
developmental blocks. Thus, the different lymphomas in the Tcf1−/− thymi were categorized 
into several phenotypically distinct subgroups or mixtures thereof: DN1, DN3, ISP, or the 
DP stage (examples of DN3, ISP, and DP lymphomas are shown in Figure 2A). The different 
phenotypes are not correlated to the age of the mice, and their frequency is: 5% DN1, 32.5% 
DN3, 40% ISP, and 22.5% DP (n = 40 Tcf1−/− tumor mice). The thymocytes overpopulating 
the thymus were present in other hematopoietic organs such as spleen, bone marrow, and 
lymph nodes (Figure 2A), suggesting the high malignant capacity of these cells to invade 
other organs as expected from the size of the organs. To examine whether this aggressive 
proliferation of thymocytes was due to clonal expansion, a Southern Blot analysis was 
performed, using the Jβ2 region of the TCRβ gene. In contrast to DNA from a Tcf1+/− control 
thymus, which shows the germline band (g.l. indicated by the arrow) and a heterogeneous 
mix of bands characteristic of a polyclonal cell population (Figure 2B, left panel, Lane 1), 
the lymphoma samples only showed between two and four distinct bands (germline and 
one or more rearranged alleles), indicating that they consisted of one or two independent 
clones (Figure 2B, left panel, Lanes 2–5). Interestingly, the same clonal band was found in 
the metastases in the secondary organs, BM, spleen, liver, and lymph nodes (Figure 2B, right 
panel). To further confirm the malignancy of these thymic lymphomas and their ability to 
grow autonomously and invade the organs in secondary recipients, 5×105 thymocytes were 
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transferred into sublethally irradiated Rag1−/− recipients. The malignant donor thymocytes 
were derived from Tcf1−/− mice, characterized by intermediate expression of CD3 and CD25, 
and control donor thymocytes were obtained from Tcf1+/− mice. Four weeks after transfer, 
the tumor cells (as characterized by the expression of CD3 and CD25) were present in pe-
ripheral blood in 50% of the recipient mice (Figure 2C). Six weeks after transfer, all animals 
were sacrificed. Recipients receiving the malignant thymocytes of Tcf1−/− origin all displayed 
an enlarged liver and spleen, and tumor cells were detectable by flow cytometry in all organs 
tested (thymus, BM, spleen; Figure 2D). Together these results demonstrate that a lack of 
Tcf1 predisposes mice to a high risk of developing thymic lymphomas, which are clonal and 
characterized by an aggressive metastatic phenotype. These results indicate that Tcf1 func-
tions as a tumor suppressor gene in the thymus.
Tcf1−/− Thymic Lymphoma Cells Exhibit Deregulated Wnt Pathway
To gain insight into the molecular mechanism underlying the Tcf1-deficient tumor develop-
ment, we compared the gene expression profile of thymocytes derived from Tcf1−/− mice 
with tumors, Tcf1−/− mice of similar age without tumors, and control Tcf1+/− mice. Samples 
of 17 mice were studied by genome-wide expression profiling using Affymetrix microarrays, 
namely five control Tcf1+/− mice, four Tcf1−/− mice without tumor, and eight thymic tumors 
from Tcf1−/− mice. Expressions of several oncogenes, known to be involved in leukomogen-
esis, were analyzed and were not up-regulated in the thymic lymphomas compared to the 
Tcf1−/− without lymphomas (Tal1, Tal2, Lyl1, Lmo1, Lmo2, SilTal, p53; unpublished data). 
Analysis of components of the Wnt pathway confirmed that Tcf1 (Tcf7) expression was ab-
sent (as expected) in the Tcf1−/− thymocytes (with and without a tumor), whilst in all but one 
Tcf1−/− tumor sample, the expression level of the transcription factor Lef1 was up-regulated 
compared to control (Tcf1+/−) thymocytes (Figure 3A, left panel).
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Figure 3. Tcf12/2 lymphomas show deregulated Wnt signaling. (A) RNA isolated from thymi of 17 different mice was used for microarray
analysis. Expression of Lef1, Tcf7, Myc, and Hes1 in the Tcf12/2 mice without lymphoma (n=4), Tcf1+/2 mice (control, n=5) and Tcf12/2 mice with a
lymphoma (Lymphoma, n=8) is shown. For the Tcf12/2 lymphoma mice, the phenotype of the tumor is indicated on the horizontal axis. Columns
represent independent RNA preparations of the differentmice groups. A principal component analysis was performed usingWnt and Notch target genes. A
PCA analysis shows clustering of the three groups as well as the effect each of the target genes has on the separation of these groupswith samples of Tcf1+/
2, Tcf12/2, and Tcf12/2with tumors indicated by red, black, and green spheres, respectively. (B) Expression levels of Tcf1, Lef1, Axin2, Cyclin D1, cMyc, Hes1,
and Deltex1 as determined by Affymetrix microarray were summarized and normalized using RMA, and the expression relative to Abl was plotted for each
sample. Statistical significant differences (p,0.05) as determined by Mann–Whitney U test are indicated by an asterisk. (C) A panel of 40 Tcf12/2 thymic
lymphomas and four control thymi (Tcf1+/2) were analyzed by RQ-PCR. Expression data for Lef1 long (containing the b-catenin interacting domain), Axin2,
Deltex1, and Hes1 are shown relative to the house keeping gene Abl. Mann–Whitney U tests were performed to calculate the indicated p values.
doi:10.1371/journal.pbio.1001430.g003
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Figure 3. Tcf1−/− lymphomas show deregulated Wnt signaling. 
(A) RNA isolated from thymi of  17 different mice was used for microarray analysis. Expression of  Lef1, Tcf7, 
Myc, and Hes1 in the Tcf1−/−mice without lymphoma (n = 4), Tcf1+/− mice (control, n = 5) and Tcf1−/− mice with 
a ly phoma (Lymphoma, n = 8) is shown. For the Tcf1−/− lymphoma mice, the phe otype of  the tumor is indicated 
on the ho izontal axis. Columns represent independent RNA preparations of  the different mice groups. A principal 
component analysis was performed using Wnt and Notch target genes. A PCA analysis shows clustering of  the three 
groups as well as the effect each of  the target genes has on the separation of  these groups with samples of  Tcf1+/−, 
Tcf1−/−, and Tcf1−/− with tumors indicated by red, black, and green spheres, respectively. (B) Expression levels of  Tcf1, 
Lef1, Axin2, Cyclin D1, cMyc, Hes1, and Deltex1 as determined by Affymetrix microarray were summarized and 
normalized using RMA, and the expression relative to Abl was plotted for each sample. Statistical significant differences 
(p<0.05) as determined by Mann–Whitney U test are indicated by an asterisk. (C) A panel of  40 Tcf1−/− thymic 
lymphomas and four control thymi (Tcf1+/−) were analyzed by RQ-PCR. Expression data for Lef1 long (containing the 
β-catenin interacting domain), Axin2, Deltex1, and Hes1 are shown relative to the house keeping gene Abl. Mann–
Whitney U tests were performed to calculate the indicated p values.
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Principal component analysis of the Wnt target genes in all 17 thymic samples confirmed the 
obvious discriminating factor between Tcf1−/− and Tcf1+/− samples to be Tcf7 (the HUGO gene 
name for Tcf1). The Tcf1−/− tumor samples were clearly distinguished by factors involved 
in the Wnt-signaling pathway, Axin2, Lef1, and Tnfrsf19, or in the Notch signaling path-
way, Deltex1 and Hes1 (Figure 3A, right panel). These results indicated that both Wnt and 
Notch signaling are affected in the Tcf1−/− tumor samples compared to the other two groups. 
Tcf1−/− samples without a tumor were distinguished by low expression of the following fac-
tors: Emp1, Krt8, Runx2, CD44, Fn1, Jag1, Id2, and Cdh1. Several of these genes are known 
to be Wnt target genes (Runx2, Id2, CD44, and Fn1). These data show ectopic up-regulation 
of Wnt signaling as demonstrated by high expression of Lef1, CyclinD1, and c-Myc as well 
as Notch target genes Hes1 and Deltex1 (Figure 3B). Collectively, these data indicate that 
interaction between the Wnt and Notch pathways is necessary for full lymphomagenesis.
Confirmation of the array data was performed with a panel of 40 Tcf1−/− thymic lymphomas 
by Q-PCR. In all tested tumor samples, the expression level of Lef1 was increased com-
pared to thymocytes of control mice (Figure 3C). The mean expression Axin2 level of the 
40 tumor samples was 4 times elevated compared to the mean expression Axin2 level of 
the control mice (1.2 versus 0.3), with 29 of the 40 tumor samples (73%) having a higher 
Axin2 level than 0.3 (Figure 3C). Moreover, the high Axin2 expression in the majority (73%) 
of lymphomas in combination with the universally up-regulated Lef1 expression indicates 
a marked increase in Wnt signaling in these lymphomas. Further analysis of this panel of 
lymphomas showed that the expression levels of Hes1 and Deltex1, two target genes of 
Notch1 signaling, were enhanced in all tumor samples compared to the control samples 
(Figure 3C), again demonstrating that both the Wnt and Notch pathway are involved in 
full lymphomagenesis. As high Lef1 expression is already present in pre-leukemic samples 
(Figure 3A), it is likely that deregulated Wnt signaling predisposes thymocytes to induc-
tion of activating somatic mutations in Notch1, which subsequently accelerate lymphoma 
development.
Wnt-Reporter Activity Is Minimally Present in Normal Tcf1−/− Thymocytes and 
Enhanced in Tcf1−/− Lymphoma Cells
To confirm the paradoxical finding that mice lacking Tcf1 suffer from thymic lymphomas 
due to deregulated high Wnt signaling rather than low, we crossed Tcf1−/− mice with a well-
established Wnt-reporter mouse strain, namely the Axin2-LacZ mice. Wnt-activity in these 
mice can be measured by the expression of β-galactosidase driven by the Axin2 promoter. 
In Figure 4A, the CD4/CD8 dot plots are shown of thymocytes of four different representa-
tive mice. The histograms show the Wnt-activity in DP, ISP, and DN3 cells for Tcf1+/− thy-
mocytes (filled), Tcf1−/− thymocytes (thin line), and tumor Tcf1−/−thymocytes (thick line). 
The thymocyte subsets of a Tcf1−/− control mouse without a tumor show severely reduced 
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Wnt-activity in ISP and DN3 thymocyte subsets compared to the Tcf1+/− control mouse (Mean 
Fluorescence Intensity [MFI] of 385 and 104 compared to 874 and 635 in control ISP and 
DN3, respectively), indicating a strongly diminished nuclear response to Wnt signals due to 
the Tcf1 deficiency. Interestingly, residual Wnt-activity can be measured in Tcf1−/− thymo-
cytes, which suggests that Lef1 is mediating low levels of Wnt-activity in Tcf1−/− mice as 
a likely compensatory mechanism (as also shown by Figure 3A). Tcf1−/− mice developing 
lymphomas show enhanced Wnt activity in the developmental stages in which the tumor 
cells are blocked (MFI of 1,425 and 1,225 for Wnt-reporter signal in DP and ISP for tumor 1 
and 2,123, 2,374, and 1,203 in DP, ISP, and DN3 for tumor 2). The thymi of the Tcf1+/− control 
mouse and the two Tcf1−/− tumor mice displaying high Wnt activity were further examined 
for the RNA expression levels of Lef1 and Hes1. The expression level of Lef1 was increased in 
both Tcf1−/− induced lymphomas, indicating that these high levels of Lef1 underlie the highly 
active Wnt signals in these tumors (Figure 4B). Interestingly, only in tumor 2 (>175×106 cells) 
were high levels of the Notch target gene Hes1 observed, indicating that Notch signaling ac-
celerates or maintains tumor development once it is initiated by deregulated Wnt-signaling. 
Indeed, when we compared the thymus size to the expression level of Hes1, we found that 
only in large Tcf1−/− tumors (>25×106 cells) is the expression level of Hes1 increased (Figure 
4C). These data suggest that a first oncogenic hit is the deregulation in Wnt-signaling due 
to high levels of Lef1 and that deregulation of the Notch-pathway is a secondary acquired 
mutation. To check for mutations in Notch1, we sequenced both the heterodimerization do-
main (HD), exon 26 and 27, and the PEST domain, encoded by exon 34. This analysis showed 
that in Tcf1−/− thymi (without tumor) and Tcf1+/− samples, no mutations were found in the 
three exons (n = 8, unpublished data). Analysis of the panel of 40 Tcf1−/− thymic lymphomas 
demonstrated mutations in exon 34 in all but one thymic lymphoma sample (unpublished 
data), which is known to promote Notch1 signaling by increasing the half-life of intracellular 
Notch, hence promoting tumor survival and growth. Together, these results suggest that 
Tcf1 deficiency leads to a pre-leukemic stage that favors additional mutations, most notably 
in Notch1.
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Discussion
During normal hematopoiesis, Tcf1 is required to induce and
maintain proliferation of developing T cells in the thymus [19] and
inhibit apoptotic signals at the DP stage [23]. Absence of Tcf1 not
only results in a severely reduced thymic cellularity but also blocks
differentiation of the thymocytes [11,19,21]. It is remarkable that
Tcf12/2 cells blocked in differentiation develop into lymphoma
cells, as we here report. We propose that Tcf12/2 blocked
thymocytes give rise to lymphoma cells due to deregulated Wnt
signaling, which is driven by expression of deregulated expression
of Lef1. This model is based on several key observations (Figure 7).
First of all, in essentially all Tcf12/2 tumors, a high expression of
Lef1 (selectively of the long form of Lef1, which is able to bind b-
catenin) was found. This up-regulation of Lef1 likely acts as a
compensatory mechanism for the lack of Tcf1 and is probably
caused by lack of repression by Tcf1. We show much higher Tcf1
than Lef1 expression in the normal thymus, including the naturally
occurring dominant negative isoforms of Tcf1. This suggests a
direct repressor function of Tcf1 for Lef1 expression given the
normally much higher Tcf1 than Lef1 expression in thymus.
Especially since Lef1 has more long-beta catenin responsive
Figure 4. Blocked Tcf12/2 thymocytes show high Wnt-signaling in lymphoma development. (A) Tcf12/2 mice were crossed to
Conductin(Axin2)-LacZ reporter mice and sacrificed at different ages. Dot plots of four representative mice are shown: one control Tcf1+/2 LacZ (age
20 wk), one control Tcf12/2 LacZ (age 9 wk), and two Tcf12/2 Axin2-LacZ mice (age 20 wk, Tumor 1+ Tumor 2). Organs were collected and
thymocytes were stained for CD4, CD8, CD3, CD44, and CD25 together with FDG to demonstrate Wnt reporter activity in the different thymocyte
subsets. The corresponding thymus sizes for the four mice shown are 1106106, 176106, 396106, and 1756106 cells, respectively. Expression of Wnt
reporter activity is shown per thymocyte subset, DP, ISP, and DN3 for control cells (filled), Tcf12/2 cells (thin line), and Tcf12/2 tumor cells (thick line).
(B) RNA was isolated of total thymus and the expression level of Lef1 and Hes1 relative to Abl is shown for the control thymus and the two tumor
samples as shown in (A). (C) The mean expression levels of Hes1 relative to Abl are shown for small tumors (n=5) and large tumors (n=25).
doi:10.1371/journal.pbio.1001430.g004
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Figure 4. Blocked Tcf1−/− thymocytes show high Wnt-signaling in lymphoma development.
(A) Tcf1−/− mice were crossed to Conductin(Axin2)-LacZ reporter mice and sacrificed at different ages. Dot plots of  
four representative mice are shown: one control Tcf1+/− LacZ (age 20 wk), one control Tcf1−/− LacZ (age 9 wk), and 
two Tcf1−/− Axin2-LacZ mice (age 20 wk, Tumor 1+ Tumor 2). Organs were collected and thymocytes were stained 
for CD4, CD8, CD3, CD44, and CD25 together with FDG to demonstrate Wnt reporter activity in the different 
thymocyte subsets. The corresponding thymus sizes for the four mice shown are 110×106, 17×106, 39×106, and 
175×106 cells, respectively. Expression of  Wnt reporter activity is shown per thymocyte subset, DP, ISP, and DN3 
for control cells (filled), Tcf1−/− cells (thin line), and Tcf1−/− tumor cells (thick line). (B) RNA was isolated of  total 
thymus and the expression level of  Lef1 and Hes1 relative to Abl is shown for the control thymus and the two tumor 
samples as shown in (A). (C) The mean expression levels of  Hes1 relative to Abl are shown for small tumors (n = 5) 
and large tumors (n = 25).
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Tcf1 Is the Major TCF/LEF Factor in the Thymus and Its Short Isoforms Function as 
Repressors of Lef1 Expression
To gain further insight into the mechanism underlying lymphomagenesis, the balance be-
tween the long and short isoforms of Lef1 and Tcf1 was investigated. It is known that the 
balance between the long and short isoforms of these factors is crucial in regulating Wnt sig-
naling, as only the long isoform can bind β-catenin and hence mediate Wnt signaling, whilst 
the short isoform is considered the natural antagonist of Wnt signaling (a simplified version 
of the short versus the long form of Lef is shown in Figure 5A). Analysis of the Tcf1−/− tumor 
samples (RNA and protein) revealed that the normal ratio of long over short isoforms for 
Lef1 was altered in favor of the long isoform of Lef1, which mediates transcription of Wnt-β-
catenin target genes (Figure 5A). The RNA levels of Tcf1 and Lef1 in normal thymus indicated 
a 10 times higher expression of Tcf1 than Lef1 in the thymus (Figure 5B). This is further 
illustrated by an example of the protein levels of Tcf1 and Lef1 in a nuclear extract protein 
sample of total thymocytes (Figure 5B, right panel). Reciprocal regulation of Tcf1 and Lef1 at 
the protein level was further examined in the major sorted thymic subsets (DN, DP, and SP). 
Of interest, the ratio between long Wnt responsive isoforms and short repressor isoforms 
is different for Tcf1 versus Lef1. For Tcf1, there is a clear expression of the inhibitory short 
isoforms in all thymocyte subsets, whilst for Lef1 in all stages the long β-catenin binding form 
is more abundant, except for the single-positive stage (Figure 5C). This suggests that major 
repressors of Wnt signaling in the thymus are formed by the Tcf1 short isoforms. Therefore, 
in the absence of Tcf1, a repression of Lef1 expression in the thymus is diminished. This 
allows for high levels of Lef1, which naturally occurs in a ratio of more Wnt responsive than 
inhibitory isoforms, hence strengthening the Wnt responsiveness of the (pre)leukemic cells. 
Thus, a major function of Tcf1 appears to control Lef1 expression via its short isoforms.
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Figure 5. Lack of Tcf1 deregulates the balance between long and short isoforms of Lef1 in Tcf1-deficient lymphomas. (A) A schematic
representation of the long and short isoform of Lef1, depicting the b-catenin binding domain and the HMG-box (DNA binding domain). The ratio of
Lef1 long isoform versus Lef1 short isoform was determined using RQ-PCR for 40 lymphomas, four control thymi, and three Tcf12/2 thymi without
tumor. The long versus short ratio for Lef1 at the protein level is depicted for four different Tcf12/2 thymic tumors (tumor size: 19, 224, 118, 306106
cells/ml, respectively). (B) Left panel, total Tcf and Lef RNA levels relative to Abl were determined using the data obtained from the Affymetrix data
shown in Figure 3A (Tcf1+/2 total thymus, n=5). In the middle panel, a Western blot analysis and quantification (right panel) for nuclear protein
extracts of total thymocytes (Tcf1+/+ mouse) is shown. (C) Representative Western blots of two independent experiments (Exp A and Exp B) of sorted
Tcf1 is a T-Cell-Specific Tumor Suppressor Gene
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Figure 5. Lack of Tcf1 deregulates the balance between long and short isoforms of Lef1 in Tcf1-
d ficient lymphomas. 
(A) A schematic represen ation of  the long and short isoform of  Lef1, epic ng the β-catenin binding domain and the 
HMG-box (DNA binding domain). The ratio of  Lef1 long isoform versus Lef1 short isoform was determined using 
RQ-PCR for 40 lymphomas, four control thymi, and three Tcf1−/− thymi without tumor. The long versus short ratio for 
Lef1 at the protein level is depicted for four different Tcf1−/−thymic tumors (tumor size: 19, 224, 118, 30×106 cells/
ml, respectively). (B) Left panel, total Tcf  and Lef  RNA levels relative to Abl were determined using the data obtained 
from the Affymetrix data shown in Figure 3A (Tcf1+/− total thymus, n = 5). In the middle panel, a Western blot 
analysis and quantification (right panel) for nuclear protein extracts of  total thymocytes (Tcf1+/+ mouse) is shown. (C) 
Representative Western blots of  two independent experiments (Exp A and Exp B) of  sorted thymocyte subsets from 
two control Tcf1+/+mice. Cell populations were sorted into the subsets DN, DP, and SP using lineage markers; CD3, 
CD4, CD8, CD44, and CD25 and total protein extracts were generated. Antibodies recognizing all isoforms of  Tcf1 
and Lef1 were used, and β-actin was used a loading control for the Western blots. Quantification of  the Tcf  and Lef  
signal of  all Western blots was performed by ImageQuant J.
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Deregulated Wnt Signaling Frequently Cooperates with Deregulated Notch Signaling 
in Tcf1−/− Induced Lymphomas
The data described above suggest that both deregulated Wnt as well as Notch signaling 
are required for development of the Tcf1-deficient lymphomas. To investigate the Wnt and 
Notch dependency, we performed a number of experiments with pharmacological drugs 
and genetic tools. Using the γ-secretase inhibitor DAPT, a potent Notch1 inhibitor, clear loss 
of survival and proliferation was observed in Tcf1−/−tumor cells (Figure 6A, left figure). More-
over, the high Lef1 levels in the tumor cells appeared not to be a result of the deregulated 
Notch signaling, as inhibition of the Tcf1−/− tumor cells by DAPT only mildly affects Lef1 levels, 
whilst both Notch target genes Hes1 and Deltex were completely down-regulated (Figure 
6A, right figure). Ongoing activation of the Wnt signaling pathway was shown to be crucial 
for the survival of the Tcf1−/− tumor cells in two different sets of experiments. First of all, 
incubation of the generated Tcf1−/− cell lines with the Wnt inhibitor Quercetin, which blocks 
the interaction between β-catenin and Tcf/Lef factors, induces rapid cell death (7 h), whilst 
the non-Wnt-dependent Jurkat cell line was minimally affected (Figure 6B). In addition, 
transfection of a dominant negative form of Tcf1/Lef1 in Tcf1−/− lymphoma cells also induced 
rapid cell death (>80% cell death after 6 h; Figure 6C). Thus, both ongoing Wnt and Notch 
signaling are required for the survival of Tcf1-deficient lymphomas.
To further investigate the Wnt and Lef1 dependency, we performed reporter gene analysis 
using the natural Lef1 promoter, which contains four consensus Tcf/Lef binding sites (Figure 
6D). The luciferase experiments with the Lef1 promoter show that this promoter is Wnt 
responsive and demonstrate that Lef1 expression can be up-regulated by β-catenin-Lef1 
complexes, providing a positive feedback loop. Such a positive feedback loop has been 
suggested before [25]. Consistent with the Wnt responsiveness, transfection of a ΔN Tcf1 
construct, which acts as a dominant negative competitor, was capable of abolishing the 
β-catenin-induced activation of Lef1-dependent transcription. Thus, the Lef1 promoter is 
Wnt responsive and negatively regulated by short Tcf1 isoforms that lack the β-catenin 
interaction domain. Taken together, these data indicate that the highly deregulated Wnt 
signaling in the tumor cells is driven by Lef1; that it is frequently associated with increased 
Notch signaling, which acts as a collaborative oncogenic event; and that it is continuously 
required for survival of these lymphomas.
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Figure 6. Tcf1-deficient lymphoma cells depend onWnt and Notch signaling for their survival. Several Tcf12/2 cell lines were established
from Tcf12/2 thymic lymphomas, and all cell lines show Notch1 mutations and a high ratio of Lef1 long over short isoform. (A) The TCF05 cell line
(phenotyped as an ISP tumor) was cultured in the absence and presence of the indicated concentrations of c-secretase inhibitor (DAPT). Percentage
of live cells was determined after 24, 48, and 72 h using flow cytometry (AnnexinV/7AAD staining). After 24 and 48 h cell cycle analysis was
determined by propidium iodide staining, and the relative expression of Hes1, Deltex, Lef1-L, and Lef1-S was determined. For the cell cycle analysis,
one representative example is shown and the mean expression levels relative to Abl are shown of two independent experiments. (B) Three cell lines
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Figure 6. Tcf1-deficient lymphoma cells depend on Wnt and Notch signaling for their survival. 
Several Tcf1−/− cell lines were establis  from Tcf1−/− thymic lymp omas, and ll c ll lin s show Notch1 mutations 
and a high ratio of  Lef1 long ov r short isofo m. (A) Th  TCF05 cell line (ph notyped as an ISP tum ) was cultured 
in the absence and presence of  the indicated concentrations of  γ-secretase inhibitor (DAPT). Percentage of  live cells 
was determined after 24, 48, and 72 h using flow cytometry (AnnexinV/7AAD staining). After 24 and 48 h cell 
cycle analysis was determined by propidium iodide staining, and the relative expression of  Hes1, Deltex, Lef1-L, and 
Lef1-S was determined. For the cell cycle analysis, one representative example is shown and the mean expression levels 
relative to Abl are shown of  two independent experiments. (B) Three cell lines (Jurkat, TCF05, and TCF07) were 
cultured for 7 h in the presence or absence of  Quercetin (25 µM), and the percentage of  live cells was determined by flow 
cytometry (7AAD/AnnexinV staining). The mean percentage (± SEM) of  live cells (7AAD−/AnnV−) is shown 
for the three cell lines of  three independent experiments. (C) The Tcf1−/− cell line TCF07 was established from a thymic 
lymphoma characterized as a DN3 tumor with a mutation in exon 34 of  Notch1. This cell line and Jurkat cells were 
transfected with a GFP construct in combination with a control construct (pcDNA3) or a dominant negative Lef1/
Tcf1 (pcDNA ΔNTCF) construct (used ratio GFP∶construct, 1∶10). The percentage of  viable cells was determined 
within the transfected (GFP+) cells after 6 h. (D) HEK 293 T cells were transfected with a LEF-1 luciferase reporter 
plasmid containing Tcf/Lef-responsive elements. The cells were cotransfected with S33-Bcat or pCI (3 µg) or Delta N 
Tcf1 together with S33 B cat. To control for transfection efficiency, all transfections included the pRLTK-renilla reporter 
(0.15 µg). Luciferase activities are shown as mean of  three independent experiments normalized to renilla activity.
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Discussion
During normal hematopoiesis, Tcf1 is required to induce and maintain proliferation of devel-
oping T cells in the thymus [19] and inhibit apoptotic signals at the DP stage [23]. Absence 
of Tcf1 not only results in a severely reduced thymic cellularity but also blocks differentiation 
of the thymocytes [11],[19],[21]. It is remarkable that Tcf1−/− cells blocked in differentiation 
develop into lymphoma cells, as we here report. We propose that Tcf1−/− blocked thymocytes 
give rise to lymphoma cells due to deregulated Wnt signaling, which is driven by expression 
of deregulated expression of Lef1. This model is based on several key observations (Figure 
7). First of all, in essentially all Tcf1−/− tumors, a high expression of Lef1 (selectively of the 
long form of Lef1, which is able to bind β-catenin) was found. This up-regulation of Lef1 
likely acts as a compensatory mechanism for the lack of Tcf1 and is probably caused by 
lack of repression by Tcf1. We show much higher Tcf1 than Lef1 expression in the normal 
thymus, including the naturally occurring dominant negative isoforms of Tcf1. This suggests 
a direct repressor function of Tcf1 for Lef1 expression given the normally much higher Tcf1 
than Lef1 expression in thymus. Especially since Lef1 has more long-beta catenin responsive 
isoforms (except in the SP stage), while Tcf1 has slightly more expression of the short form. 
Hence in the complete absence of Tcf1, Lef1 will take over as a Wnt-responsive transcription 
factor in the thymus. Thus, the lymphoma development is initiated by developmental arrest 
due to lack of Tcf1; thereby, the suppression of Lef1 expression by short Tcf1 isoforms is 
lifted. This leads to higher Lef1 expression and a propensity to higher Wnt responsiveness, 
restoring proliferation and increasing Wnt target gene expression and concomitantly to the 
possibility of induction of somatic mutations, such as those found in Notch1. Lef1 expression 
can be further enhanced by Notch, as shown in lymphomas that lack the E2A transcription 
factor [27]. Moreover, Lef1 can also positively regulate its own expression through Wnt 
dependent ([26], plus data in Figure 6D) and independent mechanisms [26],[28]. Finally, 
up-regulation of other oncogenes will lead to frank lymphoma/leukemia development. In 
this respect, up-regulation of T-ALL oncogenes such as Lmo2 and Mef2C in the Tcf1−/− thymo-
cytes may also contribute to the preleukemic nature of these cells. Importantly, the in vivo 
evidence for this model was provided by crossing Tcf mice with Axin2-LacZ-reporter mice. 
Tcf1−/− mice without tumors have a reduced level of Wnt-activity in all thymocyte subsets 
compared to Tcf1+/− mice, whilst Tcf1−/− thymic lymphoma cells show a very high level of 
Wnt-activity in blocked thymocytes.
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Flowcytometry
The following antibodies were obtained from BD Biosciences
(San Diego, CA): anti-CD3-APC (145-2C11), anti-CD4-PeCy7
(RM4-5), anti-CD8-PerCP(53-6.7), anti-CD25-PE (PC61), anti-
CD44-PE (IM7), anti-CD24-FITC (M1/69), anti-cKit-PeCy7
(2B8). Lineage markers Mac1 (M1/70), Gr1 ((RB6-8C5), B220
(Ra3-6B2), and Ter119 and Nk1.1 (PK136) were all biotinylated
and streptavidin APC-Cy7. Cells were stained in Fluorescence-
activated cell sorter (FACS) buffer (PBS, 2% bovine serum
albumin, 0.1% sodium azide) for 30 min at 4uC. Intracellular b-
galactosidase activity was measured by staining cells with 2 mM
fluorescein di-b-D-galactopyranoside (FDG) substrate (Molecular
Probes). FDG was loaded into the cells by hypotonic shock at 37uC
for 1 min, prior to cell surface antibody staining. The b-
galactosidase reaction was stopped with 1 mM phenylethyl b-D-
thiogalactopyranoside (PETG, from Molecular Probes). Cells were
(Jurkat, TCF05, and TCF07) were cultured for 7 h in the presence or absence of Quercetin (25 mM), and the percentage of live cells was determined by
flow cytometry (7AAD/AnnexinV staining). The mean percentage (6 SEM) of live cells (7AAD2/AnnV2) is shown for the three cell lines of three
independent experiments. (C) The Tcf12/2 cell line TCF07 was established from a thymic lymphoma characterized as a DN3 tumor with a mutation in
exon 34 of Notch1. This cell line and Jurkat cells were transfected with a GFP construct in combination with a control construct (pcDNA3) or a
dominant negative Lef1/Tcf1 (pcDNA DNTCF) construct (used ratio GFP:construct, 1:10). The percentage of viable cells was determined within the
transfected (GFP+) cells after 6 h. (D) HEK 293 T cells were transfected with a LEF-1 luciferase reporter plasmid containing Tcf/Lef-responsive
elements. The cells were cotransfected with S33-Bcat or pCI (3 mg) or Delta N Tcf1 together with S33 B cat. To control for transfection efficiency, all
transfections included the pRLTK-renilla reporter (0.15 mg). Luciferase activities are shown as mean of three independent experiments normalized to
renilla activity.
doi:10.1371/journal.pbio.1001430.g006
Figure 7. Mechanism of lymphomagenesis caused by Tcf1 deficiency. In the absence of Tcf1, thymocyte development is blocked at several
stages (DN1, DN3, and ISP). Arrested thymocytes lack all isoforms of Tcf1, including the repressive isoforms. Loss of these repressive isoforms results
in an up-regulation of Lef1, of which the long isoforms are most abundant in the thymus. Subsequently, Lef1 is capable of interacting with b-catenin
as a compensatory mechanism, inducing deregulated Wnt signaling as measured by the high expression of Axin2 in the vast majority of the
lymphomas, forming a pre-leukemic stage. After additional mutations are acquired, of which activating mutation in Notch1 frequently occur, and also
other oncogenes such as Mef2C and Lmo2 are likely candidates to be affected, full-blown lymphoma/leukemia develops.
doi:10.1371/journal.pbio.1001430.g007
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Figure 7. Mechanism of lymphomagenesis caused by Tcf1 deficiency. 
In the absence of  Tcf1, thymocyte development is bl cked at several stages (DN1, DN3, a d ISP). Arrested thymocytes 
lack all isoforms of  Tcf1, including the repressive isoforms. Loss of  these repressive isoforms results in an up-regulation 
of  Lef1, of  which the long isoforms are most abundant in the thymus. Subsequently, Lef1 is capable of  interacting 
with β-catenin as a compensatory mech ism, inducing deregulated Wnt signaling as m asured by the high expression 
of  Axin2 in the vast majority of  the lymphomas, forming a pre-leukemic stage. After additional mutations are acquired, 
of  which activating mutation in Notch1 frequently occur, and also other oncogenes such as Mef2C and Lmo2 are likely 
candidates to be affected, full-blown lymphoma/leukemia develops.
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It is of interest to compare the Tcf1−/− lymphomas with two other murine lymphoma mod-
els, namely those induced by activated β-catenin and by lack of E2A. The development of 
Tcf1−/− lymphomas contrasts with thymic lymphomas induced by overexpression of β-catenin 
in that the latter show no Notch1 mutations [29] but may be dependent on p53 absence [30]. 
In the E2A-deficient lymphomas, Lef1 is a Notch target gene only in the context of the lym-
phoma cells, but not in normal progenitors, and Lef1 is essential for lymphomagenesis. Thus, 
in the absence of normal regulatory mechanisms in thymic lymphoma cells provided by E2A 
or Tcf1, Lef1 can act as an important oncogene. Interestingly, the Tcf1−/− thymic lymphomas 
easily gain additional mutations in the Notch1 gene (in contrast to the β-catenin-dependent 
lymphomas), which leads to further development of these lymphomas. Once Notch1 ex-
pression is established, it may serve as an accelerator of the Lef1-mediated deregulated Wnt 
signaling, ensuring increased survival and expansion of the lymphoma cells [27].
In the human equivalent of these T-cell lymphomas, T-cell acute lymphoblastic leukemias 
(T-ALL), several genetic abnormalities have been described including Notch1 mutations 
in a large proportion of all human T-ALL [31]. While it is difficult to unravel the stepwise 
process of leukemia development in humans, the activating mutations in Notch1 are not 
always the initiating events as shown by data from a leukemia that was observed in a gene 
therapy trail for X-linked SCID [32]. In this case, it was conclusively shown that insertional 
mutagenesis near the LMO2 proto-oncogene was the first genetic aberration followed by 
Notch1 mutations and further genetic aberrations [32]. It will be of high interest to see 
if loss of Tcf1 tumor suppressor function occurs in human T-ALL. Whether loss of func-
tion of Tcf1 as a tumor suppressor gene actually occurs in human T-ALL is currently under 
investigation. Human T-ALL with mutations in Lef1 have been described, although the 
mechanistic consequence of these mutations is currently unclear [33].
Two recent studies from the Bhandoola and Gounari laboratories, respectively, have 
conclusively demonstrated a key role for Tcf1 in establishing T-cell commitment [10],[16].
Deletion of β-catenin in the thymus has been reported both to affect T-cell development 
(using Lck-CRE) or to have no effect at all, when using Mx-Cre-mediated deletion of 
β-catenin [34] or β- and γ-catenin simultaneously [35],[36]. However, our recent work on 
Wnt dosage in various hematopoietic lineages including thymocytes suggests that the lack 
of phenotype using mx-Cre might be caused by the fact that Wnt signaling was not com-
pletely abolished in these models [37],[38]. Moreover, the Held Group also published that 
the Tcf1 phenotype can be complemented by transgenic expression of a long Tcf1 isoform 
but not by a short (non/Wnt responsive) isoform [23]. Therefore, a major role for Tcf1 in 
the thymus is to integrate Wnt responsive signals and thereby allow T-cell development 
to occur normally. Nevertheless, our current work also indicates an important non/Wnt-
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dependent role of TCF, as a negative regulator of the Wnt pathway. The recent work of 
Bhandoola is also interpreted as a non/Wnt-dependent effect. Therefore, it is an intriguing 
possibility that both Wnt-dependent effects of Tcf1 (e.g., Wnt-driven proliferation of DN 
thymocytes) and Wnt-independent effects (induction of T-cell specification) collaborate in 
the early stages of T-cell development.
In summary, we here report that Tcf1 has a dual function during T-cell development: first, 
it is needed as a transcriptional activator of Wnt-induced proliferation, but unexpectedly it 
also acts as a transcriptional repressor and tumor suppressor gene to prevent the develop-
ment of thymic lymphomas and it may also function in a Wnt-independent way in these 
early stages of T-cell development, as suggested by recent work [16] perhaps by repressing 
genes of alternative (non-T) lineages. We conclude that Tcf-1 acts as a molecular switch 




C57Bl/6 Tcf1−/− ΔVII/ΔVII were originally described by Verbeek [19], C57Bl/6-CD45.1 (Ly5.1) and 
C57Bl/6-Rag1−/− mice were obtained from the Jackson Laboratory, and Conductin(Axin2)-
LacZ mice were kindly provided by B. Jerchow and W. Birchmeier (Max Delbrück Center for 
Molecular Medicine, Berlin, Germany) [39]. All mice were kept in the specified pathogen-
free (SPF) breeding section, and this study was approved by the institutional Animal Ethical 
Committee of the Erasmus MC, Rotterdam and the Leiden University Medical Center, Leiden.
Immunohistochemistry
Paraffin sections of organs of Tcf1−/− mice were stained with H&E or with antibody against 
CD3 (A045229; DAKO, Glostrup, Denmark) and biotinylated goat anti-rabbit IgG (BA-1000; 
Vector Labs, Burlingame, CA, USA) as the secondary antibody. Visualization was enforced 
with ABC staining kit (PK6100, Vector Labs) with 3,3′-diaminobenzidine tetrahydrochloride 
(DAB, D5637, Sigma-Aldrich, St Louis, MO, USA) as substrate. Mayer’s hematoxilin was uti-
lized as nuclear counterstaining.
Flowcytometry
The following antibodies were obtained from BD Biosciences (San Diego, CA): anti-CD3-
APC (145-2C11), anti-CD4-PeCy7 (RM4-5), anti-CD8-PerCP(53-6.7), anti-CD25-PE (PC61), 
anti-CD44-PE (IM7), anti-CD24-FITC (M1/69), anti-cKit-PeCy7 (2B8). Lineage markers Mac1 
(M1/70), Gr1 ((RB6-8C5), B220 (Ra3-6B2), and Ter119 and Nk1.1 (PK136) were all biotinyl-
ated and streptavidin APC-Cy7. Cells were stained in Fluorescence-activated cell sorter 
(FACS) buffer (PBS, 2% bovine serum albumin, 0.1% sodium azide) for 30 min at 4°C. Intracel-
lular β-galactosidase activity was measured by staining cells with 2 mM fluorescein di-β-
D-galactopyranoside (FDG) substrate (Molecular Probes). FDG was loaded into the cells by 
hypotonic shock at 37°C for 1 min, prior to cell surface antibody staining. The β-galactosidase 
reaction was stopped with 1 mM phenylethyl β-D-thiogalactopyranoside (PETG, from Mo-
lecular Probes). Cells were washed and immediately analyzed on a Canto I (BD Biosciences). 
Data were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
In Vivo Tumor Induction
Lymphoma or thymocyte suspensions of previously characterized mice were prepared asep-
tically. Cells (5×105) were injected in the tail vein of sublethally irradiated (4 Gy) Rag1−/− mice. 
The mice were bled every 4 wk until the end of the experiment. The presence of lymphoma 
cells was investigated by flow cytometry.
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Southern Blot Analysis
DNA (10 µg) was digested with EcoRI overnight at 37°C, separated on a 0.7% agarose gel, 
and blotted onto a positively charged nylon membrane (Hybond, Amersham). Southern 
blots were probed with a 32P-labeled 1.2 kb EcoRI-ClaI genomic fragment recognizing the Jβ2 
region of the TCRβ gene.
Western Blot Analysis
Total protein lysates and nuclear extracts were generated from total thymocytes and sorted 
populations (DN, DP, and SP). Total protein lysates were generated by immediately lysing 
the cells in boiling sample buffer (150 mM Tris-HCl pH 6.8, 300 mM DTT, 30% glycerol, 6% 
SDS, 0.1% bromophenol blue). Nuclear extracts were generated by resuspending cells in 
buffer A (10 mM Hepes, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 0.5 mM DTT and freshly 
added protein inhibitor cocktail [PIC]) for 15 min on ice. Subsequently NP40 (final concen-
tration 0.6%) was added, thoroughly mixed, and the cytoplasmic extract was removed by 
centrifugation. Remaining nuclei were lysed by incubating with buffer C (20 mM Hepes, 10% 
glycerol, 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, and freshly added DTT and PIC) for 
30 min at 4°C. Nuclear extracts were ready after centrifugation. Protein concentration was 
measured using BCA Protein Assay kit (Pierce, Rockford, MD, USA). Lysates containing 1 µg of 
protein were separated by electrophoresis on a 10% SDS-polyacrylamide gel and transferred 
onto PVDF membranes. Nonspecific binding was blocked by incubation in blocking buffer 
(2.5% BSA in TBS-Tween) followed by incubation with the primary antibodies and the ap-
propriate secondary antibodies conjugated to horseradish peroxidase. All isoforms of Tcf1 
were detected by anti-Tcf1 antibody (clone C46C7, rabbit mAb, Cell Signaling, Boston, USA), 
and all Lef1 isoforms were detected by anti-Lef1 antibody (clone C18A7, rabbit mAb, Cell 
Signaling). Equal loading was confirmed by reprobing the blots with an anti-actin antibody.
Microarray Analysis
Thymocytes were homogenized for RNA isolation using Qiagen RNeasy minicolumns. The 
quantity and quality of total RNA was determined using spectrophotometry (Nanodrop) and 
an Agilent Bioanalyzer. One µg of RNA was used to generate cRNA using Affymetrix One 
cycle cDNA synthesis kit (Affymetrix, Santa Clara, CA, USA), after which the samples were 
biotinylated using an Affymetrix IVT labeling kit (Affymetrix). The samples were hybridized 
overnight at 42°C to GeneChip mouse genome 430 2.0 Arrays (Affymetrix). Washing and 
staining steps were performed on a Fluidics station 450, and the Genechips were scanned 
using a GeneChip scanner 3000 (Affymetrix) at the Department of Immunology, Erasmus 
Medical Center. Raw data were normalized and summarized using Robust Multichip Average 
(RMA) method [40]. Array analysis was performed using R-2.14 (http://cran.r-project.org/) 
and Bioconductor 2.9 software (http://www.bioconductor.org/) using the bpca [41] and 
gplots [42] packages. From the dataset, genes were selected for display in heatmaps, 
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in which the rows of the expression matrix were ordered by hierarchical clustering of 
Eucledian distances between the samples, with the expression intensities being scaled per 
probeset. Principal component analysis was performed on a dataset of Tcf1+/−, Tcf1−/−, and 
Tcf−/− tumor samples, using selection of Wnt and Notch response genes (Emp1, Tcf7, Tn-
frsf19, Hes1, Dtx1, Notch1, Axin2, Lef1, Cd44, Runx2, Fn1, Cdh1, Jun, Ccnd1, Krt8, Id2, 
and Jag1). The first three principal components are displayed.
Real-Time Quantitative-PCR Analysis (RQ-PCR)
Total RNA was extracted using Qiagen RNeasy minicolumns. One µg of total RNA was used 
as a template for cDNA synthesis, using Superscript II reverse transcriptase (Invitrogen, 
Carlsbad, CA, USA), Oligo dT, and random hexamer primers. The RQ-PCR reaction was per-
formed using TaqMan Universal mastermix (Applied biosystems, Foster City, CA, USA) and 
was run on a PRISM 7700 sequence detection system containing a 96-well thermal cycler 
(Applied Biosystems). The following primers were used in combination with FAM-labeled 
probes from the universal probe library (Roche): Deltex1 forward primer: 5′-GAAGAACTT-
GAATGGCACTGG-3′; reverse primer: 5′-GTTTGGGTGCTCGTGTCAG-3′; Lef1 short forward 
primer: 5′-GCGACACTTCCATGTCCAG-3′; reverse primer: 5′-TCCTGTTTGACCTGAGGTGTTA-3′; 
Lef1 long forward primer: 5′-TGGTTAACGAGTCCGAAATCA-3′; reverser primer: 5′-AGAG-
GACGGGGCTTGTCT-3′; Axin2 forward primer: 5′-GCAGGAGCCTCACCCTTC-3′; reverse prim-
er: 5′-TGCCAGTTTCTTTGGCTCTT-3′; Hes1 forward primer: 5′-AAACACTGATTTTGGAGCACT-3′; 
and reverse primer: 5′-TGCTTCACAGTCATTTCCAGA-3′. RQ-PCR results were normalized 
to Abl expression in the same sample: forward primer: 5′-TGGAGATAACACTCTAAGCATA-
ACTAAAGGT-3′; reverse primer: 5′-GATGTAGTTGCTTGGGACCCA-3′; and probe: 5′-FAM-
CCATTTTTGGTTTGGGCTTCACACCATT-TAMRA-3′.
Notch1 Mutation Analysis
cDNA of total thymus was used for the amplification of exons encoding the Notch1 het-
erodimerization and PEST domains. Primers used for the identification of activating Notch1 
mutations are described elsewhere [43].
Tcf1−/− Cell Line Experiments
Several Tcf1−/− cell lines were established from Tcf1−/− thymic lymphomas, and all cell lines 
show Notch1 mutations and a high ratio of Lef1 long over short isoform. Transfection ex-
periments were performed by transfecting the cell line with eGFP together with either a 
control construct (pcDNA3) or a dominant negative Lef1/Tcf1 construct (transfection ratio 
GFP∶construct, 1∶10) using AMAXA electroporation technology. Transfected cells were iden-
tified based on GFP positivity and phenotype, and cell viability was determined 6 h after 
transfection. Discrimination between viable and dead cells was performed by staining the 
cells with AnnexinV and 7AAD (BD Bioscience). Tcf1−/− cell line cultures were performed in 
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the presence and absence of the γ-secretase inhibitor DAPT (0, 5, and 50 µM) or Quercetin 
(50 µM). At the indicated time points, cell cycle analysis was performed using propidium 
iodide, live cells were determined by 7AAD/AnnexinV stain, and RNA was isolated for gene 
expression levels.
Luciferase Reporter Gene Assays
293 T cells were cultured in Iscove’s Modified Dulbecco’s Medium supplemented with 10% 
fetal bovine serum, L-glutamin, and penicillin/streptomycin and transfected using the Fugene 
method according to the manufacturer’s procedures (Roche). The cultures were transfected 
with 1.5 µg LEF-1 4000 luciferase reporter plasmid (containing four Tcf/Lef-responsive ele-
ments) or 1.5 µg of the LEF-1 600 luciferase reporter plasmid (all Tcf/Lef-responsive elements 
deleted) (kindly provided by Dr. J. Skokowa, Hannover Medical School [44]). The cells were 
cotransfected with S33-βcatenin and/or pCI and/or ΔN-Tcf (3 µg). To control for transfec-
tion efficiency, all transfections included the pRLTK-renilla reporter (0.15 µg). Transfected 
cells were cultured for 24 h and then lysed and assayed for reporter activity. Luciferase and 
Renilla activity was measured using a dual-luciferase reporter assay system from Promega 
(Madison, USA). All luciferase activities were normalized to Renilla activities.
Statistical Analysis
Statistical analysis was performed using the Mann–Whitney U test (Prism GraphPad Soft-
ware, San Diego, CA, USA). p<0.05 was considered statistically significant.
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A precisely controlled balance between self-renewal and differentiation of hematopoietic 
stem cells (HSCs), is required to maintain the homeostasis of the hematopoietic system 
and to combat against stress situations like injury and infection efficiently. This balance is 
regulated by signals stem from the BM and the thymic microenvironments throughout the 
hematopoiesis and thymopoiesis. It has been a long-standing challenge to mimic the niche 
signals in vitro, with the aim to proliferate and manipulate HSCs and/or thymocytes for 
clinical purposes. The possibility of stimulating these cells with signaling ligands such as Wnt 
and Notch ligands is a very attractive approach since this would result in a more controlled 
therapy, compared to approaches requiring permanent gene modification. In fact, several 
reports have shown that Wnt ligands could efficiently induce the expansion of hematopoietic 
progenitors in vitro while maintaining an immature phenotype and/or repopulating capacity 
[1-4]. This would ultimately result in a faster thymic reconstitution by thymic seeding cells. 
However, most of these studies focus on canonical Wnt signaling, therefore the role of non-
canonical Wnt signaling in this process has largely remained unknown. In this thesis, we 
attempted to have a side by side investigation of canonical and non-canonical Wnt singling 
during hematopoiesis and thymopoiesis.
Loss of stemness in HSCs with high levels of Wnt signaling
Previous work from our laboratory demonstrated that Wnt signaling is regulated in a dose-
dependent manner during hematopoiesis and thymopoiesis [5]. Various Apc-mutant mouse 
models have been used to induce differential levels of Wnt signaling activation in vivo. It was 
shown that mild and intermediate levels of Wnt signaling regulate myeloid development, 
whereas, intermediate level regulates T cell development, but B-cell development is not 
controlled by Wnt signaling levels [5]. Apc encodes for a multifunctional protein responsible 
for various cellular functions [6]. However, most Apc mutant mouse models in which tumors 
are developed, depend completely on Wnt dosage. 
Consistently, It has shown by other laboratories that high Wnt levels in HSCs eventually 
results in loss of stemness and lack reconstitution after total body irradiation of recipients 
[7-9]. In chapter 2, we used gene expression profiling to investigate the mechanisms un-
derlying loss of repopulating capacity in HSCs with high levels of Wnt signaling. We showed 
at both genetic level as well as functional assays that HSCs with high levels of Wnt signaling 
activity have enhanced differentiation and decreased proliferation, without any effect on 
apoptosis. The much stronger tendency of these cells for differentiation towards mature 
blood lineages, associated with the loss of HSC proliferation is thought to be causative for 
lack of reconstitution. This observation could explain the lack of maintaining bona fide 
stemness in Apc exon 15 deleted HSCs. 
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These data are in agreement with another study described in chapter 4 in which activation 
of Wnt signaling by recombinant overexpression of Wnt3a resulted in a dose-dependent 
impact on murine HSC biology. Consistently in humans, it has been shown that treatment 
with very high levels of Wnt3a leads to loss of HSC proliferation in vitro [10].  It is worth 
to mention that also in the intestine, Wnt signaling induces maturation of Paneth cells, a 
mechanism in which active β-catenin and Tcf4 are involved [11], indicating that high Wnt 
signaling levels can lead to increased differentiation. Thus, Wnt signaling levels need to 
be strictly controlled when considering Wnt ligand as HSC expansion factor to be used for 
clinical purposes. It is plausible that intermediate Wnt levels, which has disadvantages 
for stemness status of HSCs, can be tolerated with increased HSC survival, which then 
would cause better self-renewal at this somehow higher Wnt signaling dose. It is well 
documented that PI3K/Akt signaling [12], as well as ectopic expression of Bcl2 [2],  can 
provide such signals. Apparently, higher Wnt signaling levels can be endured in HSCs in 
the case of co-activation with other survival pathways. Interestingly, the high Wnt levels in 
combination with oncogene activation in acute myeloid leukemia seem to allow the Wnt 
pathway to function as a self-renewal factor for leukemic stem cells [13], whereas high 
Wnt levels cannot do so in normal HSCs. The different anatomical sites of healthy versus 
malignant HSCs in the bone marrow niche [14] might contribute to this discrete effect of 
high Wnt dosage and opens up a therapeutic window targeting leukemic but not normal 
stem cells.
Role of Ryk in HSC repopulation
In chapter 3 we studied the role of Non-canonical Ryk receptor in hematopoiesis and thy-
mopoiesis. Our data indicate that Ryk as a co-receptor has a marginal role in hematopoiesis, 
possibly due to a redundant role with other tyrosine kinase receptors including Ror [15, 16] 
and/or Wnt signaling receptors and co-receptors such as FRZ 2 [17, 18] or FRZ8 in combina-
tion with Flamingo and LRP-5 and LRP-6 [19]  
Previous reports suggest that the role of Ryk, similar to other receptors, is context and 
tissue dependent [15, 20]. Most probably, this is defined by several factors, including 
dominant expression of specific ligands in various tissues, or the expression of discrete co-
receptors by surrounding cells. It has also been shown that Ryk can bind to both the Wnt3a 
canonical ligand [21], and Wnt5a non-canonical ligand [22] depending on the context and 
type of tissue, suggesting that different experimental settings might result in different out-
comes. Our data in chapter 3 did not support an important function for Ryk during T-cell 
development as no differences between mutant and control littermates were observed 
in vitro in presence of both the Wnt3a and Wnt5a ligands. Nevertheless, the secondary 
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transplantation revealed that Ryk plays a role in stem cell repopulation. Transplanted Ryk 
KO stem cells are more apoptotic, while more proliferative compared with wild-type cells. 
Nemeth and co-workers have suggested that Ryk, via Wnt5a binding, can prevent the pro-
liferation of LSK cells [23, 24]. In these reports, the role of Ryk in hematopoiesis has been 
investigated by using anti-Ryk polyclonal antibodies that presumably block the receptor 
[21, 22]. These researchers demonstrated that by adding polyclonal antibodies to the Ryk 
receptor a modest reduction in cell cycle at G0 phase (from 29 to 22%) occurs, which 
was interpreted as a deficiency effect, in which blocking Ryk would augment proliferation; 
this is consistent with our observation in which Ryk KO stem cells are more proliferative. 
However, polyclonal antibodies have a variable impact and could act as both activator 
and inhibitor antibodies. In addition, structural and functional studies have shown high 
levels of redundancy between Ryk and other tyrosine kinase receptor family members, 
in particular the ROR non-canonical Wnt receptors, making the study of each receptor 
specifically sophisticated [15]. A clear loss-of-function model as we employed in chapter 3 
allows a more direct interpretation of the Ryk’s function during hematopoiesis, although 
molecular redundancy by the associated Ror receptors could also play a role, and could be 
considered as a potential explanation for the marginal effect observed. 
The impacts of treatment with polyclonal Ryk antibodies on long-term hematopoietic 
reconstitution were similar to our results, that is, reduced reconstitution in Ryk deficient 
stem cells. Therefore, loss of Ryk in HSCs decreases their quiescence, resulting in prolifera-
tion-induced apoptosis and diminished self-renewal. The combined increases in apoptosis 
and loss of quiescence in HSCs, likely explain the lower self-renewal of Ryk KO LSK cells. 
The roles of canonical and non-canonical Wnts and potential cross-talk between the 
pathways, undoubtedly require more investigation, particularly, as Wnts are being used 
in stem cell expansion protocols [25, 26] including those employing designer nucleases 
for therapeutic gene editing [27]. Increasing evidence suggests the deregulation of both 
canonical and non-canonical Wnts in hematological malignancies. Previous work from Luis 
et al in combination with the data described in chapter 3  indicate that the dosage of 
canonical Wnt signaling is crucial in determining the functional outcome on reconstitution 
capacity of stem cells [5, 28]. Studying Wnt proteins for HSC expansion will require good 
in vivo reporter systems and well-defined reagents, taking the impact on apoptosis as well 
as on cell proliferation into account. 
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Distinct functions of Wnt3a and Wnt5a signaling in lymphopoiesis and 
thymopoiesis
Although binding of most Wnt proteins can trigger both canonical and non-canonical sig-
naling pathways [29], some Wnt ligands (Wnt1, Wnt3A, and Wnt8) have been related to 
canonical signaling, whereas others (Wnt5A and Wnt11) are linked to non-canonical signal-
ing. Induction of non-canonical Wnt inhibits the canonical pathway, partly because of com-
petition for receptor binding, and partly by influencing intracellular β-catenin levels. Elegant 
studies from the Suda laboratory have indicated that non-canonical Wnt signaling is required 
to maintain HSC quiescence. Together with Flamingo, Fz8 is a non-canonical Wnt receptor 
that interacts with non-canonical Wnt produced by osteoblastic cells in the niche during 
homeostasis. However, canonical Wnt signaling is activated in HSCs to induce self-renewal 
and differentiation under stress conditions [19]. Indeed, non-canonical Wnt5a signaling 
is enhanced in short-term HSC repopulation to retain HSCs in a quiescent G0 state [24]. 
Recent reports associated with aging of the hematopoietic system have also indicated the 
significance of Wnt5a in the regulation of HSC biology. Aged HSCs are defined by decreased 
repopulation capability per HSC, increased myeloid output, and reduced lymphoid offspring 
(reviewed by Geiger et al.) [30]. In aged HSCs, Florian et al. showed a shift from canonical 
to non-canonical Wnt signaling as a consequence of enhanced expression of Wnt5a [31]. 
Treatment of young HSCs with Wnt5a immediately led to an aged HSC phenotype, with 
lowered repopulation capability and a myeloid differentiation tendency via induction of the 
small Rho GTPase Cdc42. Our data in chapter 4 described the effects of overexpression of 
the canonical Wnt3a and non-canonical Wnt5a in HSCs by lentiviral vector transduction of 
LSK cells from fetal liver, following by transplantation of the transduced LSKs into irradiated 
recipients [32]. Wnt3a overexpression led to increased B lymphopoiesis and fewer myeloid 
cells, whereas Wnt5a augments myelopoiesis in the bone marrow (BM) and spleen. Thus, 
canonical and non-canonical Wnt signaling have discrete roles in hematopoiesis, similar to 
other developmental systems [33]. We concluded that Wnt signaling affects cell fate deci-
sions in HSCs; canonical Wnt signaling is vital for self-renewal and lymphoid developmental 
potential, whereas non-canonical Wnt signaling regulates quiescence and short-term my-
eloid offspring.
Wnt1 and Wnt4 have been shown to function as growth factors for DN cells, thus they 
are important for thymocyte proliferation [34] as Wnt1 and Wnt4 KO mice exhibit low 
thymic cellularity. Consistently, overexpression of Wnt4 has shown to selectively induce 
expansion of thymic output from transduced HSCs. Previous work from our laboratory 
showed that Wnt3a plays a critical role in fetal thymopoiesis, as Wnt3a KO thymi exhibit 
diminished numbers of DP cells due to an arrest at the ISP stage [35].
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On the other hand Liang et al. identified that non-canonical signaling induces apoptosis 
in fetal thymic cells. They showed that exogenous Wnt5a is responsible for the induction 
of apoptosis in DP stage, while its deficiency diminished the PKC activation and simul-
taneously reduced the activity of CamKII [36]. In chapter 4 we performed a side by side 
comparison of the impact of Wnt3a canonical and Wnt5a non-canonical pathways during 
T cell development. We demonstrated that the activation of canonical Wnt signaling via 
Wnt3a is crucial for T cell development, and functions in dosage dependent fashion. While 
intermediate to low doses of canonical Wnt signaling would accelerate thymopoiesis, 
higher doses support B lymphopoiesis in vivo. On the other hand, Wnt5a non-canonical 
Wnt signaling triggers myelopoiesis in vivo and it does not function in a strict dosage 
dependent fashion. Additionally, Wnt5a signaling activation results in apoptosis in devel-
oping thymocytes in vitro. 
These data are consistent with the previous studies in our laboratory in which we showed 
that canonical Wnt signaling functions in a dosage dependent fashion by using Apc hypo-
morphic mutations [5]. Although the Apc hypomorphic mutations proved to be a faithful 
model to alter canonical Wnt signaling in the hematopoietic system, it lacks the feedback 
mechanisms operating during normal thymopoiesis. In fact, control of Wnt signaling at the 
intracellular level is sophisticated because of multiple interactions with other pathways, 
including Notch and Hedgehog pathways. In the study described in chapter 4, we used 
Wnt3a, a natural ligand of canonical Wnt signaling, and we obtained identical data. This 
suggests that Wnt3a triggers canonical Wnt signaling via β-catenin and TCF/LEF dependent 
pathway in the thymus, [37] and it is possible to manipulate canonical Wnt signaling via 
differential concentration of Wnt3a in vivo. It is very likely that in the thymus, developing 
thymocytes are exposed to different types and concentration of Wnt ligands. Another pos-
sibility is that thymocytes express different FZD receptors with various binding affinity to 
the secreted Wnt proteins within the thymic microenvironment. Previous gene expression 
profiling in our laboratory proposed that this might be the case [38], although experimen-
tal proof awaits the development of specific antibodies for each Frizzled receptor suitable 
for flow cytometry. As a consequence, developing thymocytes would undergo different 
levels of Wnt signaling due to the accumulation of different amounts of β-catenin proteins 
in the cytoplasm. 
Crucial role of Tcf-1 as a lineage fidelity factor during T cell development
Precise sequential analysis of B cells and T cell developmental pathways reveals that both 
pathways are very similar in several aspects including the proliferation of progenitors, lin-
eage restriction process, immune receptor rearrangements and checkpoints for a pre- and 
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mature immune receptors. In contrast to B cell development, exact roles and relationships 
of transcriptional factors T cell development have remained largely unknown. This is mainly 
due to the fact that several transcription factors such as Tcf-1, Gata-3, and Bcl11b are in-
volved during the process of T cell commitment and most of the studies have only focused 
on one of them separately [39-48].
Our results in chapter 5 show that Tcf-1 transcription factor functions as a lineage fidel-
ity factor during T cell development. Tcf-1 deficiency results in the partial block during 
early stages of T cells development in particular during T cell commitment stages. We 
also showed that DN3 cells lacking Tcf-1 that supposed to be fully committed T cells have 
promiscuous gene expression and differentiate into DN-1 like cells, as well as cells from 
non-T cells lineages, including B cells and myeloid cells. In fact, crucial transcription fac-
tors that drive alternative lineages such as Bcl11a, Pax5, and Pu.1 are highly expressed 
in Tcf1-KO DN3 and DN4 cells, whereas in wild-type cells these factors are almost absent 
in these stages. This observation is similar to the findings of Dr. Busslinger and his co-
workers on the role of Pax-5 during B cell development. They showed that fully committed 
B cells that lack Pax5 de-differentiate to multipotent progenitor cells that can replenish all 
hematopoietic lineages, even in vivo [49, 50].
Our data together with other studies have shown that Bcl11b and Gata3 are important 
target genes of Tcf1 [39, 47]. Therefore, we re-introduced these transcription factors in 
Tcf1 deficient cells to see if they could rescue the thymic phenotype. Gata3 overexpres-
sion in Tcf-1 KO stem cells suppressed B cell fate but also myeloid fate in the thymus. 
Interestingly, in the Bone marrow, myeloid suppression was not observed, but the effect 
on B cell development was also seen outside the thymus. Reversely, overexpression of 
Bcl11b promotes T cell commitment without affecting alternative lineage development in 
the thymus, resulting in a bypass of T cell developmental block caused by the lack of Tcf-1.
Therefore our data obtained in chapter 5 indicate a gene network in which Notch signals 
via RBP-JϏ launch the expression of Tcf1 which in turn activates Gata3 and Bcl11b, most 
likely in collaboration with Notch signals that can also directly act on these promoters. 
Interestingly, in skin stem cells, lineage infidelity predisposes to malignancy [51]. As Tcf1 
deficiency leads to rapid development of T cell lymphomas (discussed in chapter 6), lineage 
infidelity may be a previously unrecognized factor in leukemogenesis, also in humans.
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Tcf-1 as a tumor suppressor during lymphoma development
Our data in chapter 5 as well as other studies have demonstrated crucial roles for Tcf1 in T cell 
development and Lef1 in B cell development [52, 53]. Tcf1 KO mice have a severe reduction 
of thymic cellularity and multiple partial blocks at DN stages of thymocyte development, and 
eventually at the transition from the CD8+ ISP stage to the CD4+CD8+ double positive stage. 
ISP and DN subsets of Tcf1 KO mice do not proliferate as strongly as their wild-type counter-
parts [44]. Although Lef1 KO mice have a normal T cell development, Lef1 and Tcf1 double 
KO mice have a complete block at the ISP stage, which implicates redundancy between these 
two transcription factors [54]. Our study in chapter 6 demonstrated that Tcf1 has another 
essential function in the thymus in addition to functioning as the nuclear effector of Wnt 
signaling in thymocytes, namely a role as a tumor suppressor gene for the occurrence of 
thymic lymphomas, the murine counterpart of human T cell acute lymphoblastic leukemia 
(T-ALL). Tcf1 KO mice develop thymic lymphomas with high frequency at older ages due 
to ectopic upregulation of Lef1 and, paradoxically, extremely high Wnt signaling levels that 
initiate leukemia development [46], which is often followed by additional oncogenic hits 
such as Notch1 mutations.
Xu et al. have shown that β-catenin mediated Wnt signaling is required for the T-cell de-
velopment to bypass the β-selection checkpoint using T cell specific deletion of β-catenin 
which ultimately results in diminished splenic T cells [55]. Furthermore, they have dem-
onstrated that pre-TCR induced signals stabilize β-catenin via the activation of Erk [56]. 
Disruption of the β-catenin/Tcf and Lef interaction by using the inhibitor of β-catenin 
(ICAT) leads to Block at DN stages but not at later DP stages indicating a crucial role of Wnt 
signaling during DN to DP transition [57]. After allogeneic HSC transplantation in adults, 
development of the T-cell lineage is slow and inadequate. In fact, lack of proper thymic 
reconstitution results in a reduction in T-cell development and eventually hampers the di-
versity of T-cell repertoire [58, 59]. Interestingly, Shen et al. have shown that the activation 
of Wnt signaling by inhibiting GSK-3β with 6-bromoindirubin 30-oxime (BIO) affected the 
naive T-cell due to the decreased T cell differentiation [60]. Our data in chapter 6 indicates 
that the development of thymic lymphoma in Tcf1 KO mice is due to the activation of 
canonical Wnt signaling via Tcf1 and Lef1. Tcf-1 functions as a tumor suppressor, and a 
transcriptional repressor to inhibit the development of thymic lymphomas by suppression 
of genes of alternate (non- T) cell lineages. Therefore, Tcf-1 acts like a molecular switch 
between the proliferation of early thymocytes and repression of non-T cell development. 
Tcf-1 is also activated by Notch signaling and lack of Tcf-1 impairs the expansion of early 
T-cell progenitors which is most probably a Wnt independent effect [39]. Last but not least, 
Martins et al recently suggested that natural cell competition between young BM-derived 
and old thymic progenitors is crucial for inhibition of T-ALL development [61] Indicating 
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that thymic progenitor fitness is necessary for normal T cell development. This could be 
facilitated by tight regulation of Notch and Wnt signaling.
Deregulation of Wnt signaling in leukemia
Many studies implicate the deregulation of Wnt signaling in leukemia and tumors develop-
ment. Gene expression analysis in various myelodysplastic syndrome (MDS) has revealed 
deregulation of cell cycle pathways and involvement of Wnt signaling and thrombopoietin 
[62]. A commonly deleted region in most of the MDS patients is 5q region which contains the 
APC binding domain. Consistently, It has been shown that deletion of APC in mice induces 
HSC deficiency and lack of reconstitution [63]. Acute myeloid leukemia (AML) stem cells have 
higher intracellular β-catenin level relative to the normal cells [64]. Chronic myelogenous 
leukemia (CML) cells undergo a higher level of Wnt signaling activity which is crucial for their 
growth [65]. Elevated levels of nuclear β-catenin were observed in Granulocyte–Macrophage 
progenitors in CML patients leading to higher self-renewal capacity [65]. Methylation of APC 
region in combination with the overexpression of β-catenin is also observed in a number 
of T-cell Acute Lymphoblastic Leukemia (T-ALL) cases [69]. Consistently, inhibition of Wnt 
signaling by overexpressing the dominant negative form of β-catenin leads to the reduced 
proliferation of thymocytes. It has been shown that 85 % of the T-ALL patient samples repre-
sent elevated levels of β-catenin expression as well as Wnt target genes including c-Myc [70]. 
At least in two different stages of leukemogenesis, the deregulation of Wnt signaling is 
playing a role. First of all the initiation phase of the disease, high level of Wnt signaling 
could be the important factor to progress from a pre-LSC into an LSC (as for AML) and as 
has been recently investigated for T-ALL where the absence of the Wnt-nuclear factor Tcf1 
appears to predispose to T-ALL development (chapter 6). Secondly, in the progression of 
established disease, as described for CML, ectopically activated Wnt signaling is essential. 
Thus, depending on the differentiation status of the cell and/or the localization of the 
leukemia-initiating cells in its niche, Wnt signaling plays various roles during leukemogen-
esis. 
There seem to be at least five different mechanisms playing a role in the deregulation 
of Wnt signaling during leukemias. First, aberrant levels of Wnt proteins (and/or Wnt 
antagonists) can be secreted by tumor cells themselves and/or the microenvironment, 
frequently reported as an autocrine feedback loop of the tumor cells. Second, the sensitiv-
ity of the tumor cells towards the Wnt proteins (and antagonists) might be modified (for 
instance alteration in Fzd, Ror or LRP expression). Thirdly, epigenetic changes are repeat-
edly observed in most types of leukemias. Both methylation of Wnt antagonists (thereby 
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interfering with their suppressive function) and of the Wnt5a promoter (leading to low 
levels of Wnt5a, which acts a tumor suppressor) have been discovered. Fourth, activating 
mutations in β-catenin or inactivating mutations in APC, or Axin has been described in ALL, 
and fifth, the balance of the Tcf/Lef factors within a tumor cell appears to be an important 
determining factor whether Wnt signaling derails during development.
Needless to say, these changes in Wnt signaling offer possibilities for therapeutic inter-
vention, especially because the levels of Wnt signaling in hematological malignancies are 
significantly higher than their normal counterparts [14, 71]. Moreover, combined with 
classical abnormalities that are targeted by tyrosine kinase inhibitors in CML (imatinib, ne-
ratinib) [72, 73], Notch inhibitors in T-ALL [74], BTK inhibitors in precursor B-ALL (ibrutinib) 
[75], the dosage needed is expected to be lower as one can envision combination therapy 
targeting Wnt signaling together with the other genetic alterations to work synergistically. 
Therefore, the fundamental knowledge about the regulation of normal and malignant 
development can be rapidly translated into clinical practice.
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Future perspectives
In recent years, there has been a serious attempt to expand HSCs by using cytokines or 
other signals [76, 77]. Among signaling pathways the main focus is denoted into the Wnt 
and Notch signaling pathways as they are the most evolutionary conserved pathways during 
hematopoiesis and thymopoiesis [78]. Therefore, there is a great attraction in applying these 
pathways for ex vivo expansion of HSCs for transplantation purposes [79]. Zon et al. have 
shown that prostaglandin E2 (PGE2), can induce the expansion of human HSCs via activation 
of Wnt signaling [80] [81]. The effect of  Wnt3a on HSC expansion before transplantation has 
also been investigated, however, the dosage might have been too high to induce positive 
effects [10]. It has been shown that the combination of inducing Wnt signaling by using 
inhibitors of GSK3-β on the one hand and blocking of mTOR pathway by using rapamycin on 
the other hand [26], results in pro-survival signals in HSCs. Interestingly, activation of canoni-
cal Wnt signaling together with the inhibition of mTOR signaling increased the number of 
murine long-term HSCs in vivo. Under cytokine-free conditions, similar effects were also 
observed in human and mouse long-term HSCs ex vivo [26].
Our data described in chapters 2-4 indicate that optimal concentration of the activating 
agents is crucial to provide just the right level of Wnt signaling required for stem cell expan-
sion [32]. In chapter 4 we showed that optimal activation of Wnt signaling in transplanted 
stem cells could lead to the accelerated T cell reconstitution in vitro and in vivo. In fact, 
acute myelogenous leukemia (AML) stem cells also require Wnt/β-catenin signaling for 
their survival [13] though at higher levels than normal HSCs [14]. Therefore, it is essential 
to understand the correct kinetic and optimal dosages of the Wnt signaling pathway at the 
different context, cell type and stages of the development.
As Wnt signaling is important for the survival and proliferation of both stem cells and 
cancer cells, the manipulation of this pathway, either positively or negatively, may be of 
therapeutic significance. The controlled induction of the Wnt pathway could be beneficial 
for stem cell repopulation and T cell reconstitution when regeneration is required. On the 
other hand, the downregulation of Wnt signaling could be used as an effective strategy to 
prevent uncontrolled self-renewal and expansion of tumorigenic cells.
In chapter 5 we unravel the transcriptional hierarchy driving T cell development in the 
mouse. The network of transcription factors plays two crucial roles at the early stages of T 
cell development; Firstly proliferation of T cell progenitors in order to establish an adequate 
pool of cells, secondly the inhibition of expansion and upregulation of T specific genes and 
TCR signaling. Precise tuning of these two stages becomes possible via the sophisticated 
transcriptional network and is required for a successful T cell commitment. While some of 
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these factors should be highly expressed in phase 1, the same factor should be irrevers-
ibly silent for the initiation and completion of phase 2. The results obtained in chapter 5 
should also be examined in human stem cells and thymocyte differentiation schemes. This 
is important, as, despite many fundamental similarities, significant differences between 
mice and humans exist in the stem cell compartment and thymus alike, necessitating the 
study of the human immune system not only to understand our own species but also to 
translate findings into clinical treatment modalities. As the thymus is not only involved in 
rare diseases such as SCID and DiGeorge syndrome, but also target of more common viral 
infections (e.g., HIV disease), directly involved in auto immune diseases, and involuted 
during ageing, leading to senescent T cell responses, better knowledge of human T cell 
development (often using concepts first discovered in the mouse system) is crucial in a 
wide variety of diseases and conditions.
On the way to translate fundamental knowledge into clinical settings several in vitro and 
in vivo models have been developed to closely mimic the human physiological situations. 
One of the interesting models being used recently is humanized mouse models e.g. NSG 
and NOG [82-83]. Combing advanced genetic techniques such as the CRISPR-CAS9 system, 
which allow the loss of function studies on human cells, with the NSG xenotransplantation 
models would shed important light on the biology of human hematopoiesis and thymo-
poiesis.
Another intriguing in vitro model is using induced pluripotent stem cells (iPSC) derived 
HSCs and T cells. Establishment of a robust protocol for differentiation of iPSC’s towards 
HSCs and T cells would provide an outstanding opportunity for the translation of our basic 
knowledge obtained from the mouse into a clinically relevant model. The model could 
not only be applied in regenerative medicine but also could be used in drug discovery via 
high throughput efficacy screening in various iPSC derived disease models. A fascinating 
HTS platform is the library of Wnt signaling modulators which might result in the discovery 
of new chemical entities (NCEs) with the ability to better control the right dosage of Wnt 
signaling in order to accelerate T cell reconstitution in healthy conditions or to inhibit the 
growth of cancer stem cells in hematological malignancies.
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The immune system of mammals is responsible for protecting our body against pathogens 
and foreign substances (antigens), and it consists of two discrete lines of defense. The first 
line called innate immunity and provide a quick and nonspecific defense. The innate immu-
nity includes different cells types, such as mast cells, macrophages, neutrophils, eosinophils, 
dendritic cells and natural killer (NK) cells. The second line of defense called adaptive im-
munity responds in an antigen-specific manner, and comprised of  B and T lymphocyte cells. 
All types of immune cells mentioned above are derived from a unique cell type that re-
sides in bone marrow (BM), called hematopoietic stem cells (HSCs). This rare cell type is 
characterized as multipotent cells because they can differentiate into any type of immune 
cells just by receiving the “right” signal, but also they have the potential to repopulate 
(self-renewal) in order to maintain enough pool of precursor cells. 
All classes of immune cells except T lymphocytes develop and maturate in the bone mar-
row. For T cell development, HSCs should migrate into the thymus via the circulation and 
seed the thymus. Thymic seeding progenitors (formerly HSCs) will first expand in the thy-
mus in order to sustain sufficient pool of progenitor T cells and subsequently they develop 
towards mature and functional T cells. It is known that thymus is the only organ in our 
body which could provide right signals for T cell development.  
This thesis focuses on one of the signals which are known to play an important role dur-
ing HSC repopulation and T cell development that is Wnt signaling pathway. Depending 
on the tissue/cell types (microenvironment) and specific class of Wnt proteins binding to 
the corresponding receptors on the developing lymphocytes, two discrete downstream 
pathways will be activated namely canonical or non-canonical Wnt pathway. The main aim 
of this thesis is to dissect the roles of these two distinct pathways during hematopoiesis 
and lymphocyte development in murine as a physiologically relevant animal model.  
In chapter 2 we investigated the role of canonical Wnt signaling in HSCs repopulation and 
differentiation in the BM. One of the most common approaches to study roles of genes is 
manipulation of the genes of interest e.g. knocking out or overexpressing by mutations. In 
this chapter, we used such a genetic tool to overexpress canonical Wnt signaling at various 
levels (low to high) in HSCs. The aim of this study is to solve the controversy of the previous 
studies observed due to the application of different gain of function and loss of function 
genetic models. Our results show that high levels of Wnt signaling results in the loss of 
stem cell repopulation. We further explored the mechanisms underlying this phenomenon 
using gene expression and functional analysis approaches. Our data revealed that high 
204 SUMMARY IN ENGLISH 
levels of Wnt signaling in HSCs is in favor of differentiation thereby reduce the self-renewal 
of stem cells. This led to the exhaustion of HSCs pool. Therefore, an optimal dosage of Wnt 
signaling is crucial for the homeostasis of HSCs by maintaining sufficient pool on one hand 
and the induction of differentiation towards mature immune cells on the other hand. 
In chapter 3 we focused on the role of non-canonical Wnt signaling in HSCs by using 
another genetic model in which one of the non-canonical Wnt receptors called Ryk is 
knocked out. We performed functional experiments by transplanting the Ryk KO stem cells 
into the irradiated mice and monitored the reconstitution of the immune system over 
time. Our data suggest that the absence of non-canonical Wnt signaling via Ryk deficiency 
results in a mild decrease of stem cell repopulation. Further mechanistic studies showed 
that the loss of stemness is caused by an increased apoptosis (programmed cell death) and 
decreased proliferation in the HSCs 
In chapter 4 we performed a side by side study of the effect canonical and non-canonical 
Wnt signaling in lymphocyte and in particular T cell development. Here we used a gain of 
function approach by overexpressing canonical Wnt ligands (Wnt3a) and non-canonical 
Wnt ligand (Wnt5a). Our in vitro studies revealed that high levels of Wnt signaling inhibit 
T cell development while intermediate levels accelerate this process, confirming that the 
optimal dosage of Wnt signaling is also crucial during T cell development in the thymus. On 
the other hand, activation of Wnt5a non-canonical Wnt signaling is harmful to the T lym-
phopoiesis and increase apoptosis in the developing T cell progenitors. Our in vivo studies 
(transplantation assays) showed that overexpression of Wnt3a is in favor of lymphopoiesis 
while overexpression of non-canonical pathways promotes myeloid differentiation. The 
latter considered as an inefficient hematopoiesis which happens at the older ages and 
known as senescence of the stem cells. These findings (chapters 2-4) enhanced our under-
standing of the biology of HSCs and T cell development and could help us to develop more 
efficient protocols for HSC expansion and T cell reconstitution in future. 
Aberrant Wnt signaling, e.g. genetic mutations in one of the key components of the 
pathway, has been reported in various types of leukemia and lymphomas ( white blood 
cell’s cancer). Mutations in TCF-1 (T cell factor) has been shown in several patients with 
leukemia. TCF-1 is a crucial transcription factor during T cell development and its expres-
sion is regulated by canonical Wnt signaling pathway. In chapters 5 and 6 we studied 
the role Tcf-1 during normal T cell development (chapter 5) and during an occurrence of 
thymic malignancy (chapter 6) by using a loss of function model of TCF-1.  
Our data in chapter 5 revealed that deficiency in Tcf-1 results in partial blocks at vari-
ous stages of T cell development while inducing development of non-T cells within the 
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thymus. Overexpression of Bcl-11b (another crucial gene for T cell commitment) rescues 
the T cell development even in the absence of Tcf-1 showing that Tcf-1 functions via Bcl-
11b to promote T cell development. However, in order to suppress the development of 
non-T cells, we upregulated another gene called Gata-3. These results reveal that T cell 
development is controlled by a minimal transcription factor network involving Tcf1, and 
the subsequent division of labor between Bcl11b and Gata3, thereby ensuring a properly 
regulated T cell gene expression program.  
At older ages, mice with deficiency of Tcf-1 develop highly metastatic thymic lymphoma. 
In chapter 6 we performed mechanistic studies to understand the cause of lymphoma 
development.  Deregulation of Wnt signaling (high expression of Wnt target genes) ob-
served in the leukemic T cells. Further studies revealed that Tcf1 is higher expressed than 
Lef1 (another transcription factor downstream of Wnt pathway), with a predominance of 
Wnt inhibitory isoforms. Loss of Tcf1 as the repressor of Lef1 leads to high Wnt activity 
and is the initiating event in lymphoma development. Thus, we showed that Tcf1 acts 
as a molecular switch between proliferative and repressive signals during T-lymphocyte 
development in the thymus.   
It has been a long-standing challenge to mimic the physiological signals in vitro or ex vivo, 
with the aim to proliferate and manipulate HSCs and/or thymocytes for clinical purposes. 
The possibility of stimulating these cells with Wnt ligands is a very attractive approach 
since this would result in a more controlled therapy, compared to approaches requiring 
permanent gene modification. This would ultimately result in a faster thymic reconstitu-
tion by thymic seeding cells. The finding obtained in this thesis could be used for the 
above-mentioned purposes in future. 
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Het afweersysteem van zoogdieren is verantwoordelijk voor de bescherming van ons 
lichaam tegen ziekteverwekkers en lichaamsvreemde stoffen (antigenen), en het bestaat uit 
twee afzonderlijke verdedigingslinies. De eerste lijn, de aangeboren immuniteit  zorgt voor 
een snelle en niet-specifieke verdediging. Deze aangeboren immuniteit omvat verschillende 
soorten cellen, zoals mestcellen, macrofagen, neutrofielen, eosinofielen, dendritische cellen 
en natural killercellen (NK). De tweede verdedigingslinie de adaptieve immuniteit, reageert 
op een antigen-specifieke manier en bestaat uit witte bloedcellen (ook bekend als B- en 
T-lymfocytcellen). 
 Alle typen immuun cellen die hierboven zijn genoemd, zijn afkomstig van een uniek 
celtype dat in het beenmerg (BM) voorkomt, de zogenaamde hematopoietische stamcel 
(HSC). Dit zeldzame celtype wordt gekarakteriseerd als multipotent omdat ze kunnen dif-
ferentiëren in elk type immuun cellen wanneer ze het “juiste” signaal te ontvangen, maar 
ook omdat ze beschikken over zelfvernieuwing om daarmee een  voldoende  grote pool 
van precursorcellen te behouden. 
Alle typen immuun cellen behalve T-lymfocyten ontwikkelen zich in het beenmerg. Voor 
de ontwikkeling van T-cellen moeten HSC’s migreren naar de thymus via de bloedsomloop 
en de thymus bevolken. Thymic-seeding-voorlopers zullen eerst expanderen in de thymus 
om een groot genoeg pool van voorlopercellen van T-cellen in stand te houden en vervol-
gens ontwikkelen ze zich tot rijpe en functionele T-cellen. Het is bekend dat thymus het 
enige orgaan in ons lichaam is dat de juiste  signalen kan geven voor de ontwikkeling van 
T-cellen. 
Dit proefschrift richt zich op een van de signalen waarvan bekend is dat ze een belangrijke 
rol spelen tijdens HSC-repopulatie en ontwikkeling van T-cellen, nl. de zogenaamde die 
Wnt-signaalroute. Afhankelijk van het weefsel  of celtype (micro-omgeving) en van de 
specifieke klasse van Wnt-eiwitten die binden aan hun specifieke receptoren op de zich 
ontwikkelende lymfocyten, zullen twee verschillende signaalroutes worden geactiveerd, 
namelijk de canonieke of niet-canonieke Wnt-route. Het hoofddoel van dit proefschrift is 
om de rollen van deze twee verschillende routes te ontleden tijdens de ontwikkeling van 
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